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NMD nonsense-mediated decay
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NUFIP Nuclear FMRP Interacting Protein
PABP poly(A)-binding protein
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RBPs RNA binding proteins
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RNA RiboNucleic Acid
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ROS reactive oxygen species
RP retinis pigmentosa
RRM RNA recognition motif
SLA amyotrophic lateral sclerosis
SLBP stem-loop-binding protein
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snoRNAs Small nucleolar RNAs
snRNA small nuclear RNA
snRNPs small nuclear Ribonucleoprotein Particles
Sod1 Super Oxide dismutase 1
SR proteins serine/arginine-rich proteins
SSLIP Sod1 Stem Loops Interacting with FMRP
TIA-1 T-cell intracellular antigen 1
TIAR TIA-1-related protein
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tRNA transfer RNA
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UTRs untranslated regions
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40S small ribosomal subunit
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Introduction
1. From the nucleus to different locations : following the
mRNA in its mission.
Following the lives of eukaryotic mRNAs from their birth in the nucleus until they are
processed by gangs of exonucleases lying in wait in dark recesses of the cytoplasm will be the
main interest of this chapter.
Throughout their lifetimes, mRNAs are escorted by a host of associated factors, called
RNA binding proteins (RBPs), some of which remain stably bound while others are subject to
dynamic exchange so that mRNAs may be shuttled to and from or anchored at specific
subcellular locations, be temporarily withheld from the translation apparatus, have their 3'
ends trimmed and extended, fraternize with like-minded mRNAs encoding proteins of related
function, and be scrutinized by the quality-control police.
Although some of these processes were originally thought to affect only select mRNA
populations or be largely limited to highly specialized cell types like germ cells and neurons,
recent work suggests that the majority of mRNAs in multiple cell types are subject to a
diverse array of regulatory activities affecting essentially every aspect of their lives. It is the
unique combination of factors accompanying any particular mRNA, as well as their relative
positions along the transcript, that dictates almost everything that happens to that mRNA in
the cytoplasm.
RBPs are able to recognize and bind to specific RNA sequences and structures through
their RNA binding domains (RBDs). In humans, more than 40 different RBDs are found,
providing an exhaustive regulation of diverse pathways. Two RBDs, the RNA recognition
motif (RRM) which is represented in nearly 500 different human genes and the heterogeneous
nuclear ribonucleoprotein K-homology (KH) domain, are present in almost all RBPs for
single stranded RNA recognition (Messias and Sattler 2004). Other motifs as the double-
stranded RNA binding domain (dsRBD), zinc fingers, RGG boxes, and the Pumilio homology
domain in PUF proteins are also found (Sontheimer 2005) (Stefl et al. 2005).
RBPs orchestrate and regulate several coordinated post-transcriptional pathways,
leading to a normal development and cellular homeostasis. Given the critical importance of
RBPs in the dynamic gene expression system, it is not surprising that a deficiency in the
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normal function of RBPs will disrupt RNP organization and cause a number of clinical
disorders. Once born, the pre-mRNA is captured by specific hosts leading it to “splicing”
1.1. Splicing
Gene regulation can be monitored by the splicing process which appears to be
especially common for genes expressed in the nervous system. The identity, properties and
types of neurons are a reflect of different protein isoforms generated by this mechanism.
Splicing occurs when a precursor mRNAs is processed into the mature forms found in the
cytoplasm via the precise joining of exonic sequences and the removal of introns that can be
hundreds of kilobases long. The borders of pre-mRNA exons and introns are delineated by the
5’ splice site at the upstream end of the intron and the 3’ splice site at the downstream end.
The spliceosome, a large ribonucleoprotein complex, is able to identify bone fide exons,
ignore pre-mRNA segments that resemble exons (pseudoexons), join contiguous exons
without inadvertent skipping and appropriately regulate alternative splicing to meet the
physiological requirements of cells and tissues.
1.1.1. The spliceosome and constitutive splicing
The core of the splicing machinery is essentially composed of five small nuclear
ribonucleoproteins (snRNPs) U1, U2, U4, U5, U6 and more than hundred other auxiliary
proteins. Each snRNP results from the association of single uridine-rich small nuclear RNA
(snRNA) with multiple proteins. The assembly of this complex is highly dynamic involving
rearrangements of RNA:RNA, RNA:protein and protein:protein interactions (Du and Rosbash
2002) (Lallena et al. 2002). Both the recognition of the intron/exon boundaries and the
catalysis of the cut-and-paste reaction are mutually orchestrated by both cis elements as the
short and degenerate splice sites consensus and the exonic and intronic splicing enhancers and
suppressors (ESEs, ISEs and ESSs, ISSs) and the trans acting factors. Enhancer elements
promote the inclusion of an exon, and silencers promote its skipping or exclusion from the
final mRNA. Establishment of a correct network of interaction between cis elements and
trans factors permits exon recognition (Figure 1). In addition to the classical splice site
sequences, recognition of constitutive exons also depends on different sets of auxiliary
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elements. Spliceosome assembly and splice site choice can be altered by transcription
elongation rates and the secondary structure of a pre-mRNA that blocks the access to the
splice sites. However, the best understood alterations in splicing are determined by proteins
that bind to the pre-mRNA and enhance or repress spliceosome assembly at various steps.
Small changes in the relative rates of spliceosome assembly at different splice sites can lead
to large changes in the choice of splicing pattern for a transcript (Matlin et al. 2005). A large
number of diseases are correlated to mutations either masking or creating novel cis elements
and generating an abnormal splicing pattern.
1.1.2. Exonic Splicing Enhancers and Suppressors (ESE and ESSs)
Based on nucleotide composition, two classes of ESEs have been defined: purine-rich
and A/C-rich. The purine-rich ESEs are recognized by a conserved family of serine/arginine-
rich (SR) proteins that recruit spliceosome components (such as U2 auxiliary factor, U2AF) to
the splice sites (Blencowe 2000). The A/C-rich ESEs (ACEs) bind the cold-box protein, YB-
1, and promote splicing. Both can enhance splicing by inhibiting adjacent ESSs (Zhu et al.
2001). Combining results obtained using functional systematic evolution of ligands by
exponential enrichment (SELEX , (Liu et al. 2000)) and computational analysis of human
genomic sequence lead to the identification of additional ESEs (Fairbrother et al. 2002). An
ESE prediction program was then developed (http://exon.cshl.org/ESE) and used to identify
ESE mutations causing exon skipping by disrupting binding sites of SR proteins leading
pathogenic splicing abnormalities (Cartegni et al. 2002).
1.1.3. Alternative splicing
Almost all cells in the organism use this process to permit a gene to encode multiple
protein isoforms with diverse and even antagonistic functions. The primary source of human
proteomic repertoire is strongly due to this mechanism that controls the inclusion of a
particular exon or the shifting of an individual splice site. Splicing pathways can be
modulated according to cell type, development stage, gender or in response to external
stimuli. Intonic repressor and activator elements, distinct from the classical splicing sequence,
play a major role in the regulation of cell-specific alternative splicing. Cell specificity
emerges from two features: first, the repression of splicing in the inappropriate cell type is
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combined with activation of splicing in the appropriate cell type; and, second, combinatorial
control is exerted by multiple components involving cooperative assembly of activation
and/or repression complexes on the cis-acting elements surrounding the regulated splice sites
(Smith and Valcarcel 2000). These complexes serve to enhance or inhibit recognition of the
classical splice sites by the basal splicing machinery. Activating and repressing activities
coexist within cells, and it remains unclear why activation dominates in one cell type whereas
repression dominates in another. Importantly, mutations that perturb this balance can result in
aberrant regulation of alternative splicing, causing the expression of protein isoforms that are
inappropriate for a cell type or developmental stage. Recently, combined microarray and
computational analyses have identified subsets of commonly regulated splicing events that
share cis-acting elements that seem to be associated only with alternative splicing. These
elements are bound by factors that are not generally associated with the spliceosome, such as
FOX proteins, CUG-BP- and ETR-3-like (CELF) proteins, muscleblind-like (MBNL), the
neuro-oncological ventral antigen (NOVA) proteins and TIA1. Regulation of alternative
splicing in vertebrates involves a dynamic interplay of antagonistic regulatory factors; for
example, between the SR and hnRNP protein families (Black 2003) and between pairs of
proteins including NOVA–polypyrimidine tract binding protein (PTB), CELF–PTB,
CELF–MBNL, TIA1–PTB, and PTB–FOX (for review (Blencowe 2006))
1.1.4. Alternative splicing during neuronal development
Alternative splicing is highly abundant in brain relative to other tissues (Blencowe
2006) where the production of  particular protein isoforms helps to determine the properties of
the many different types of neurons. It also regulates many aspects of  neurophysiology
through spatial and temporal alterations in proteins that comprise ion channels and
membrane-bound receptors involved in neurotransmitter storage and release (Lipscombe
2005). In almost every step of neuronal development, splicing events are key actors for
establishing a homogenous network of communications. It affects the pattering of the neural
tube, the cell fate determination, the axon guidance and many features of synaptogenesis (for
review (Li et al. 2007)) .
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1.2. Translation control
The final step in the gene expression pathway is the translation of mRNA into protein.
Fine tuning gene expression by the regulation of  translation is a mechanism used in a wide
range of biological situations. Emerging from early embryonic development to cell
differentiation and metabolism, translation is regulated in both time and space (Wikens et al.,
2000). There are two general modes of translation control: the global control, in which the
translation of most mRNAs in the cell is regulated and occurs by modification of translation-
initiation factors; and the mRNA-specific control where the translation of a specific subset of
mRNAs is modulated without affecting general protein biosynthesis; the principal actors of
the latter mechanism are regulatory protein complexes that recognize particular elements
present in the 5’ and/or the 3’ untranslated regions (UTRs) of the target mRNA (Figure 2A).
1.2.1.  Translation initiation
Two crucial events that take place during the initiation of translation are the
recruitment of mRNA to the ribosomal complex, and the selection of the AUG initiation
codon. In eukaryotes this complex process is assisted by more than 25 polypeptides ( for
review (Pestova et al. 2001)). The small (40S) ribosomal subunit initially binds to the 5' end
of the mRNA and scans it in a 5'- 3' direction until the initiation codon is identified. The large
(60S) ribosomal subunit then joins the 40S subunit at this position to form the catalytically
competent 80S ribosome (Figure 2B).
The small ribosomal subunit, together with other factors, forms a 43S pre-initiation
complex that binds to the mRNA. This 43S assembly contains the Eukaryotic Initiation
Factors (eIFs) 3, 1, 1A and 5, and a ternary complex, which comprises the methionine-loaded
initiator tRNA that will recognize the AUG codon during initiation and eIF2 that is coupled to
GTP. At least in mammals, binding of the 43S pre-initiation complex to the mRNA is thought
to involve bridging interactions between eIF3 and the eIF4F protein complex, which
associates with the 5' cap structure of the mRNA (Lamphear et al. 1995).
The eIF4F complex contains several proteins, which include: eIF4E, which physically
binds to the m7GpppN cap structure; eIF4A, a dead box RNA helicase and eIF4G that
interacts with the poly(A)-binding protein (PABP), and the simultaneous interaction of eIF4E
and PABP with eIF4G is believed to circularize the mRNA, which brings the 3' UTR in close
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proximity to the 5' end of the mRNA (Wells et al. 1998). This provides (at least conceptually)
a spatial framework in which the 3'-UTR-binding factors can regulate translation initiation. In
fact, most known regulatory sequences are found within the 3' UTR, even though translation
begins at the 5' end of the mRNA, which highlights the functional connection between the
mRNA ends during translation.
The global control of protein synthesis initiation is achieved by changes in the
phosphorylation state of  initiation factors or their interacting regulators. Phosphorylation of
the α-subunit of eIF2  by several known kinases inhibits global mRNA translation but can
also result in translation activation of specific mRNAs.
1.2.2. Other mechanisms
Specific RNA binding proteins regulate the translation of specific mRNA by several
mechanisms. Steric blockage, observed with the Iron Regulatory Protein that binds a stem
loop motif in the 5’UTR of the ferritin mRNAs blocking therefore the recruitment of the 43S
complex (Muckenthaler et al. 1998). Another well known mechanism is provided by the
cytoplasmic-polyadenylation-element-binding protein (CPEB) that binds to uridin rich
sequence located in the 3’UTR of target mRNAs. CPEB binds to Maskin that competes with
eIF4G for binding to eIF4E preventing the EIF4F complex formation (Stebbins-Boaz et al.
1999).
It has been admitted that translation initiation can also be regulated in a cap-
independent manner. The discovery of Internal Ribosome Entry Site (IRES) in a vast
repertoire of mRNAs lead to the establishment of their role in the translation initiation and
their regulation by trans factors ITAF (IRES Trans Acting Facotrs) (for review (Jackson
2005)). Another mechanism of translation regulation is provided by small RNA molecules of
around 22 nucleotides in length known as microRNAs (miRNAs). They hybridize by
incomplete base pairing to target mRNAs and regulate their translation at several levels
affecting the initiation (Mathonnet et al. 2007), the elongation and/or termination (Filipowicz
et al. 2008).
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1.3. Quality control
RNA quality-control mechanisms are known to target aberrant RNAs for degradation
by a few conserved nucleases (for review (Houseley et al. 2006)). Over the past five years,
most of the enzymes involved in mRNA decay have been identified and the complex
regulation that determines the path and rate of mRNA degradation is beginning to be
unraveled. Furthermore, the recent discovery that there are specific cytoplasmic sites, known
as mRNA-processing (P) bodies, where mRNA turnover occurs, was quite unexpected.
Eukaryotic mRNAs are created with two integral stability determinants - the 5' 7-
methylguanosine cap and the 3' poly(A) tail - that are incorporated co-transcriptionally. These
two structures interact with the cytoplasmic proteins eIF4E and the poly(A)-binding protein
(PABP), respectively, to protect the transcript from exonucleases and to enhance translation
initiation. To initiate decay, either one of these two structures must be compromised or the
mRNA must be cleaved internally by endonucleolytic attack.
In eukaryotes, the bulk of mRNAs undergo decay by a pathway that is initiated by
poly(A)-tail shortening. This first step in the turnover pathway is unique in that it is
reversible; transcripts that bear the correct signals can be readenylated and return to
polysomes. Nevertheless, once the cell determines that an mRNA must be destroyed, one of
two irreversible routes is taken. Either the 5' cap is removed by a process known as
decapping, which allows the mRNA body to be degraded in the 5'-3' direction by the XRN1
exoribonuclease, or the unprotected 3' end is attacked by a large complex of 3'-5'
exonucleases known as the exosome. These two pathways are not mutually exclusive and the
relative contribution of each mechanism remains a subject of debate. In Saccharomyces
cerevisiae, knocking out components of either the 3'-5' or the 5'-3' pathway had minimal
effects on the transcriptome, which implies redundancy (He et al. 2003). Results obtained by
using a sensitive assay to detect decay intermediates indicate that both 5'-3' and 3'-5' pathways
are involved in the decay of unstable ARE-containing mRNAs in mammalian cells (Murray
and Schoenberg 2007). It therefore seems that the precise pathway of mRNA decay might be
flexible.
In the nucleus, the exosome plays the major role in RNA quality control, although a
paralog of Xrn1p, termed Xrn2/Rat1p in yeast, may also affect nuclear RNA degradation
(Bousquet-Antonelli et al. 2000; Danin-Kreiselman et al. 2003). In the yeast nucleus, the core
exosome complex also associates with an additional 3’-5’ exonuclease called Rrp6p (Allmang
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et al. 1999; Burkard and Butler 2000), whereas in mammals the Rrp6p ortholog, PM/Scl100,
is observed in both the cytoplasm and nucleus (Lejeune et al. 2003).
In the cytoplasm, several quality-control mechanisms degrade eukaryotic mRNAs that
have abnormalities in translation. An emerging principle is that aberrant mRNAs can be
distinguished from normal mRNAs by adaptor proteins that interact with the translation
machinery and direct the aberrant mRNAs into a degradation pathway referred to as
nonsense-mediated decay (NMD) (Figure 3).
1.3.1. Nonsense-mediated decay.
NMD generally eliminates the production of mRNAs that prematurely terminate
translation and occurs, although by varying mechanisms, in every eukaryotic cell. NMD
appears to have evolved to protect cells from the potentially deleterious effects of routine
abnormalities in gene expression that result in the premature termination of translation. For
example, transcription initiation upstream of the proper site could generate an mRNA
harboring a nonsense codon upstream of or within the usual translational reading frame if
translation initiates upstream of the normal site. As another example, inefficient or inaccurate
pre-mRNA splicing could result in an mRNA harboring an intron-derived nonsense codon or
a nonsense codon downstream from the site of missplicing. NMD detects and degrades
transcripts that contain premature termination codons (PTCs). PTCs can arise from mutations,
frame-shifts, inefficient processing, leaky translation initiation and extended 3' UTRs. These
transcripts, if translated, could produce truncated proteins with aberrant functions. The NMD
pathway has been found in all eukaryotes and the core proteins of the NMD complex, UPF1,
UPF2 and UPF3, are highly conserved (Conti and Izaurralde 2005). Beyond this conservation,
however, the detection of the PTC and the method of decay of the transcript seem to have
diverged. Nevertheless, a common thread is the recognition of an aberrant mRNP
conformation.
During a normal translation-termination event, the stop codon is recognized by the
peptide-release factors eRF1 and eRF3 leading to peptidyl-transfer RNA (tRNA) hydrolysis.
When termination occurs at a PTC, peptide release is delayed and the ribosome remains
stalled at the stop codon. This allows the binding of UPF1 and the SMG1 kinase to the release
factors, forming a complex, known as SURF, on the stalled ribosome (Kashima et al. 2006).
At this point, through binding to UPF2, UPF1 interacts with the EJC, which lies at an

Introduction
9
exon–exon junction downstream of the termination site. Formation of this bridge between
SURF at the ribosome and the EJC leads to phosphorylation of UPF1 by SMG1 and
dissociation of the release factors (Kashima et al. 2006). Finally, SMG7, a 14-3-3-related
protein, associates with the complex and triggers decay (Unterholzner and Izaurralde 2004).
NMD pathway is not solely reserved for the decay of aberrant transcripts, but has an
important role in the regulation of normal gene expression. Microarray analysis of the
transcriptome in UPF1-depleted mammalian cells identified numerous upregulated normal
transcripts, some of which contained upstream ORFs, 3'-UTR introns, frameshifts or other
features that mimic a PTC. Furthermore, mRNAs that apparently lack any feature resembling
a PTC, namely histone mRNAs and the ARF1 mRNA, degrade in a UPF1-dependent manner.
Intriguingly, in these cases, UPF1 is recruited to the transcript through interaction with a
factor bound to the 3' UTR- the stem-loop-binding protein (SLBP) in the case of histone
mRNAs and Staufen in the case of ARF1. Neither of these mechanisms requires UPF2 or
UPF3, which indicates that these pathways are distinct from classic NMD.
1.3.2. Non Stop Decay, No-Go Decay, and Ribosome Extension-
Mediated Decay
In a process referred to as nonstop decay (NSD), ribosomes that have reached the end
of mRNAs lacking translation termination codons recruit the exosome through the action of
Ski7p-a paralog of the eEF1A (eukaryotic translation elongation factor 1A) and eRF3
(eukaryotic release factor 3) proteins, which interact with the ribosomal A site during
elongation or termination, respectively (Frischmeyer et al. 2002; van Hoof et al. 2002). This
suggests that Ski7p recognizes the empty A site produced when a ribosome reaches the 3’ end
of an mRNA.
Similarly, when mRNAs have strong pauses in elongation, the mRNA is targeted for
endonucleolytic cleavage in a process referred to as No-Go decay (NGD) (Doma and Parker
2006). NGD is promoted by the Hbs1 and Dom34 proteins, which are paralogs of the
translation termination factors eRF3 and eRF1 (eukaryotic release factor 1) and presumably
interact with the stalled ribosome.
Finally, when ribosomes inappropriately translate and then terminate within the
3’UTR at least some mRNAs are destabilized in a process referred to as ribosome extension-
mediated decay (REMD) (Inada and Aiba 2005; Kong and Liebhaber 2007).
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1.4. RNA transport and localization.
A wide range of cell types and eukaryotic organisms restrict local protein synthesis via
localization of mRNA. This phenomenon is crucial for establishment of an efficient
asymmetric distribution of cytoplasmic factors leading therefore to what is known as polarity
of a cell. Destination of mRNAs is often attributed by signals (localization elements or
zipcodes) generally found in their 3’ UTR. Zipcodes recruit trans factors, a panoply of RNA
binding proteins that recognize sequence and/ or structure of these signals, resulting in mRNP
formation. These travelling mRNPs rely on active motor-protein dependant transport that
occurs both along actin and microtubules filaments.
Zipcode Binding Protein 1 (ZBP1) is one of the most studied trans factors involved in the
localization of β-actin mRNA within the cell. ZBP1 contain 2 RRM and 4 KH motifs
allowing both recognition and  binding to  β-actin mRNA  zipcode. Mutations affecting the
zipcode sequence were shown to reduce the interaction ZBP1/β-actin mRNA (Ross et al.
1997). In mature neurons, it was shown that ZBP1/β-actin mRNA resides in dendritic shafts
and spines (Tiruchinapalli et al. 2003).
The microtubule depending transport of localized RNAs was analyzed in several
organisms and cell types. In drosophila oocytes and embryonic development, it was
demonstrated that oskar mRNA localization, determinant for posterior pole plasm, depends
on kinesin I whereas, bicoid mRNA, determinant for anterior structures development, relies
on dynein as a microtubule-associated motor (for review (Palacios and St Johnston 2001)).
In neurons, isolation of complexes containing localized mRNAs and their associated motor
proteins shed new lights on the molecular composition of these mRNPs (Kohrmann et al.
1999; Mallardo et al. 2003). As a component of motile RNP particles that move within
dendrites using kinesin motors, the authors isolated enriched Staufen-containing RNP
complexes and were able to demonstrate that these RNPs contained Staufen, kinesin heavy
chain together with BC1and Ca2+/calmodulin-depenedant kinase as dendritic RNAs.
Another study of Staufen RNPs revealed that these particles also contain Purα and the
Fragile X Mental Retardation Protein (FMRP) (Ohashi et al. 2002). The components of the
Staufen containing RNPs were therefore demonstrated to be subjects of dynamic remodelling
(Barbee et al. 2006). Recently, Davidovic and colleagues showed that FMRP interacts with a
neurospecific kinesin KIF3C, to act as a molecular adaptor between RNA granules and the
microtubule linked motor KIF3C (Davidovic et al. 2007) (Figure 4)
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2. RNA, RNA Binding Proteins and  related neurologic
disorders
It has been widely admitted that misregulation of mRNAs lead to specific disorder,
however, correlation between human diseases and defects in RNA binding proteins was
assessed for only few of them. In this chapter , I will give a general overview about human
diseases and defects in RNA processing and I will focus the next chapter on the analysis of
the Fragile X Mental retardation Protein (FMRP), an RNA binding protein whose absence
results in the Fragile X Syndrome.
2.1. Splicing and diseases
Several criteria have been used to classify splicing mutations that can disrupt a
splicing cis-element affecting therefore the expression of a single gene. Other mutations
would disrupt a trans component of the splicing machinery or the splicing regulatory complex
altering the expression of several genes. On the other hand, some mutations create either
unnatural splicing patterns or aberrant regulation of  splicing by disrupting choice of
alternatively splice sites. A list of splicing mutations is available via the Human Gene
Mutation Database (HGMD, http://www.uwcm.ac.uk/uwcm/mg/hgmd0.html).
2.1.1. Cis-acting splicing disorders and Neurologic diseases
Exonic mutations are assumed to cause disease by affecting only the coding potential
but 50% of point mutations resulting in human disease  are caused by cis-acting defects in
pre-mRNA splicing. These mutations may weaken or strengthen splicing enhancer and
silencer elements, and may create or destroy splice sites altering therefore the splicing of
constituve or alternative exons. Ideally, a detailed analysis of mRNA linear structure for
correct splicing and mRNA steady-state levels is the definitive test to correlate a splicing
defect with a disease. RNA from the affected tissue should be analyzed because cis-acting
splicing mutations can have cell specific effects (Slaugenhaupt et al. 2001).
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2.1.1.1. Frontotemporal dementia and Parkinsonism linked to
Chromosome 17 (FTDP-17)
A well characterized neurodegenerative disease due to mutations in the Tau gene.
FTDP-17 patients exhibit behavioral, cognitive and motor disturbances and frontotemporal
atrophy associated with gliosis and the formation of intraneuronal Tau containing deposits.
The Tau gene generates six major protein isoforms via alternative splicing  highly regulated
spatially and developmentally (D'Souza et al. 1999). Tau is a microtubule associated protein
(MAP) thought to promote and stabilize microtubule association and contribute to neuronal
vesicular transport in a microtubule dependant manner and highly enriched in axons of mature
and growing neurons. Tau interacts with microtubules via its C terminal domain through
repetitive microtubule binding motifs (R) encoded by exon 9 through 12. Inclusion or
skipping of exon 10 produces protein isoforms containing four R or three R respectively. Two
molecular mechanisms were proposed for FTDP-17 depending on the mutation. Missense
mutations, but not all, impair Tau function by altering its interaction with microtubules. A
substitution N279K within the exon 10 has no effect on Tau binding to microtubules,
however, patients carrying this mutation exhibit a two fold increase in the 4R/3R ratio that
leads to the formation of neurofibrillary tangles (NFTs) and neurodegeneration.
Misexpression of Tau isoforms due to mutations within exon 10 could affect its alternative
splicing.
Exon trapping and minigene experiments in cultured cell lines were used to test the
effect of several exon 10 and intron 10 mutations on exon 10 splicing efficiency. These
mutations disrupt the formation of a stem loop structure present at the 3’ boundary of exon 10
which normally functions to restrict spliceosome assembly by preventing efficient interaction
of  the U1 snRNA with the 5’ splice site (Grover et al. 1999). N279K significantly increases
the activity of  a purine rich ESE by changing TAAGAAG to GAAGAAG favourizing the
inclusion of exon 10 and an increase of the 4R/3R ratio. A missense mutation within exon 10,
L284L, result in almost complete exon inclusion.
A ∆280K  mutation results in complete exon skipping in a minigene construct,
presumably because it weakens an ESE  (D'Souza et al. 1999). This mutation also decreases
the 4R-tau protein function in vitro. Other intronic mutations also alter the hairpin structure in
the 5’splice site leading to the inclusion of exon 10 (Hutton et al. 1998). Alterations in
splicing of exons 2, 3 and 6 of the Tau protein were also involved in other diseases including
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gliopathy, spinal cord degeneration, Alzheimer’s disease and myotonic dystrophy (Andreadis
2005) (Leroy et al. 2006).
2.1.2. Trans-acting mutations
An efficient function of the spliceosome is accomplished by a dynamic association of
several kinases, phosphatases, helicases and many other mRNA export factors and
transcription factors (Jurica and Moore 2003). Despite the expectation that dysfunction of the
basal splicing machinery should be lethal regardless of cell type, mutations that disrupt the
assembly or function of  spliceosomal snRNPs are responsible for two human diseases in
which two different subsets of neurons are affected : Spinal muscular atrophy (SMA) and
retinis pigmentosa (RP). These two neurospecific diseases affect different subsets of neurons
and this cell specificity may be due either to the wide range of sensitivities to deficiencies of
essential splicing factors exhibited by different exons, or to specific subset of pre-mRNAs
affected in either disease by deficiencies of the splicing factors.
2.1.2.1. Spinal muscular atrophy (SMA)
SMA, one of the most common causes of childhood mortality, is an autosomal
recessive neurodegenerative disorder characterized by progressive degeneration of the spinal
cord motor neurons. SMN gene falls in a complex inverted repeat of around 500Kb on
chromosome 5q13 resulting in telomeric SMN1 and centromeric SMN-2 copies. SMN1 is
deleted (93% of cases), interrupted (5.6%) or mutated in nearly all SMA patients (Lefebvre et
al. 1995). SMN1 and SMN2 genes are remarkably similar, differing only in five nucleotides
in their 3’ region.
SMN1 produces full length SMN protein, but SMN2 produces a similar protein
lacking exon 7 due to alternative splicing caused by a C-T transition of the sixth nucleotide of
SMN-2 exon 7. This substitution disrupts an ESE and causes complete exon 7 skipping  and
the SMN∆7 has a limited ability to complement the deficiency of the full length protein
(Lorson et al. 1999). SMN is a ubiquitous protein with particularly high levels in motor
neurons. It shuttles between the cytoplasm and the nucleus where it is found in dot-like
structures that colocalize with cajal bodies creating the Gemini of cajal bodies. SMN is a part
of a large complex consisting of at least six other interacting proteins (Gemins 2-7). This
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complex is believed to play a role in the assembly of snRNPs in the cytoplasm and the
regeneration of snRNPs during the splicing cycle in the nucleus, promoting high fidelity
interactions between RNA binding proteins and their target sequences (for review (Monani
2005)).
Involvement of SMN in SMA was contrastingly reported by two different schools of
thought. The first one suggests that SMA is a direct consequence of a disruption in SMN's
role in snRNP biogenesis and pre-mRNA splicing based on observations from both SMA
patients where snRNP assembly is compromised. The other school thought claims that SMA
is a consequence of a motor neuron-specific function of the SMN protein, based on
observations of both in vitro and in vivo experiments demonstrating that SMN accumulates,
in axons and growth cones, in granules that associate with microtubules and exhibit
bidirectional movement between the cell body and the growth cone. These observations lead
to the conclusion that SMN has specific role in neuronal cells and even more specific one in
motor neurons (Monani 2005).
SMN interaction with β-actin mRNA mediated by hnRNP-R together with
observations from primary motor neurons of SMA mice models that exhibit reduced growth
cone size, β-actin levels, and shorter neuritis support the hypothesis that SMN might be
constituent of a different RNP complex involved not just in mRNA transport and localization
but also in regulating translation in neuritis. Recently, it has been shown that SMN complex is
associated with the Fragile X Mental Retardation Protein (FMRP) suggesting that both
proteins may have a complementary effect of the actin neurofilament organization and
strengthening the role of SMN in localized translation and actin metabolism (Piazzon et al.
2007). A more detailed work aiming to the identification and characterization of specific
RNAs associated with SMN granules in growth cones and the association of SMN to
polyribosomes in axons may be critical to better understand the function of SMN protein.
2.1.2.2. Amyotrophic lateral sclerosis (ALS)
ALS is an adult onset, progressive disorder characterized by degeneration of cortical
motor neurons and spinal/bulbar motor neurons. Oxidative stress is thought to contribute to
motor neuron degeneration in a large proportion of ALS cases, either through mutations in
SOD1 (found in 15–25% offamilial ALS cases) or through glutamate-mediated excitotoxicity.
A decrease in the excitatory amino-acid transporter EAAT2 has been observed in around two-
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thirds of patients with sporadic ALS. EAAT2, which is expressed by astrocytes, pumps
glutamate from the extracellular space into cells, where it is metabolized.
Motor neurons are particularly susceptible to excitotoxicity as a result of exposure to
high levels of glutamate, and decreased EAAT2 levels might therefore account for their
selective vulnerability in ALS. Interestingly, the level of  EAAT2 RNA in the motor cortex is
unchanged in ALS patients. The selective loss of EAAT2 protein appears to be the result of
aberrant splicing of EAAT2 pre-mRNA in the specific regions of the brain affected in ALS
(Lin et al. 1998). The basis of this splicing misregulation is still unknown. The striking cell-
specificity of  the pre-mRNA affected suggests that there is not a general disruption of the
splicing machinery but, rather, one or few cell-specific auxiliary splicing factors are
functioning aberrantly. A precise analysis of additional RNAs whose splicing is similarly
affected and whether these RNAs have regulatory sequences in common with EAAT2 will
bring new lights on the mechanism that govern the EAAT2 splicing.
2.1.3. Trans effects : mutations that affect regulators of
alternative splicing.
In this kind of mutations, aberrant splicing of pre-mRNA occurs indirectly as a result
of dysfunction in another gene which leads to a secondary splicing defect. Some repeat
expansion mutations present in RNAs act as dominant negative sinks for splicing regulatory
factors. When amplified by disease causing mutations, these repeats bind to and sequestrate
splicing regulatory factors which leads to altered splicing of pre-mRNAs that would normally
be regulated by these factors (Ranum and Cooper 2006). Another involvement of RNA
dominant diseases is observed in the Fragile-X-Associated Tremor/Ataxia syndrome
(FXTAS) a late-onset neurologic disorder that will be detailed on the next chapter, is also due
to an RNA gain-of-function mutation. A similar molecular mechanism as DM was proposed,
resulting from observations revealing the presence of  two RNA binding proteins, hnRNP A2
and MBNL1 in intranuclear inclusions isolated from FXTAS brain specimens (Iwahashi et al.
2006) features and characteristics of this disease will be discussed in the next chapter.
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2.1.3.1. Myotonic Dystrophy (DM)
DM, a dominantly inherited neuromuscular disorder, is characterized by progressive
skeletal muscle weakness, myotonia, cardiac conduction defects, dilated cardiomyopathy,
endocrinopathy, alterations in smooth muscle function, cognitive impairment and behavioral
disturbances. Two types of DM were identified. DM1 is caused by CTG trinucleotide
expansion in the 3’ UTR of  the dystrophia myotonica-protein kinase (DMPK) gene on
chromosome 19. Severely affected individuals have more than 1500 repeats whereas in
unaffected individuals the CTG repeats range from 5 to 38.
DM2 results from a CCTG expansion in the intron 1 of the zinc finger 9 (ZNF9) gene
on chromosome 3 where the repeats can reach more than 11.000. Both diseases are clinically
similar, however, differences such as the absence of congenital form in DM2 where proximal
muscles are affected. However, in DM1, distal muscles are affected and an overall increased
severity of both muscular dystrophy and the CNS symptoms allow to distinguish between
both forms of DM (for review (Ranum and Cooper 2006)).
At a molecular level, DM is due to misregulation of alternative splicing that can affect
essentially MAPT together with NMDAR1 and APP genes in brain, and the Insulin receptor
(IR), the Chloride Ion Channel (ClC-1) in skeletal muscles. Mouse model expressing CUG
repeats in the 3’UTR of the muscle skeletal alpha actin protein showed alterations in the
splicing of ClC-1 pre-mRNAs revealing the effect in trans of the repeats. Co-transfection
experiments of CUG repeat-containing mRNA with splicing reporter minigenes resulted in
the same splicing pattern observed in DM patients, confirming the trans acting effect of the
repeats (Wang et al. 1995).
The mechanism by which these repeats induce a trans dominant effect on splicing is
still unclear but an explanation could be raised out from the sequestration of splicing
regulators by these repeats resulting in nuclear depletion and loss of function of these
regulators. Two RNA binding proteins, involved in several steps of RNA processing, were
identified to bind the CUG repeats, CUG-BP1 (CUG Binding Protein 1) member of the CELF
family, and MBNL (muscleblind like protein) (Lu et al. 1999; Timchenko et al. 1999). A
growing list of evidences link an altered function of these two proteins with DM. MBNL
binds the CUG repeats and localizes in nuclear Foci of CUG or CCUG repeats containing
RNAs, in vivo experiments showed that MBNL is able to bind directly some intronic
elements of  the IR gene and the cTNT gene, whose splicing is misregulated in DM. Finally, a
mouse knockout model of MBNL exhibits a DM-like phenotype.
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CUG-BP1 binds short single stranded CUG repeats but unlike MBNL, it doesn’t bind
proportionally to the length of the repeat RNA and doesn’t colocalize with CUG or CCUG
RNA repeats foci. CUG-BP1 regulates the splicing of ClC1, IR, and cTNT genes mostly
affected in DM. The expression level of CUG-BP1 is significantly increased in tissues and
cell cultures from individuals with DM (Miller et al. 2000).
Put together, all these evidences prove that both MBNL and CUG-BP1
antagonistically regulate the splicing of  affected genes where a loss of function of MBNL,
thought to be the dominant cause of DM, and a gain of function of CUG-BP1 are observed.
Nevertheless, another alternative model suggests that the loss of activity of MBNL is not
sufficient to explain the splicing abnormalities in DM. This model is based on co-transfection
experiments of  RNA-containing CUG repeats with cTNT and IR minigenes , to analyze the
splicing pattern of these minigenes when depleting MBNL by siRNA. The results of these
assays lead the authors to conclude the importance of the direct effect of CUG-BP1 binding to
its target pre-mRNAs altering their splicing pattern in a MBNL independent manner.
2.2. NMD and diseases
Recently NMD was linked to Mental retardation by Tarpey and colleagues. In a large
screening aiming to identify novels genes involved in mental retardation, they found three
truncating mutations in UPF3B gene in three different families. Two of these mutations were
deletions within the exons resulting in frameshift and truncated protein while the third
mutation was nonsense mutation, all of them leading to a PTC.
The authors checked whether this PTC in the UPF3B mRNA would be targeted by NMD.
Given that UPF3B is involved in this pathway, mutations affecting this protein would lead to
an alteration in the NMD. Quantitative analysis showed that UPF3B mRNA level from
affected individuals was significantly lower than that of normal individuals suggesting that
targeting of NMD for UPF3B mRNA degradation was not altered in the absence of UPF3B
protein. They also checked alteration of the classical and alternative NMD pathways and
demonstrated that only the classical NMD pathway is affected whereas the alternative
pathway is intact (Tarpey et al. 2007).
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2.3. RNA binding proteins in Neurologic diseases
The neuron-specific inclusion or skipping of alternative exons is primarily achieved by
tissue-specific expression of particular RBPs. Over a dozen neuron-specific RBPs have been
identified, the Nova and the Hu protein families that regulate a wide range of target gene
transcripts, encoding proteins involved in cytoskeletal rearrangement, vesicular transport, cell
adhesion, signal transduction pathways, and synaptic activity.
2.3.1. Paraneoplastic encephalomyelitis
Paraneoplastic encephalomyelitis is a neurological disorder associated to certain types
of tumors, with predominantly small cell carcinoma of the lung expressing a particular Hu
antigen. Indeed, Hu proteins were first identified as the targets of autoantibodies found in
affected patients. This neuroimmune disorder results from the ability of these antibodies to
cross the blood brain barrier. Hu proteins are the human homologues of Drosophila ELAV, an
RNA-binding protein whose deletion results in an embryonic lethal abnormal vision
phenotype in flies. Neuronal specific members of the Hu family, HuB, HuC and HuD are
thought to be one of the earliest markers of neuronal differentiation showing a unique pattern
of spatial and temporal expression, while the fourth member, HuA is expressed in other
tissues (for review (Deschenes-Furry et al. 2006) and references theirin). Hu proteins harbour
three RRM similar to those observed in splicing regulators, however, the best characterized
function of “Hu” is in the stabilization of specific messenger mRNAs.
2.3.2. Paraneoplastic opsoclonus myoclonus ataxia (POMA)
Nova proteins form the second family of RNA binding proteins associated with the
paraneoplastic opsoclonus myoclonus ataxia (POMA). This disorder is mostly characterized
by cerebellar ataxia, dysphasia, mutism, and irritability. Nova 1 and 2 have been identified as
the two members of the nova protein family. Nova1 and Nova2, are complementary expressed
in brain regions and contain three KH domains involved in recognition and binding to specific
RNA targets (Lewis et al. 1999; Lewis et al. 2000). The authors showed that a UCAUY (Y
can be any pyrimidine) element in the context of a stem loop is recognized by the protein.
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This UCAY sequence bound by the KH3 domain was used to identify putative targets for
Nova1. Involvement of Nova1 in both splicing and neuronal survival emerged from Nova1
null mice that showed apoptotic death of the ventral spinal cord motor neurons and alteration
in the splicing pattern of the glycine receptor (GlyRα2) (Jensen et al. 2000). Recently,
affymetrix microarrays analysis showed that the splicing pattern of a small set of exons was
affected in  Nova1-/- and Nova2-/- mice brains suggesting therefore that Nova forms one of the
multiple factors that regulate splicing of these exons (Ule et al. 2005).
Another neurological disorder related to RNA binding proteins is the Fragile X
syndrome that will be detailed in the next chapter.
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3. The Fragile X syndrome: An unstable repeat expansion
disorder
3.1. The Fragile X mental retardation gene
3.1.1. discovery of the FMR1 gene
When the chromosome sets of mentaly-retarded patients were studied, a peculiar
constriction was observed at the tip of the long arm of the X chromosome at position q27.3.
Under specific culture conditions, this constriction appeared sensitive to low folate
concentrations.  This particular site turned out to undergo a local instability of chromatin, and
was so designated as ‘fragile’. This fragile X signature was confirmed through studies of
families with X-linked mental retardation and the term of Fragile X was adopted. FXS affects
in average 1/4000 males and 1/7000 females. In 1991, the Fragile X Mental retardation 1
(FMR1) gene was mapped on the X chromosome at position Xq27.3 and spans around 40 kb
(Verkek et al. 1991). Footprint analysis revealed the existence of many cis elements in its
5’UTR (GC boxes, E-box and palindrome sequence) of FMR1, that are able to bind several
transcription factors such as Sp1, USF1 and USF2 regulating therefore its expression (Hwu
WL 1993; Kumari D 2001). In addition CGG repeats present int the 5’UTR of the gene
contribute to the recruitment of CGG binding proteins and other components of the
transcriptional machinery that control FMR1 gene expression. The human FMR1 gene is
transcribed in a 3.9 kb mRNA constituted by 17 exons. Alternative splicing play a crucial role
in the generation of several transcript isoforms by affecting the inclusion or skipping of exons
12 and 14 in one hand and the choice of the splicing acceptor sites in exons 15 and 17
(Verkek et al. 1993).
The 5’-untranslated region of FMR1, that controls its normal expression, is located at
this particular fragile site and shown to contain a stretch of unstable CGG repeats (Figure 5).
FXS was therefore classified among the 14 documented trinucleotide repeat expansion
disorders that affect humans (summarized in Table 1). All these disorders cause neurological
dysfunction and involve a dynamic mutation  affecting the number of repetitions of a
nucleotidic triplet: CAG (that codes for glutamine (Q)) in the case of polyQ diseases such as
Huntington’s disease, and other repeats in non-polyQ disease such as FXS, myotonic
distrophy or Friedreich’s ataxia.
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The exact molecular mechanism for the expansion of CGG repeats in the 5’UTR of the
FMR1  gene is still poorly understood, however several studies suggest that a DNA
polymerase slippage occur during replication due to the hairpin structures adopted by the
CGG repeats. The presence of the AGG that interrupt the CGG repeats would act as a “switch
off” for the formation and the dimerization of hairpins, stabilizing therefore the repeats.
3.1.2. Mutations in the CGG repeats induce abnormal FMR1
expression
3.1.2.1. The premutation and FXTAS
The 5’UTR of the FMR1 gene of normal individuals carries between six and fifty four
CGG repeats, often interrupted by one or two AGG. Intermediate sizes ranging from 52 to
200 have been detected in parents of children affected with FXS, and since these parents did
not express any clinical or cytogenetic phenotype, they were considered as ‘carriers’ of a
premutation. This premutation is unstable during oogenesis and is associated with a
significant risk of further expansion, upon maternal transmission, to a full mutation in
succeeding generations. Initially, the premutation was believed to be medically and
psychologically benign, however, the existence of phenotypic features specific to the
premutation condition had been recently reported. First, premature ovarian failure (POF),
defined by cessation of menses prior to age 40, occurs in 20% of females with the
premutation as compared to 1% of the general population (Sherman 2000). Second, a fragile
X-associated tremor/ataxia syndrome (FXTAS) occurs in a significant proportion of older
males and in occasional older females with the premutation. It had been also shown that
premutation carriers present reduced hippocampal volume and gray matter density. The
primary features of FXTAS include intention tremor, ataxia, brain atrophy with white matter
disease, autonomic dysfunction including high blood pressure and impotence, sensory
neuropathy in a stocking distribution in the lower extremities, and cognitive decline beginning
with memory deficits. This neurodegenerative phenotype is entirely distinct from FXS.
In these individuals, FMR1 mRNA level had been shown to be particularly elevated up
to five to ten folds above the normal range. This increase was suggested to be the cause of
toxic gain of function in neurons leading to inclusion formation, neuronal cell death, brain
atrophy, and white matter disease (Hagerman PJ 2004). However, the downstream effects of
these molecular mechanisms on psychiatric/psychological functioning have not yet been fully
elucidated.
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3.1.2.2. The full mutation and silencing of the FMR1 gene
When the number of repeats exceeds two hundred, the CGG expansions create CpG
islands which are targets to hypermethylation (Verkek et al. 1991). This increased
methylation coupled with decreased histone acetylation (Coffee B et al. 1999) results in the
inactivation of the FMR1 gene. These events affecting chromatin structure are thought to be
at the basis of silencing of the FMR1 gene in patients, eventhough which of these two
mechanisms occur first is still in debate. It is known that methylated CpGs lead to the
recruitment of several repressive complexes which compel the chromatin to adopt structures
that are inaccessible for transcriptional activators. In another hand it has been shown that
acetylation of histones H3 and H4 is decreased in fragile X cells where lysine 9 of histone H3
(H3-K9) is methylated, reflecting a pattern observed in inactive genes. Both observations lead
to conclude that methylation of CpG islands and chromatin condensation in FXS patients
prevent the transcription factors to bind to the FMR1 promoter and provoke its silencing.
Since the discovery of the FMR1 gene, its silencing mechanisms and the establishment of the
clinical features of FXS patients, several other mutations were reported in patients exhibiting
the FXS traits but not showing any abnormal CGG repeat expansions.
3.1.2.3. Other mutations affecting FMR1 gene
Eventhough the vast majority of Fragile X patients bear abnormal expansions of the
CGG repeats in the 5’UTR of FMR1 gene, several point mutations in the coding sequence of
the gene have been reported. First, Lugenbeel and colleagues reported that  one patient
showed the absence of an adenosine residue in position +373 in exon 5, resulting in a
frameshift and predicting a premature STOP codon. A second patient showed a two base
pairchange (GG-TA) in the splice acceptor site of exon 2 resulting in two RT-PCR products,
one reflected the skipping of exon 2 while the other reflected the exclusion of both exon 2 and
3 in the mRNA. Exclusion of exon 2 creates a frameshift and a premature STOP codon, while
the absence of both exon 2 and 3 doesn’t disrupt the reading frame but removes 49 amino
acids from the protein. In both patient, FMRP was not detected suggesting that their FMR1
mRNA product is unstable and may be degraded by the NMD (Lugenbeel et al. 1995).
Wang and colleagues performed a large scale screening and reported a point mutation
in three FXS patients modifying a C into T in position 14 of intron 10. This substitution
affects the splicing pattern of the FMR1 mRNA causing both the exclusion of exon 10 and a
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frameshift after exon 11 creating a premature STOP codon. Furthermore, the authors showed
that one of the three patients presents another substitution in exon 15 where a G is substituted
by an A leading to an Arginine to Histidine shift in amino acid position 546. They concluded
that this mutation would have no significance in FXS formation, simply due to its existence
downstream of the STOP codon created by the abnormal splicing pattern in this patient
{Wang, 1997 #1557}. The authors didn’t examine the protein level in these patients where it’s
probably absent due to degradation of the mRNA with premature STOP codons. It’s of a great
interest to mention that Arg546His substitution falls in an active functional domain of FMRP.
A more detailed analysis of this substitution at a protein level would enlighten its importance
and predict if it results in any alteration of  FMRP function.
Another missense mutation was described by De Boulle and colleagues, a T to A
conversion leads to substitution of an isoleucine by an asparagine in amino acid position 304
(Ile304Asn). This mutation was found in a patient severely affected by FXS where FMRP is
detected but presents functional alterations (De Boulle et al. 1993). This mutation and its
consequence on the protein function will be discussed later.
Other deletions affecting the FMR1 gene were also described (for review (Bardoni and
Mandel 2002)). All the described mutations affecting directly the FMR1 gene allowed to
confirm its role as an exclusive cause for FXS manifestation.
3.2. Clinical features of Fragile X syndrome
3.2.1. Phenotypic hallmarks of the FXS
Mental retardation, the “hallmark” of the FXS is also accompanied by some
behavioral phenotype including hyperarousal, social anxiety and withdrawal, social deficits
with peers, abnormalities in communication, unusual responses to sensory stimuli, stereotypic
behaviour (mood swings, self injury, aggression), autism spectrum disorders, inattention,
impulsivity, and hyperactivity. All these characteristics vary among patients, some exhibit
mild mental retardation with an IQ average around 50 while others can be more severely
affected (Hagerman and Cronister 1996).
In addition to impaired higher cognitive functions, various physical features are now
recognised, such as facial dysmorphism with large and inverted ears, long face and prominent
jaws, often accompanied by flat feet and large testicles (macro-orchidism) in FXS male
patients. Some forms of connective tissue dysplasia, such as hyperextensible joints, flat feet
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and hand calluses can also be observed. FXS is actually considered as a complex syndrome,
since symptoms are multiple and highly heterogenous, also varying in severity from one
patient to another.
3.2.2. Neuroanatomic features
Selective changes in brain size of FXS patients had been observed by neuroimaging
and magnetic resonance studies. Most importantly, a reduction of both the posterior cerebellar
vermis and the temporal lobe volume occurs with an age-dependant increase in hippocampal
volume and enlarged caudate nucleus and thalamus and parietal white matter (for review
(Kates WR 2002)). Furthermore, a detailed analysis of the alteration of the integrity and
connectivity of the white matter, suggested a relative involvement of the white matter in both
frontostriatal pathways and parietal sensory motor tracts (Barnea-Goraly N 2003), however,
the size difference remain subtle.
At the cellular level, the only abnormality detected in postmortem microscopic
observations of FXS patients was the dendritic spines (Irwin SA 2001). Dendritic spines are
membranous protrusions emanating from dendrites that constitute the postsynaptic
compartment of major excitatory synapses in brain. FXS patients exhibit higher density of
spines, with increased number of long and thin immature spines together with a decreased
number of short and mature spines in the temporal and visual cortex (Figure 6). These spine
abnormalities are a general phenomenon in disorders related to mental retardation, and are
thought to be at the basis of the alterations of higher cognitive functions observed in fragile X
patients. The role of FMRP in this context will be discussed in the following part.
Fmr1 KO mice, like FXS patients, display phenotype traits including enlarged testes,
hyperactivity and a mild spatial learning impairment (Bakker et al. 1994), characteristics of
the phenotype of fragile X patients. They present dendritic spines that are longer, thinner and
denser than the ones of wild-type mice (Comery et al. 1997; Irwin et al. 2000). (Figure 6).
These mice display alteration of some forms of synaptic plasticity. Indeed, in mice
hippocampal LTD is increased in the absence of Fmrp (Nosyreva and Huber 2006) and,
conversely, cortical LTP is reduced in Fmr1 null mice (Wilson and Cox 2007). These animals
show an increased susceptibility to audiogenic seizures (AGS) at all ages (Musumeci et al.
2000) (Yan et al. 2004).
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3.2.3. Expression pattern of fmr1
Two major techniques were used to follow the expression of FMR1 gene during
embryonic development, in situ and immunohistochemistry in both human and mouse tissues.
Results obtained using these experiments were confusing or even contradictory due to the
probe used in the study. The probe was able to recognize the mRNA of  FMR1 two
homologues FXR1 and FXR2. Nevertheless, they have allowed to define a scheme of the
dynamic expression of FMR1 during development. Bakker and colleagues established a “time
course “ expression of FMRP in mice embryos. In These embryos, FMRP was detected after
2 days of gestation, its ubiquitous expression gets gradually elevated between days 2 and 14
especially in ectodermic derived tissues and testes. A more specific expression of FMRP is
observed after day 14, till birth and kept in adult. Always high levels in testes and brain,
FMRP expression decreases in heart and skeletal muscle (Bakker et al. 2000). Similar results
were observed in human embryos where FMRP was highly expressed in testes and brain,
especially in hippocampus and nucleus basalis magnocellularis, both regions involved in
learning and memory (Abitbol M 1993; Tamanini et al. 1997).
In both human and mice adults, FMRP was not detected neither in heart , blood
vessels nor in skeletal muscles, whereas it was highly expressed in the brain, testes and
ovaries. More specifically, both hippocampal pyramidal neurons and cerebellum Purkinje
cells showed a significant increase in FMRP expression. In adult testes, FMRP expression is
restricted to spermatogonia (Devys et al. 1993).
The ubiquitous expression of FMRP reflects the function of this protein in several tissues
and can be correlated with symptoms other than mental retardation in FXS patients. However,
it’s worth mentioning that both brain and testes, the most affected tissues in FXS patients, are
sites where FMRP is highly expressed.
3.3. The Fragile X gene family
3.3.1. FXR1 and FXR2
The human FMR1 belongs to a gene family which includes two other autosomal
members that are not present on the X chromosome: FXR1 and FXR2, that map at 3q28 and
17p13.1, respectively (Coy et al. 1995; Siomi et al. 1995).
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3.3.1.1. FXR1
The FXR1 mRNA is highly subjected to alternative splicing, its pre-mRNA gives rise
to several FXR1 mRNA isoforms  including or not exons 15, 16 and 17 with insertion or
deletion of sequences belonging to exons 12 and 13 (Kirkpatrick et al. 1999). Thus, an
affluent repertoire of FXR1P isoforms are produced and expressed in a tissue specific manner
(Khandjian et al. 1998; Dubé et al. 2000) . Both aspects of FXR1P distribution and function
will be discussed later. Interestingly, homozygous Fxr1 -/- mice die shortly after birth most
likely due to cardiac and/or respiratory failure. These animals showed a less well developed
limb musculature and a reduced size of heart, lung, spleen and testes compared to WT
animals (Mientjes et al. 2004). At a cellular level, a reduction of the cytoplasmic volume was
observed in both cardiac and skeletal muscle accompanied by an alteration of  contractile
filaments and an increase in nuclei number. A deeper observation showed that costameric
proteins such as vinculin, dystrophin and α-actinin were completely delocalized. The
costameric regions are probably involved in translational control. For this reason, Mijentes
and colleagues suggested a putative function of FXR1P similar to that of FMRP (Mientjes et
al. 2004).
3.3.1.2. FXR2
As FXR2 has not been correlated to any known pathology or defect in humans, its
molecular function had been poorly investigated. Mahishi and colleagues analyzed the
promoter region of FXR2 and identified the transcription factors involved in the regulation of
its activity. Interestingly, Sp1, Nrf1 and AP-2 were found to be bound by the promoter region.
These factors were also shown to regulate the transcription of FMR1 (Mahishi and Usdin
2006). FXR2 pre-mRNA is not subjected to alternative splicing, giving therefore a unique
full-length transcript.
Mouse models were generated for behavioral tests. Fxr2 null mice are viable and
shown some behavioural phenotypes similar to those observed in Fmr1 knockout mice,
suggesting a role for FXR2 in the developing of cognitive functions (Bontekoe et al. 2002).
Fxr2/Fmr1 double KO mice were generated and analyzed by a battery of behavioral assays to
assess multiple aspects of CNS function. Exaggerated behavioral aspects such as
hyperactivity, a decreased acoustic startle response and decreased conditioned fear were
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observed suggested a genetic interaction between Fmr1 and Fxr2 and the possibility that
FXR2P may compensate for the absence of FMRP in FXS patients (Spencer et al. 2006).
3.3.2. Evolutionary conservation of the fragile X family
The fragile X gene family has been highly conserved during evolution, since members
of this family have been found from the jellyfish to human. Vertebrates, such as human and
mouse, as well as the zebrafish Danio rerio possess three members of the FXRP family, the
frog Xenopus laevis has two, and the fruitfly Drosophila melanogaster only one. Even
Hydractinia, an evolutionary relative of coral and jellyfish belonging to the Cnidarian phylum
possesses an homologue of the FMR1 gene that is expressed in its nervous cells. Since
Cnidarians represent the most primitive alive metazoans possessing a nervous system, the
surprising preservation of the FXRP family evokes the fascinating possibility that these
proteins have been conserved by evolution to carry out an essential function relative to the
nervous system.
3.3.3. Animal models
The evolutionarily conservation of the fragile X family has enabled the development
of various animal models that essentially recapitulate the phenotypic traits observed in fragile
X patients.
In addition to the mouse model (discussed above), a model for fragile X syndrome was
also generated in zebrafish. Indeed, inactivation of zFmr1 gene by morpholinos causes
abnormal axonal branching of Rohon–Beard and trigeminal ganglion neurons together with
guidance and defasciculation defects in the lateral longitudinal fasciculus. Interestingly
enough, Tucker and colleagues described novel findings of abnormalities in the abundance of
trigeminal ganglion neurons and of craniofacial abnormalities apparently due to dysmorphic
cartilage formation. The authors suggested that these abnormalities may be related to a role
for zFmr1 in neural crest cell specification and possibly in migration (Tucker et al. 2006).
In flies, dFMR1 mutants have abnormal circadian rhythms and courtship behavior
(Inoue et al. 2002; McBride et al. 2005). In the CNS mutant interneurons have abnormal
neurite extension, guidance and branching (Morales et al. 2002). In addition, these flies
showed developmental defects of mushroom body lobe morphogenesis, of which the most
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common is a failure of b lobes to stop at the brain midline (Michel et al. 2004). Interestingly,
this is an highly plastic brain region, known to have a role in multimodal sensory integration,
olfactory associative learning and visual context generalization. However, also peripheral
phenotypes have been observed including overgrown, dysfunctional motor neuron terminals
(Zhang et al. 2001) and overgrown sensory neuron dendritic arborescences (Lee et al. 2003).
The dFMR1 profile of expression is reminiscent of FXR proteins, since in addition to nervous
system a high expression is also found in muscle and gonads (Schenck et al. 2002). While the
eventual implication of dFMR in muscle development in fly was never investigated, in testis
Zhang and colleagues reported that dFMR mutants lose specifically the central pair
microtubules in the sperm tail axoneme. The frequency of central pair microtubule loss
becomes progressively greater as spermatogenesis progresses, suggesting that dFMR
regulates microtubule stability (Zhang et al. 2004).
The drosophila model provided a great input to understand the molecular function of
FMRP and was determinant for the identification of Futsch (homologue of MAP1B), the
interaction of dFMR with the RISC complex and the implication of dFMR in the Rac
pathway.
4. The Fragile X Mental Retardation Protein (FMRP)
4.1. Structural and Functional architecture of FMRP
As discussed in a previous paragraph, at a molecular level, FXS results from either an
absence of FMRP (in almost all cases of FXS patients) or from alterations in both structure
and function of FMRP (rare cases). RT-PCR analysis revealed the existence of more than 20
splice variants of FMR1 mRNA, which are translated in several FMRP isoforms, most
probably ten, detected as four to six different bands by western blot ranging between 70 and
80 KDa. The longest isoform, Iso1, encoded by the 17 exons , comprises 632 amino acids
while the most frequent isoform, Iso7, lacks exon 12 (Khandjian et al. 1995) (Figure 7).
FMRP is predominantly localized in the cytoplasm where it interacts with several
other proteins, however a small proportion of FMRP was also found in the nucleus suggesting
that FMRP could shuttle between the nucleus and the cytoplasm. Structural comparisons
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succeeded to predict the RNA binding capacities of FMRP and the major focus of this part is
the analysis of the function of FMRP through its different structural domains.
4.1.1. The N-terminus region of FMRP : a trap for proteins and
RNAs
4.1.1.1. Structural analysis of the N-terminus region of FMRP
Spanning the first 217 amino acids, this region shows a high affinity domain for
protein-protein interaction. Adinolfi and colleagues have identified an independently folded
domain within this region termed NDF (N-terminal Domain of FMRP) (residues 1-134)
(Adinolfi et al. 2003).  The structure of the NDF domain was investigated in details (Ramos et
al. 2006). NDF is formed by two repeats NDF1 (residues 3-50) and NDF2 (residues 63-113),
linked by an unstructured tail of 20 residues. The C- terminal domain of  NDF is formed by
residues 114-134, contains a single turn helix (α1 aa 122-126), but is unstructured. NDF2 is
less compact than NDF1, nevertheless both NDF1 and 2 are folded in four stranded
antiparallel β-sheet with a fifth strand serving to close the cavity of the sheet. Interactions
between these two domains occur mostly assisted by Trp and Phe residues. The succession of
these three structural motifs is essential for NDF stability, moreover mutations that destabilize
the NDF fold can dramatically affect the subcellular localization of FMRP. Double mutation
of amino acids 125 and 126 of the α1 helix of  FMRP Iso 12 (Iso 12 was previously shown to
distribute in the nucleus, mostly in perinucleolar region (Bardoni and Mandel 2002)) causes a
complete diffusion of Iso12 in the nucleus where a small portion (2-6% of observed cells)
remain perinucleolar reflecting the importance of the correctly folded NDF in the nucleolar
localization of FMRP.
Maurer-Stroh and colleagues used a comparative sequence analysis to predict that the
repeats observed in NDF domains share significant similarities with members of the “Royal”
superfamily including Tudor and Agenet domains. A four β-strand fold is a common feature
for the members of this family (Maurer-Stroh et al. 2003). When Ramos and colleagues
established the structure of the NDF domain, they demonstrated that its tudor  domains are
highly similar to those observed in SMN protein even if domains of both proteins share low
sequence identity (15%). Other similarities were found with the DNA binding domain of
HIV-1 integrase and the transcription elongation factor NusG from Thermus thermophilus
(Ramos et al. 2006). The hydrophobic pockets formed on the surface of NDF are mainly
involved in protein-protein interaction, nevertheless the high plasticity and dynamic
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exposures of hydrophobic cavities of NDF2 play a crucial role in the interaction with NUFIP
and 82-FIP (Bardoni et al. 2003a; Bardoni et al. 2003b; Bardoni et al. 2003c). (Figure 8)
4.1.1.2. Exon 7 and the Protein-Protein Interacting Domain
The secondary structure of the region encoded by exon 7 was predicted by multilple
alignment to fold in a helix-loop-helix motif . This region contains the dimerisation unit of
FMRP. Dimerisation could occur through pairing of the two motifs resulting in a four helix
bundle (Adinolfi et al. 2003). The domain encoded by exon 7 enables FMRP to interact with
itself, its other two homologues FXR1P and FXR2P, as well as CYFIP1 and CYFIP2
(Cytoplasmic FMRP Interacting Protein 1/2)  (detailed in next paragraphs)
4.1.2. NLS/NES condition the nucleocytoplasmic shuttling of FMRP
4.1.2.1. FMRP N-terminus contains a Nuclear Localisation signal
Exon six and seven encodes the second part of the N-terminus region of FMRP,
corresponding to amino acids 135-217. This segment reveals two important function of the
protein: a non classical nuclear localisation signal (NLS) and another platform for
dimerisation and protein- protein interaction.
Two different studies demonstrated the existence of an NLS in this region. Eberhart
and co-workers used truncated portions of the protein to better define the NLS. They were
able to prove that the first 167 amino acids of FMRP are sufficient for its localisation in the
nucleus. To strengthen their observations, they analysed the first 184 amino acids of FMRP
and showed that this region contains clusters of Lysine and Arginine (K, R ; 24 residues)
observed in most known NLSs (Eberhart et al. 1996). They suggested that FMRP may contain
a novel NLS sequence as the one observed in the U1A protein (Kambach and Mattaj 1992). A
more acute analysis performed by Bardoni and colleagues had refined the localisation of
FMRP NLS reported by the pervious group. The authors pointed out that the NLS activity is
localized in the region between residues 114-150, could be reinforced by residues 151-196
and that the cluster KK and KR in position 151-152 and 179-180 might positively modulate
the NLS activity (Bardoni et al. 1997)
Both studies demonstrated the absence of known NLS consensus which usually
consists of stretches of  Lys-Arg/Lys-X-Arg/Lys where X could be lysine, proline, arginine,
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valine or alanine (Chelsky et al. 1989). FMRP localization in the nucleus could be explained
by a three dimensional (3D) signal interacting with a nuclear carrier. Either the identification
of this partner or the destabilisation of the 3D fold by suitable mutations would better
enlighten the mechanism by which FMRP enters the nucleus.
4.1.2.2. Exon 14 encodes NES
Immunofluorescence experiments on cells transfected with FMRP isoforms lacking
exon 14 showed that the protein was completely captured in the nucleus (Sittler et al. 1996).
These observations lead to the identification of a NES encoded by exon 14 (Eberhart et al.
1996). Standing at the C-terminal end of the KH2 domain, this region did not seem participate
in the stabilization of KH2. The sequence involved in the nuclear export LRLERLQI is
similar to that observed in the Rev protein. The fold adopted by the NES was predicted to be a
coiled-coil which would not be possible due to its length and composition. It is more probable
that the sequence encoded by the exon 14 forms a helix which may interacts with other
regions of FMRP. The presence of both NLS and NES in the sequence of the protein
suggested that FMRP is able to shuttle between the nucleus and the cytoplasm. This
hypothesis was confirmed by Tamanini and colleagues who blocked the nuclear export by
treating cells with leptomycin B. In these conditions, a clear accumulation of FMRP in the
nucleus was observed (Tamanini et al. 2000). Using electron microscopy, Feng and
colleagues showed that FMRP is present near the nuclear pores (Feng et al. 1997), this would
suggest that some of FMRP are in their “transit” way from the nucleus to the cytoplasm.
4.1.3. The Phosphorylation domain : keep a low profile and execute
silently
Analysis of the phosphorylation status of FMRP revealed that only one region could
be affected (aa 483-521) with either one, two or three phosphoresidues. The 38 amino acid
peptide was assigned as the phosphorylation domain of FMRP located between the NES and
the RGG box (Ceman et al. 2003). The effect of this post translational modification on FMRP
function was analysed by two different groups resulting in contradictory observations. In
mouse, the phosphorylation does not affect the ability of FMRP to associate with RNA
(Ceman et al. 2003) which was not the case observed in drosophila (Siomi et al. 2002).
Under steady-state conditions, the phosphorylation status of FMRP does not seem to
play a role neither in the subcellular localization of FMRP nor in its association to polysomes
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(Ceman et al. 2003). However, ribosome run-off experiments performed by this group
showed that unphosphorylated FMRP (associated with actively translating polysomes) runs-
off more quickly than phosphorylated FMRP, which appears resistant to run-off and may be
associated with stalled polyribosomes.
Recently, it was shown that FMRP interacts with MSP58, an RNA binding protein,
through its phosphorylation domain. The RNA binding characterization of MSP58 is the
subject of publication 3.
4.1.4. The RNA-binding domains
4.1.4.1. A glance at the N-terminus region of FMRP as an RNA binding
domain
Structural definition of the N-terminus domain established by Adinolfi and colleagues,
showed an amino acids distribution typical of globular domains. A helical predominance, as a
secondary structure element was predicted by multiple alignment suggesting that the first 217
amino acids of the protein should be able to fold, either alone, or with other region of the
protein, into a globular domain. An α-helix structure was revealed by Circular Dichroism
analysis but the three dimensional globular fold was not demonstrated.
The N-terminus region showed an affinity for RNA homopolymers at physiological
salt concentrations, but this binding was completely abolished at high salt concentrations
where only specific interactions occur due to high ionic strength. In the absence of any
specific mRNA sequence bound by FMRP, the authors used the RNA homopolymers. They
suggested that the disability of the N-terminus region to bind these stretches at high salt
concentrations is only because they are recognized and bound to the protein fragment by
electrostatic forces which are completely destabilized at high salt concentrations (Adinolfi et
al. 1999). The authors did not define the motif responsible for this interaction nevertheless,
they hypothesised that both the RNA binding site would act in competition with the NLS and
that in the nucleus, the protein would bind to a mRNA (the specificity of this interaction is
conferred by other regions of the protein) and to some other proteins. Once the complex is
formed, the NLS is therefore masked and the complex is exported to the cytoplasm.
Four years later, the same group developed an extensive biochemichal and biophysical
characterization of the N-terminus of FMRP and showed that the NDF is not only able to
interact with NUFIP1 and 82-FIP but to homodimerize as well as  to bind RNA
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homopolymers even at high salt concentrations. The authors demonstrated that the NDF binds
with high affinity to polyU and polyA homopolymers and that this affinity decreases
progressively with the length of the fragment. Furthermore they showed different sequence
specificities for the homoplymers when using different fragments of the N-terminus region
suggesting that different binding sites could exist along the N-terminus and act cooperatively
for the binding to RNAs (Adinolfi et al. 2003).
4.1.4.2. The KH  homology domains of FMRP
The fascinating diversity of functions accomplished by FMRP as an RNA binding
protein would suggest a large diversity in the structures that are responsible for the RNA
recognition. However, like other RNA binding proteins, FMRP contains “multiple copies” of
RNA binding domains in a various structural arrangements expanding its specificity while
fishing its target mRNAs. The “multiple copies” of these modules allow any protein to bind
RNA with high affinity and specificity than would be possible with individual domains which
often binds RNAs with a weak affinity. The advantage of having multiple copies of the same
domain as an interaction surface will result in high affinity and specificity by combining
multiple weak interactions permitting a very dynamic assembly/disassembly of the
protein/RNA complex when needed.
In addition to the tudor domains, FMRP also contains 2 KH domains spanning amino
acids 216-404. Both of them present the characteristics of KH domains type I.
The heterogeneous nuclear (hn)RNP K-homology domain (KH domain) is around 70 amino
acids with a functionally important signature sequence of (I/L/V)IGXXGXX(I/L/V) mostly
located in the centre of the domain. A three stranded β-sheet packed against three α helices is
the most common feature of all known KH domains.
KH are divided in two distinct types : type I KH domains fold in a βααββα topology with an
antiparallel β-sheet that features β3 as the central strand , while type II domains have a
αββααβ topology and a β-sheet in which β2 is the central strand that is parallel to β3 and
antiparallel to β1. The two consecutive a-helices are connected by the so-called ‘GXXG
loop’, which is part of the conserved sequence motif.. Four nucleotides are recognized in a
cleft that is formed by the GXXG loop, the flanking helices, the β-strand that follows a2 (type
I) or a3 (type II) and the variable loop between β2 and β3 (type I) or between a2 and β2 (type
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II). This binding platform is free of aromatic amino acids; recognition is achieved instead by
hydrogen bonding, electrostatic interactions and shape complementarity.
The crucial role(s) that the KH domains may play in FMRP functions were widely
debated after the I304N mutation was reported. Indeed, while in almost all FXS patients
FMRP is not detected, one patient presenting severe symptoms appeared to have a mutation in
the KH2 domain were an Isoleucine in position 304 is replaced by an Asparagine (De Boulle
et al. 1993). The effect of this mutation on FMRP function is dramatic, partial or complete
abolishment of its RNA binding properties were reported (Siomi et al. 1994; Brown et al.
1998), nevertheless this property was very slightly affected when the binding of the mutant
protein to EF-1A mRNA was analyzed (Sung et al. 2003).  Its association to polyribosomes
was also altered (Feng et al. 1997) and its presumed role in translation regulation of its target
mRNAs was completely abolished (Laggerbauer et al. 2001). Same observations were
reported in KH mutants in drosophila (Banerjee et al. 2007). In the absence of any three-
dimensional structure, it had been suggested that the mutation would disrupt the folding of the
domain. This hypothesis was issued from comparison with the a similar mutation in the KH
domains of vigilin and Nova resulting in an unfolded domain (for review(Musco et al. 1996)).
Another hypothesis was also given for the direct involvement of the mutated residue in RNA
binding.
The mystery of this scavenging mutation was brought to light by Valverde and
colleagues who provided for the first time the structure of the KH1-KH2 domain (Figure 9).
Two major points were revealed by the authors. First they demonstrated that the KH1-KH2
domain is a monomer in solution by both gel filtration chromatography and sedimentation
equilibrium ultracentrifugation measurements. Second, they showed that the Isoleucine 304
forms part of an extensive network of hydrophobic residues stabilizing the a1, a2 and a’ on
the b sheet of the KH2. This position is completely inaccessible, thus demonstrating that the
Ile304 doesn’t participate in direct contact with RNAs and the fact that it resides in a
hydrophobic core, its substitution with an Asparagin would disrupt the core and destabilize
the protein. In sum, this mutation causes a decrease in both the secondary structure of FMRP
and its stability (Valverde et al. 2007).
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4.1.4.3. The RGG box : a real “hotspot” box trapping specifically mRNAs.
Despite their low homology degree in the C-terminus region, the three FXR family
members contain clusters of Glycin and Arginin named RGG box which was first identified in
hnRNPU protein. Many other RNA binding proteins were than shown to contain this motif
(Kiledjian and Dreyfuss 1992). The Glycin-Arginin rich sequence is able to confer to its
containing protein, the ability to bind RNA. It was also predicted that the interaction with the
RNA occurs through electrostatic forces in an unspecific manner. The RGG box of FMRP
spans residues 527 to 558, this fragment of the protein was shown to be unstructured when
produced alone (Ramos et al. 2003), however it was used for in vitro binding assays and
showed to be able to bind an RNA structure called “G-quartet”(Darnell et al. 2001).
Biophysical analysis revealed that G-quartets are required but not sufficient for FMRP RGG
box binding and that this interaction, when it occurs, should act on stabilizing the G-quartet
structure (Zanotti et al. 2006). This domain was also shown to be necessary for driving FMRP
to granules and its RNP complex assembly (Mazroui et al. 2002). The authors used truncated
fragments of the protein and the question of the “intact” global folding of FMRP in the
absence of some domains was not verified. The interaction RGG-G-quartet will be discussed
later and was the aim of publication 2.
4.2. Protein interactors
4.2.1. FMRP is able to homo and hetero-dimerize
The ability of exon 7 to confer a platform for homo/heterodimerization was clarified
by Adinolfi and colleagues. The authors used biophysical coupled to structural techniques
claiming that previous studies were carried out with deletion mutants of the N-terminus
region of FMRP based on exon boundaries without any structural indications. The major risk
with such approach is that a negative result does not reflect necessarily the direct involvement
of a region in the interaction but the loss of a region structurally essential. The authors
suggested that NDF strongly mediates the dimerization and that it remains possible that other
dimerization sites can cooperatively determine the dimer stability of the full-length protein.
One candidate to such hypothesis is the helix-loop-helix encoded by exon 7 that could pack
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either against other proteins or against distal regions of FMRP such as the KH
domains(Adinolfi et al. 2003). Only a three dimensional structure of the full length protein
would enlighten the potential of either hypothesis to fine tune the dimerization of the protein.
 FMRP together with FXR1P and FXR2P share a high sequence homology degree that
can also be reflected in their functional domains. The RNA binding domains especially the
KH and the Tudor domains are very similar in all of the three proteins. Their ability to shuttle
between the nucleus and the cytoplasm and their belonging to several RNPs especially the
polyribosomes and their involvement in the translational control was extensively analyzed. By
comparison, It was suggested that these proteins may have a similar or redundant function and
that they could to some extent compensate the absence of FMRP (Figure 10), therefore
explaining the heterogeneity of symptoms in FXS patients. Molecular function of FXR2P is
still poorly investigated, nevertheless FXR1P started to arise attention.
4.2.1.1. FXR1P and FMRP : similar but so different.
FXR1P is widely expressed in all cell lines and mouse tissues analyzed. Seven distinct
protein isoforms were detected among which, the two longest 82 and 84 KDa (Isoe and Isof)
are only expressed in skeletal muscle and heart (Bakker et al. 2000; Dubé et al. 2000). FXR1P
Isoe and Isof expressed at low level are sequestered in the nuclei of undifferentiated
myoblasts, whereas they are associated with cytoplasmic mRNPs in myotubes. Moreover,
accumulation of FXR1P Isoe and Isof coincides with expression of different myogenic
markers (Dubé et al. 2000).
In testis, FXR1P showed a restricted expression  in A-type spermatogonia in young
animals (6 days). At day 14, an increased presence of FXR1P was observed in primary
spermatocytes at early pachytene stage, whereas at day 20 a positive cytoplasmic signal was
observed in almost all cells ranging from pachytene to round spermatids. In adult mice no
staining was observed in lumen devoid of mature spermatozoa. FXR1P is localized in tail of
mature spermatozoa associated to microtubules (Huot et al. 2001). Interestingly, the isoforms
present in spermatozoa tail are Isog and Isoe, also found in adult muscle.
Involvement of FXR1P in several processes was reported. It was suggested to be a target for
autoimmune response in humans. Patients affected by scleroderma or progressive systemic
sclerosis (PSS) showed autoimmune IgGs to FXR1P (Bolivar et al. 1998).
In addition, FXR1P has been reported to bind the AU rich element (ARE) and, through
the interaction with this element, to regulate the expression of the proinflammatory cytokine
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tumor necrosis factor (TNFα) RNA in macrophages (Garnon et al. 2005). Starting from this
observation, Vasudevan and Steitz have shown that the TNFα ARE upregulates translation in
response to cell-cycle arrest in HEK293 cells and in THP-1 monocytes when induced by
serum starvation or other treatment. Since this upregulation appears to have a physiological
relevance because the cell-cycle accompanies the differentiation of monocytes into
macrophages in vivo, the authors identified different ARE-associated proteins. They found
that FXR1P and AGO2 associate with TNFα ARE and function as translation activators in
response to serum starvation. Indeed the mechanism of translation activation by the
FXR1P/AGO2 ARE complex seems to involve the recruitment of the TNFα mRNP to heavy
polyribosomes upon serum starvation (Vasudevan and Steitz 2007).
Furthermore, they extended their analysis to better decipher the mechanism that leads
to translation activation. They found that base-paring of the microRNA miR369-3 with two
UAUUAUU sequences contained in the TNFα ARE may be at the basis of recruitment of
microRNP that may mediate translational activation in G1/G0 phases of cell cycle
(Vasudevan et al. 2007). On another hand, FXR1 was reported to be one of the most
frequently overexpressed genes in the center of the amplified chromosomal domain in
squamous cell carcinomas together with CLAPM1 and EIF4G (Comtesse et al. 2007).
Specific function of FXR1P in brain is still unknown, however, some emerging
hypothesis about its key role in muscle development start to elucidate its molecular properties.
Huot and colleagues used a Xenopus model and by microinjecting morpholino
oligonucleotides targeting the xFxr1 sequence, they were able to show that MyoD expression
is disrupted, somitic myotomal cell rotation and segmentation are inhibited and an abnormal
dermatome formation leading to a dramatic muscle specific effect during embryogenesis.
Moreover, using microarray analyses, the authors demonstrated that genes whose expressions
are altered by the inactivation of xFxr1 are mostly involved in development of nervous system
and myogenesis (Huot et al. 2005).
A better understanding of the molecular functional analogy between FMRP and
FXR1P was the aim of publication 2 and will be discussed later.
4.2.1.2. FXR2P and FMRP : back to back or separate ?
Little is known about the function of FXR2P, its RNA binding properties were never
investigated despite the high homology that it shares with FMRP in the functional domains.
However, a pattern of expression was established form both human and mouse tissue sections.
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FXR2P is expressed in organs affected by the FXS and the pattern of tissue distribution is
highly similar with slight differences between the three members. A clear cytoplasmic
expression of FXR2P in the Purkinje, cortex and brain stem neurons is found. However a
stronger labelling of the FXR proteins was seen in the proximal dendrites of cortex and brain
stem neurons. This distribution was not affected in the absence of FMRP in brain tissue
section of FXS patients. In adult testes, FX2P is expressed in early spermatogonia and its
expression is also detected at high levels in maturing spermatogenic cells (Bakker et al. 2000).
4.2.2. FMRP interacts with the nucleocytoplasmic RNA binding
proteins NUFIP1 and 82-FIP
4.2.2.1. NUFIP (Nuclear FMRP Interacting Protein)
NUFIP1 is a 495 amino acid protein containing a C2H2 zinc finger motif. This motif is
a folded domain that contain conserved cysteines and histidines coordinated to zinc. Proteins
with such motifs can bind to either DNA or RNA basically by the same mechanism of
recognition. Generally, A single C2H2 zinc finger, composed of a β-hairpin and an α-helix
held together by a tetrahedrally coordinated zinc ion, will span a DNA or RNA sequence of
three or four consecutive base pairs. Frequently, the contacts are made by the side chains of
amino acids located at positions -1, +2, +3 and +6 of the α-helix.
NUFIP1 is able to bind RNA  probably via another unknown motif. Mutations in the
zinc finger domain of the mouse NUFIP1 did not alter its binding to RNA homopolymers in
vitro. It possesses a NLS and a Nuclear Export Signal (NES) that allows it to shuttle between
the nucleus and the cytoplasm where it is associated to polyribosomes and colocalizes with
ribosomes in active synaptoneurosomes. In the nucleus, NUFIP1 is found in a micropunctuate
pattern where it colocalizes with FMRP’s nuclear isoforms. NUFIP1 is expressed in neurons
of the cortex, the hippocampus and the cerebellum suggesting that NUFIP1/FMRP interaction
is relevant for neuronal function in vivo. NUFIP1 interacts specifically with FMRP but
doesn’t reveal any interaction with neither FXR1P nor FXR2P despite the high homology
degree that the FXR proteins share. Co-transfection experiments of both NUFIP1 and FMRP
ISO12 modifies the distribution of the latter in a dot-like nuclear structure suggesting that
NUFIP1/FMRP interaction in the nucleus may target the latter to specific subdomains
relevant for its putative nuclear function (Bardoni et al. 1999).
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NUFIP1 was previously reported to show a specific NUFIP1/BCRA1 interaction that
stimulates specifically the activator-independent pol II transcription in the nucleus (Cabart et
al. 2004). More recently, NUFIP was characterized as one of the four novel box C/D snoRNP
biogenesis factors : BCD1, NOP17, NUFIP and TAF that are associated with U3 and U8 pre-
snoRNP complexes and involved in their biogenesis. In the nucleolus, the eukaryotic rRNAs
are cotranscribed as a large precursor RNA (pre-rRNA) which will be subjected to a complex
series of processing and modification steps to generate the mature rRNAs. Small nucleolar
RNAs (snoRNAs) are an evolutionarily conserved group of noncoding RNAs involved in the
modification and processing of rRNAs. Two classes of snoRNA have been defined; the
H/ACA and box C/D snoRNAs. NUFIP interacts with all four of the core box C/D snoRNP
proteins and play a crucial  role in the early stages of pre-snoRNP assembly, possibly in the
initial recruitment of the box C/D core proteins. One of the proposed mechanism is that these
biogenesis factors may form an extensive and potentially repeating scaffold around which the
pre-snoRNP is assembled (McKeegan et al. 2007)
Taken together, all these observations may suggest that NUFIP1 may shuttle between
different complexes linking transcription, biogenesis and assembly of snoRNPs and mRNA
export from the nucleus.
4.2.2.2.  82-FIP (82 KDa FMRP Interacting Protein)
82-FIP is a 695 amino acids protein, its sequence shows no homology to any protein of
known function. In neurons of the cortex, 82-FIP is distributed in both nucleus and cytoplasm,
colocalizing with FMRP. Nevertheless, it shows a specific cytoplasmic pattern in neurons of
the dentate gyrus, in the olfactive bulb, in the ependymal epithelium and in the granular layer
of the cerebellum. 82-FIP is an RNA binding protein with high affinity for A-homopolymers,
it binds specifically to FMRP but shows no affinity to neither FXR1P nor FXR2P. In the
cytoplasm, it is associated to polyribosomes and this association is not altered in the absence
of FMRP. Surprisingly, the distribution of 82-FIP is cell cycle dependant, being mostly
cytoplasmic in the G2/M phase and strictly nuclear in G1 phase. These observations
suggested the highly dynamics of FMRP containing mRNPs could be modulated by the cell
cycle in growing cells (Bardoni et al. 2003a).
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Both NUFIP1 and 82-FIP binds to FMRP via its NDF, partially overlapping the NLS.
This would suggest, that FMRP is either driven to the nucleus with one or both of them or that
it remains in the cytoplasm due to the interaction that might mask its NLS.
4.2.3. FMRP interacts with the cytoskeleton-linked proteins
CYFIP1 and CYFIP2
4.2.3.1. Cytoplasmic FMRP Interactor Proteins
Identified by yeast two hybrid system, CYFIP1 and its homologue CYFIP2 showed a
high homology degree (88%). Highly conserved among species, their sequences didn’t match
with any known functional motifs. In the cytoplasm, their pattern expression completely
overlaps with that of FMRP and colocalize with the latter on ribosomes. They were also
observed in dendrites. Both of them exhibited a direct interaction with FMRP via the exon 7
previously described as the dimerization motif, suggesting a role for CYFIP1/2 in the
modulation of homo and heterodimerization and therefore affecting the RNA binding
properties of FMRP, FXR1P and FXR2P. They didn’t show any affinity for RNAs, however
both proteins are linked with Wave complex involved in the regulation of actin nucleation via
Rac1 (Schenck et al. 2001). Indeed, CYFIP2 interacts with FXR1P and FXR2P from one side
and with WAVE-1 (member of Wiskott-aldrich syndrom protein) from another, this protein
family is involved in connecting stimulatory signals to actin cytoskeletal organization.
Whereas CYFIP1 interacts only with FMRP and show no affinity for neither FXR1P nor
FXR2P, it also interacts with RhoGTPase Rac1 (component of RhoGTPases involved in
Mental Retardation). The Drosophila CYFIP was shown to play a pivotal role in
establishment of neuronal connectivity, defining interaction between Rac1 and FMRP
(Schenck et al. 2003).
4.2.4. Other Interactors
Many RNA binding proteins were found to interact with FMRP. Beside those already
discussed above, FMRP was shown to interact with IMP1, dicer and eIF2C2, and to be part of
a large mRNP complex containing nucleolin, YB1/p50, purα, and Staufen. These interactions
were only demonstrated by immunoprecipitation analysis and a direct interaction between
FMRP and those partners still needs to be clarified. All these interactors would link FMRP to
several pathways involved in mRNA metabolism.
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4.3. FMRP RNA targets : fishing for specificity
4.3.1. FMRP and mRNA  : Identification of  in vivo putative targets
How does FMRP bind to its target mRNAs in vivo ? Does it act alone or assisted by its
partners? What might be the fate of its ligands?
A critical step in the understanding of FMRP function is first, the identification of its
mRNA targets and second, the characterization of the functional significance of each
validated target. This  would give new insight in global mechanism of mRNA translation
regulation mediated by FMRP.
In order to identify “global” FMRP-related mechanisms of mRNA recognition,
different methodologies have been developed and applied by several groups.  Starting from
mouse brains, a large screen with microarrays analysis was used by Brown and colleagues
who were able to identify 432 mouse mRNAs co-immunoprecipitated with FMRP-RNP
complex. In the same study, they analyzed polyribosomal fractions obtained from human
lymhoblasts. They obtained 251 mRNAs differentially distributed along the polyribosomes in
patients and normal individuals (Brown et al. 2001). Some mRNAs with an important
neuronal function were identified, such as MAP1B, Semaphorin. Only eight of the idendified
mRNAs were predicted to contain a G-quartet structure (Darnell et al. 2001).
Miyashiro and colleagues had developed an in situ approach, APRA (Antibody
Positioned RNA Amplification) to identify direct mRNA binding to FMRP/ FMRP-associated
RNP particles. 81 mRNAs were identified by this study and 60% were shown to be directly
associated to FMRP. A subset of these mRNAs displayed slight changes in either expression
levels and/or subcellular localization in Fmr1 knockout mice brains. Important neuronal
functions such as cytoskeleton structure and function, synaptic signaling and nuclear
trafficking were the most relevant functions of proteins encoded by these mRNAs (Miyashiro
et al. 2003). The Sod1 (Super Oxide dismutase 1), one of the identified mRNAs by this study,
was analyzed in detail and is the subject of publication 1.
The weak overlap between the mRNA populations identified in both studies is mostly
due to the microarrays where only a small overlap of probes was present and the distinct
experimental procedures used by both groups.
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A huge amount of data about putative FMRP mRNA targets was delivered but only a few
specific interactions were analyzed and the functional significance of FMRP-mRNA
interaction is still poorly investigated. In the next part I will overview the approaches used by
several groups to analyze FMRP targets.
4.3.1.1. Targets (if any!) of the N-terminus
BC1 (Brain Cytoplasmic RNA 1) and BC200 (Brain Cytoplasmic RNA 200-nt) RNAs
are small non coding RNAs (ncRNAs) transcribed by RNA polymerase III. Most ncRNAs
associate with proteins and contribute to the assembly of RNP complexes. BC1 and BC200
share little sequence homology but predicted to form similar secondary structure (Figure 11).
Both of these cytoplasmic RNAs are specifically expressed in neurons and are actively
transported to dendrites (Tiedge et al. 1993a; Tiedge et al. 1993b). In cultured hippocampal
neurons, the expression of BC1 is first detected at the onset of synaptogenesis, and the
expression level is reversibly regulated by neuronal activity (Muslimov et al. 1998). Owing to
their evolutionary origins, BC1 and BC200 have been subject to speculation that they
participate in the regulation of protein synthesis in neuronal dendrites because BC1 arose
from a tRNA and BC200 represents the Alu domain of SRP RNA, the domain involved in
translation arrest. Both RNAs interacted with poly(A)-binding protein, a regulator of
translation initiation. BC1 affected translation by inhibiting the formation of the pre-initiation
complex, and the inhibitory effect was not restricted to particular mRNAs (Wang et al. 2002).
A very speculative model for RNA translation regulation by FMRP via its interaction
with BC1 was proposed by Zalfa and colleagues. The authors used an extremely elegant
analysis proving the direct interaction between FMRP and BC1 in both co-
immunoprecipitation and band shift analysis at “high-stringent” salt concentrations (Zalfa et
al. 2003). They claimed that BC1 binds to FMRP and associates with mRNAs thus bridging
FMRP to mRNAs.
Two years later, the authors went further to analyze the specific interaction
FMRP/BC1 and demonstrated that the N-terminus region of FMRP binds BC1/BC200 RNA.
More precisely they delimited the interaction domain and sequence and concluded that the
helix-loop-helix formed by the amino acids 181-214 binds to a stem loop formed by
BC1/BC200 (Zalfa et al. 2005).
FMRP/BC1 interaction was controversially debated and many technical points
achieved by Zalfa and colleagues were severely criticized.
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The use of “non physiological conditions” together with a high molar excess of
recombinant protein able to shift a small fraction of labelled BC1 in gel shift experiments.
Recently, several laboratories have shown that any specific interaction between FMRP and
BC1 could occur neither in vitro using gel shift and filter binding assays in presence of
specific RNAs as competitors, nor in vivo proving that the “love story” FMRP/BC1 was an
illusionary artefact (Iacoangeli et al. 2008).
In summary, the N-terminus domain of FMRP contains an RNA binding motif  for whom no
specific mRNA target was actually found.
4.3.1.2. KH2 and mRNAs : the Kissing complex, another genuine love
story.
The clinical relevance of the I304N mutation had, to some extent, attributed to the
KH2 domain a crucial role in FMRP functions. Up to date, any mRNA was shown to be
specifically bound by this domain, however, using the SELEX technique, Darnell and
colleagues provided a synthetic aptamer structure called the “Kissing complex” able to be
recognized by the KH2 domain (Darnell et al. 2005). This kissing loop-loop interaction were
first described in tRNAs and in most cases polycistronic messengers of diverse origins
(retrovirus, yeast retrotransposon Ty, several prokaryotes) are also affected. It occurs by the
hybridyzation between two stem-loops which starts with the formation of base pairs between
the complementary loop regions of two hairpins generating a kissing hairpin complex. They
are known to be involved in protein expression and especially in the modulation of the
translation rate of several messages (for review (Paillart et al. 1996)). Recently, Bindewald
and colleagues have developed an algorithm predicting the putative formation of a kissing
loop between two sequences (Bindewald et al. 2008). The kissing complex (Kc1) identified
by Darnell and colleagues, is a 96 mer-RNA. It harbors two stem-loops, with a short single
stranded region between them. Specifically recognized by the KH2 of FMRP when both stem-
loops are present in the same molecule. The interaction KH2-Kc1 is coordinated by Mg2+
which is necessary for the folding and stabilization of the stem region and that pairing of
loops occurs through 4 bases (Figure 12). The mutated KH2 domain (I304N) was not able to
recognize the Kc1.
The I304N mutation was reported to disrupt the association of FMRP to
polyribosomes, reflecting the importance of the KH2 domain in this phenomenon (Sung et al.
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2003). Darnell and colleagues analyzed the effect of the kissing complex structure on FMRP
association to polyribososmes. They incubated brain extracts with increasing amount of
kissing complex and followed the distribution of FMRP on polyribosomes after
ultracentrifugation. They were able to demonstrate that 100 nM of Kissing complex compete
FMRP off the polyribosomes, leading to a general conclusion that such structures would
mediate the association of FMRP to polyribosomes (Darnell et al. 2005). Still a nascent hope,
using the algorithm developed by Bindewald and colleagues, to find in vivo kissing complex
structures, analyze their physiological relevance of their interaction with FMRP and its
putative involvement in the disease.
4.3.2. The G-quartets structure
4.3.2.1. The G-quartets : where are they? What do they do?
A very simplistic way to define these structures is:”G-quartets are nucleic acid
structures in which four guanine residues are arranged in an planar conformation stabilized by
Hoogsteen-type hydrogen bonds, several of theses structures can stack and be stabilized by
different ions” (Keniry 2000). A number of techniques have been proposed to monitor G-
quartet formation: NMR, crystallography, circular dichroism, Raman spectroscopy, gel
electrophoresis, nuclease sensitivity, photocrosslinking, chemical probing, calorimetry and
ultraviolet absorption. These structures are stabilized by the coordination of monovalent
cations. G-quartets can be either intermolecular or intramolecular. There are several major
differences between these two species. Intermolecular quartets involving four “independent”
strands are usually parallel-stranded, and in many cases, all guanines are in the anti-
conformation, they are stabilized by high Na+ concentrations and form very slowly in vitro.
Whereas, the intramolecular G-quartets fold rapidly adopting different conformations and
stabilized by K+ and completely destabilized by either Na+ or Li+. In cells, predominantly
existing is the stable intramolecular structure due to high K+ concentration (Figure 13).
Several bioinformatics programs were developed to search for sequences that may
adopt a G-quartet structure (RNABOB and RNAMOT). Based on the use of a “canonical
sequence”: DDGG-N(0-2)-DDGG-N(0-2)-DDGG-N(0-2)-DDGG (D could be any nucleotide
except C), such programs might be useful to some extent, nevertheless they do not take the
purine quartets into account and predicting the presence of G-quartets needs to be confirmed
experimentally.
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The major contribution of G-quartets at the DNA level is the stabilization of telomeres
whereas several involvements of these structures were observed at the RNA level. They
would affect the splicing simply by preventing the binding of splicing factors as observed in
the case of human growth hormone (Cogan et al. 1997). Intermolecular G-quartets were also
shown to inhibit the translation initiation of gene 2 of bacteriophage Fd (Oliver et al. 2000).
Another aspect of translational control affected by the presence of G-quartets was observed in
the fibroblast growth factor 2 FGF-2 where it mediates an IRES dependant translation that
generates four FGF-2 isoforms.
4.3.2.2. RGG-G-quartet interaction : the hidden facet of FMRP
predilection
In 2001 , two different groups demonstrated for the first time a specific interaction
between FMRP and a G-quartet structure (Darnell et al. 2001; Schaeffer et al. 2001).
Nevertheless, little is known about the structural features that rule this interactions. The first
group established, using the SELEX technique, an aptamer (SC1) forming G-quartet and
bound by the RGG box (Figure 13).
The SC1 was shown to have only two G-tetrads and its binding to the RGG box may
be assisted by hairpin structures formed by the surrounding nucleotides establishing necessary
contacts to stabilize the complex structure (Darnell et al. 2001).
Meanwhile, the second group came out with the “physiological” mRNA containing a
G-quartet and specifically bound by FMRP (Schaeffer et al. 2001). Based on previous
observations assuming that FMRP is able to bind its own mRNA (Ashley et al. 1993; Ceman
et al. 1999). Schaeffer and colleagues proceeded by deletion and ladder selection experiments
to define the precise binding site within the 3.69 Kb FMR1 mRNA. They were able to isolate
a fragment of 100 bases corresponding to nucleotides 1557-1658 in the 3’ terminal part of the
FMR1 mRNA coding region. Using a vast repertoire of chemical and enzymes for probing
experiments combined to reverse transcription assays in presence of different ions, they
showed that this fragment is able to fold in a G-quartet structure bound by FMRP with high
affinity (1 nM). Two major conclusions were drawn from these observations, the authors
relocated the binding site of FMRP in the coding region of FMR1 mRNA and not in its
3’UTR as previously reported (Brown et al. 1998), the binding occurs “specifically” with an
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affinity higher at least 10 folds than that observed by Brown and colleagues who performed
their binding assays in the absence of specific competitors (Brown et al. 1998).
To conclude, Schaeffer and colleagues subtly provided firm proofs about experimental
procedures for both the detection of a G-quartet structure and the RNA binding affinities of
FMRP.
Only two mRNAs were analyzed in detail and showed a G-quartet fold in their
structure , FMR1 (Schaeffer et al. 2001) and PP2A (Castets et al. 2005a). However several
other mRNAs were reported as putative G-quartet containing mRNAs. These reports were
based on binding assay experiments in presence of different cations, MAP1B (Darnell et al.
2001), Semaphorin 3F (Darnell et al. 2001; Menon and Mihailescu 2007), or prediction by
alignments with “canonical motif” in the absence of any structural experimental assay, PSD-
95 (Todd et al. 2003), APP (Westmark and Malter 2007).
4.3.2.3. Functional relevance of FMRP-G-quartet interaction : “up close
and so tight !”
It is very tempting, at some points, to simply speculate: “FMRP binds tightly G-
quartets, keeps them along its travel and releases them just to obey cell laws.” A large debate
of “how could FMRP regulate its G-quartet containing mRNAs?” persists. I will detail
thereafter the mRNA “containing” G-quartet recognized by FMRP.
MAP1B
The MAP1B (Microtubule Associated Protein 1B), homologue of the drosophila futsh
protein, plays a microtubule stabilizing role and it is required for dendritic and axonal
development. Futsch mutant flies show defects in microtubule loop domains similar to those
appearing in collapsing growth cones. MAP1B is a scaffold protein that interacts with several
other proteins such as gigaxonin that links microtubules and intermediate filaments and is
involved in giant axonal neuropathy (Roos et al. 2000). MAP1B mRNA was predicted to have
a putative G-quartet present in its 5’UTR, bound by FMRP in vitro (Darnell et al. 2001), co-
immunoprecipitated with FMRP and its distribution along the polyribosomes was altered in
the absence of FMRP (Brown et al. 2001). A further analysis of this mRNA in brain neuron
development was reported by Lu and colleagues. In this study the authors confirmed the “so-
called” direct interaction FMRP-MAP1B mRNA by immunoprecipitation experiments and
stipulated that FMRP exerted a negative translational control on this mRNA (Lu et al. 2004).
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To my knowledge, any experimental data was delivered proving the presence of a G-quartet
in the MAP1B mRNA, moreover, the detection of an mRNA by immunoprecipitating FMRP
reflects its belonging to the FMRP-RNP complex and, in any case, its direct interaction with a
any specific protein of this complex.
Zhang and colleagues had previously reported the link dFMR-Futsch-control of
synaptic structure and function (Zhang et al. 2001) suggesting that this mechanism could be
evolutionary conserved. However, giving a deeper alignment analysis among different species
of the region predicted to form a G-quartet in the MAP1B, it is clearly obvious that this region
is not conserved between MAP1B and Futsch. Thus, a direct interaction FMRP-MAP1B via a
G-quartet, if any, should be investigated in a more detailed analysis.
PSD95
Another mRNA, PSD95 (Post Synaptic Density 95) was also among the mRNAs
predicted to form a G-quartet structure in its 3’UTR (Todd et al. 2003). This observation was
also provided by alignment comparisons with the “canonical sequence”. Any direct
interaction was analyzed until Zalfa and colleagues scrutinized the FMRP-PSD95 interaction
and showed that PSD95 mRNA does not form a G-quartet structure, nevertheless it binds in a
sequence specific manner to the C-terminus part of FMRP. They also demonstrated that
FMRP-PSD95 interaction is not affected by the presence of high Lithium salt concentrations
excluding definitely the presence of a G-quartet in this mRNA. In this study the authors
revealed that FMRP would positively regulate the stability of this mRNA.(Zalfa et al. 2007).
Any information about the specificity and the affinity of this interaction was reported by the
authors. As discussed above, the C-terminus region of FMRP recognizes mRNAs most
probably via a “fit” mechanism thus it is more convincing that it is able to recognize a
“structure” rather than a sequence. Once again, a more “appropriate” analysis is of great
interest to better understand the FMRP/PSD95 direct interaction, and a more “appropriate”
experimental procedure is needed to prove or exclude the presence of G-quartet in PSD95
mRNA.
APP
The most intriguing case in the FMRP-G-quartet story was provided recently by
Westmark and colleagues. The authors showed that FMRP binds the amyloid precursor
protein (APP) mRNA and negatively regulates its translation (Westmark and Malter 2007).
APP plays crucial role in synapse formation in developing brain and is at the basis of senile
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plaques found in brain patients affected by Alzheimer disease. The authors used the alignment
with the canonical sequence and showed a perfect match, predicting the presence of a putative
G-quartet formed by the nucleotides in position 951 to 972 within the coding region of APP
mRNA. Nevertheless, this  motif did not seem to be recognized by FMRP as shown in
Ribonucleases (T1) digestion assays. Strikingly, FMRP recognized, bound and protected a G-
rich sequence just upstream the putative G-quartet (699-796). This interaction did not affect
the stability of the APP mRNA as shown for PSD95. FMRP-APP interaction should be
revisited with a sharper approach to better define both domains (protein and RNA)
contributing to this interaction.
FMRP-PP2A mRNA interaction will be the aim of publication 4.
5. FMRP functions in translational control
5.1.1. FMRP shuttling among several mRNPs
5.1.1.1. FMRP and Polyribosomes : where is FMRP’s throne ?
Immunofluorescence and immunogold labeling of endogenous FMRP observations
revealed that, in the cytoplasm, FMRP is distributed in granular pattern and it colocalizes with
ribosomal structure especially at the perinuclear rough endoplasmic reticulum (RER)
(Khandjian et al. 1996; Feng et al. 1997; Mazroui et al. 2002). Subcellular fractionation on
sucrose gradient allowed to demonstate that FMRP is associated to polyribosomes and that
I304N mutation completely abolishes this association as previously discussed (Khandjian et
al. 1996; Corbin et al. 1997; Feng et al. 1997).
In brain, Zalfa and colleagues showed that FMRP is not associated to polyribosomes
(Zalfa et al. 2003). This observation was reviewed by biochemical experts who demonstrated
that using ionic detergent (Deoxycholate) is able to shift FMRP from polysomal fractions
(Khandjian et al. 2004; Stefani et al. 2004). It is widely accepted that FMRP is associated to
polyribosomes in cells and brain.
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5.1.1.2. FMRP and Stress granules (SG) : “ drag off ” and protect.
Interestingly, it has been shown that, in cultured fibroblasts, FMRP moves from
polyribosomes into stress granules during application of stress such as heat shock or arsenite
(oxidative stress) (Mazroui et al. 2002). Stress granules (SG) are cytpoplasmic microdomains
where the housekeeping mRNAs are sequestered. They contain two specific RNA-binding
proteins, T-cell intracellular antigen 1 (TIA-1) and TIA-1-related protein (TIAR), that are not
present in polyribosomes(Kedersha et al. 1999). Kim and colleagues showed that FMRP shifts
into stress granules in response to oxidative stress, using arsenite to treat hippocampal tissue
and  to in vivo electrode insertion.
The authors showed that arsenite causes a shift of FMRP in addition to the shift of
abortive preinitiation complexes. They have also examined the change of FMRP level in the
polyribosome and stress granule compartments in vivo, in response to insertion of an electrode
into the hippocampus. They demonstrated a bidirectional shift of FMRP after
electrophysiological stress (Kim et al. 2006) suggesting that translocation of FMRP and its
associated mRNAs into SG could result in partial translational arrest during stress, whereas
the movement back into polyribosomes could be a mechanism for restarting baseline
translation during recovery.
5.1.1.3. FMRP –Staufen-RISC- P bodies : continuous reshaping and
remodelling
FMRP is suggested to be component of granules that are in a state of dynamic flux, in
activity- regulated equilibrium with the surrounding translational control granules. In
drosophila, it has been shown that dFmr1 is part of the RISC complex (RNA-Induced
Silencing Complex) where it interacts with both Argonaute 2 and Dicer proteins (Caudy et al.
2002; Ishizuka et al. 2002). In vertebrates, FMRP-RISC association still occurs, Jin and
colleagues demonstrated that FMRP associates with both eIF2C2, the vertebrate orthologue of
drosophila AGO1 and AGO2, and Dicer (Jin et al. 2004; Lugli et al. 2005). It will be
important to analyze the specific interaction FMRP-AGO and determine if the association of
FMRP occurs with AGO1 or AGO2 due to their distinct role in mRNA processing.
Moreover, Barbee and colleagues recently reported that, in drosophila, Staufen and
dfmr1 colocalized extensively but not completely, indicating that dfmr1 and Staufen exist
substantially in the same granules but can also be observed in separate yet related particles.
This colocalization can be increased by overexpressing either protein. They also showed that,
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Me31B localizes to dfmr1-containing RNPs especially at neurite branch points in cultured
drosophila neurons and that it coimmunoprecipitates with dfmr1 from drosophila head extract.
This physical interaction links FMRP to P bodies as Me31B homologs in yeast and mammals
have been shown to function in P body formation in somatic cells. Me31B acts, at least in
part, within neurons to promote translation repression and/or mRNA degradation in response
to miRNAs (Barbee et al. 2006).
5.1.2. FMRP and translation : more than a decade of
“repression”
The ability of FMRP to shuttle among different RNPs suggested that it plays a role in
translation of its target mRNAs.
Li and colleagues used a rabbit reticulocyte lysate and showed that FMRP is able to
repress a large subset of mRNAs (Li et al. 2001) whereas Laggerbauer and colleagues
demonstrated that FMRP represses translation in both Xenopus oocytes and in vitro. This
effect was not observed with the mutant I304N (Laggerbauer et al. 2001).
In drosophila, the translation of futsch mRNA (discussed above) was shown to be
derepressed in the absence of dfmr1(Zhang et al. 2001). In parallel, MAP1B mRNA (see
above) distribution on polyribosomes shifted towards more active translating particles in the
absence of FMRP (Lu et al. 2004). Two different analysis using transient transfection system
showed that FMRP acts also as a translational repressor on the eEF1A and SIX3 mRNAs
(Mazroui et al. 2002; Sung et al. 2003). All these data support the hypothesis that FMRP is a
negative translational regulator in vitro and in vivo but how can such a function be compatible
with its predominant presence in so-called actively translating polyribosomes? Although
many hypothesis involving FMRP had emerged such as “stalled polyribosomes” or
translational control by miRNA, a direct link of FMRP in these processes should be more
clarified.
A lack of interpretation of the huge amount of results obtained from several groups
would lead to a global misunderstanding of FMRP functions. While, only the population of
mRNAs that were shifted towards heavy polysomes in the absence of FMRP was considered
as a solid clue strengthening the “translation repression” dogma of FMRP, the other
population  of mRNAs (that shifts towards light polysomes fractions in the absence of FMRP)
in the same study was not considered. Therefore should this observation stipulate that FMRP
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is exclusively a translational repressor ? In another hand, overexpressing FMRP in a cell
system would reflect, in any case, the endogenous behavior of the protein. As discussed in the
previous paragraph, FMRP shuttles among several dynamic mRNPs, disturbing the
stocheometry composition of these particles would have a dramatic effect on their belonging
and fate.
FMRP was recently reported to act on the stabilization of the PSD95 mRNA, by
binding to an undefined structure (Zalfa et al. 2007).
6. Neuronal functions accomplished by FMRP : shaping
dendritic spines
The only observed abnormalities observed in the brain of fragile X patients and Fmr1
KO mice concern the neuronal dendrites, the branched projections of neurons that conduct the
electrical stimulation received from synapses established with upstream neurons. It was
shown that the brain cortex of fragile X patients display a higher density of dendritic spines
which are the membrane protrusions emanating from a dendrite and forming one half of a
synapse. In addition, even in adult FXS patients’ brain, these surnumerary spines appear
longer, thinner and more tortuous than normal, looking alike immature, not fully
differentiated spines. It is thought that, in the developing brain of FXS patients, a suboptimal
development and maturation of dendritic spines is at the basis of mental retardation. But how
does FMRP control dendritic spines development at the molecular level?
6.1. What are dendritic spines ?
Dendritic spines constitute the post-synaptic compartment of most synapses. They are
typically between 0.5-2 µm in length and occur at a density of 1-10 spines per µm of dendrite
length on principal neurons. Their shape had been categorized as “mushroom”, “thin” or
“stubby” but a continuum exists between these categories as shown by electron microscopy.
Functional mature spines present a bulbous head receiving a single excitatory synapse and a
constricted neck serving as connection with the parent dendrite and inspecting diffusion of
molecules to and from the parent dendritic shaft. These structures constitute
microcompartments in which biochemical changes leading to specific pathways activation can
occur upon distinct receptor activity.
Introduction
52
They are highly heterogeneous structures, showing dynamic motility especially during
development, where a growing body of evidences links spine shapes and sizes to different
development stages and/or altered strength of synapses (Kasai H 2003; Hayashi Y 2005).
Imaging experiments showed that the volume of spine heads increases with stimuli that
strengthen the synapse and decreases with those that weaken the synapse leading to both
conclusions that the number, size and shape of the spines are subjected to plastic remodelling
correlated with modifications of the synaptic strength and interneuronal connectivity, and the
key role of the spine neck as a diffusion barrier controlled by neuronal activity (Bloodgood
BL 2005; Hayashi Y 2005).
It is important to note that changes in dendritic spine density and shape underlie many
brain higher cognitive functions, such as motivation, learning, and memory. In particular, the
development and maturation of new dendritic spines participates in the reinforcement of
neuronal pathways. By strengthening the connection between two neurons, the ability of the
presynaptic cell to activate the postsynaptic cell is enhanced. This type of synaptic regulation
forms the basis of synaptic plasticity and is crucial for the establishment of an optimal brain
neuronal network during development. Strong synaptic connections are provided by dendritic
spines with large heads which are generally stable and express large numbers of (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) receptors (AMPARs), they are called “memory
spines”. Whereas, small head spines contribute to weak synaptic connections, are less stable
and preferentially undergo long-term potentiation (LTP) so that may represent the “plasticity
spines”. These small thin spines are more susceptible to induction of LTP, due to the
geometry of their neck that shows greater Ca2+ increases mediated by activation of the (N-
methyl-D-aspartic acid) receptors (NMDARs). They contain few AMPAR. The activation of
NMDARs, conferring morphological changes in spines, may contribute to activity-dependent
formation and elimination of synaptic connections. LTP-inducing stimuli cause formation of
new spines and enlargement of existing spines, whereas long-term depression (LTD)-inducing
stimulation is associated with shrinkage and/or retraction of spines (K. Okamoto 2004; U.V.
Nagerl 2004).
Spine morphogenesis is controlled by a complex network of regulatory proteins, including
the Rho-family GTPases which orchestrate actin cytoskeleton rearrangement. In addition, a
highly-specialized localised protein synthesis occurs in dendritic spines and that directly
control synapse growth and dendritic plasticity. As we will see in the next paragraphs, FMRP
plays a crucial role in these processes.
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6.2. FMRP and localized synaptic translation
6.2.1. FMRP regulates localized synaptic translation
Most dendritic spines contain smooth endoplasmic reticulum, which in the largest
spines takes the form of a specialized organelle called the "spine apparatus". In addition,
polyribosomes and protein translational machinery are often anchored at the base of spines
including initiation and elongation factors, poly(A) binding protein, some microRNAs and
brain specific small RNAs. These observations lead different group to suggest a local
”synaptic” translation (Rao A 1991; Torre ER 1992; Weiler and Greenough 1993) {Steward,
2003 #1233}(Schratt et al. 2006) demonstrated in either synaptosomal fractions or in
dendrites physically separated from their cell body. This local translation enables neurons to
quickly mediate mRNA-specific postsynaptic responses to signalling events and is at the basis
of the long-lasting form of synaptic plasticity. This hypothesis was proven by Ostroff and
colleagues who demonstrated a relocalization of the polyribosomes from the dendritic shaft
into the dendritic spines after induction of LTP (Ostroff LE 2002).
In particular, stimulation of the metabotropic glutamate receptor (mGluR1) stimulation
initiates a phosphorylation cascade, triggering rapid association of some mRNAs with
translation machinery near synapses, and leading to protein synthesis. Fmr1, associates with
translational complexes after mGluR1 stimulation of synaptosomes, correlated with an
increased expression of FMRP after mGluR1 stimulation. Finally, FMRP is associated with
synaptic polyribosomal complexes (Weiler et al. 1997) (Feng et al. 1997)and Fmr1 KO mice
display a reduced number of post-synaptic polyribosomes aggregates (Weiler et al. 2004)
pointing out its critical role in the regulation of local translation.
6.2.2. FMRP is involved in the trafficking of RNA granules towards
the synapse
Local postsynaptic protein translation relies on the presence of mRNAs at the base of
dendritic spines, that are transported along microtubules of the neuronal arborization by
mRNP complexes called RNA granules. RNA granules transport mRNAs with RNA-binding
proteins, translation factors and ribosomal subunits to the site where the translation occurs.
Among the RNA-binding proteins encountered in RNA granules lies FMRP, together with
several of its interacting proteins : FXR1P, FXR2P, MSP58. A FMRP-GFP fusion allowed to
visualize the movement of FMRP containing granules in neuronal cell lines. This movement
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appeared microtubule-dependant and bidirectional (De Diego Otero et al. 2002). Another
study, aiming to reveal the importance of kinesin 5 in the transport of RNA granules,
identified several proteins including FMRP, FXR1P, FXR2P, Purα , and Staufen and a
number of mRNAs {Kanai, 2004 #780). Moreover, Miyashiro and colleagues observed some
subtle differences in some RNAs localization in the absence of FMRP (Miyashiro et al. 2003).
These observations suggested a role of FMRP in transport and localization of some mRNAs.
More recently, Davidovic and colleagues established a direct interaction between FMRP and
the neurospecific kinesin KIF3C suggesting that FMRP acts as a molecular adaptor between
RNA granules, providing new insight into FMRP functions in the transport of mRNAs
(Davidovic et al. 2007). Finally, in Fmr1 knockout brain, a significant decrease in the amount
of mRNA granules is observed relative to WT mice (Aschrafi et al. 2005). All these data point
out the important role of FMRP in RNA granules formation and transport. (See Figure 14 for
neuronal function of FMRP).
6.3. FMRP modulates synaptic actin-cytoskeleton
6.3.1. Via regulating translation of actin-linked mRNA
6.3.1.1. MAP1B
The link FMRP-microtubule-actin was assessed in drosophila with Futsch protein
(discussed above) which reshapes cytoskeletal loops for the period of synaptic bouton
division. MAP1B light chain binds actin stress fibers in vivo (Togel et al. 1998). Increased
Futsch expression leads to an overall increase in growth, branching and number of these
boutons in dfmr1 null fly, whereas an overexpression of FMRP leads to an opposite effect
(Gao 2002) suggesting that synaptic structure and function is regulated by dfmr1 repression of
futsch mRNA. Another regulation of the cytoskeleton was provided by Castets and
colleagues, demonstrating the link FMRP-Rac1 via PP2A. This aspect will be discussed in
publication 4.
6.3.2. Via an interaction with the Rac1 pathway mediated by CYFIP
Another mode of regulation was proposed by the link FMRP-CYFIP1-Rac-1. Rac-1,
plays a crucial role in dendritic spine maturation and maintenance by regulating the actin
cyroskeleton, is constitutively active in the absence of FMRP (Schenck et al. 2003; Tashiro
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and Yuste 2004). Another confirmation for the involvement of FMRP in the regulation of
actin cytoskeleton via Rac-1 pathway, was provided by Castets and colleagues (Castets et al.
2005a) and will be discussed in publication 4.
Furthermore, it has been shown that FMRP interacts with the human zipcode binding
protein1 ortholog IMP1 (Rackham and Brown 2004) which binds to β-actin mRNA. Both
proteins share the KH as RNA binding domain and are able to associate with each other
independently of a bridging RNA. IMP1 binds to β-actin mRNA and associates with FMRP
via protein-protein interaction, forming a complex and promoting formation of transport
granules. If FMRP accomplishes its role as a translation repressor, when absent, the
translation of β-actin would lower the efficiency of its dendritic localization, although net
production would not be changed. The system used by the authors seemed to be very
promising, nevertheless, it would have been of great interest to use an adequate cell model for
such analysis.
Taken together, all these observations converge into the hypothesis of FMRP
orchestrating the synaptic connections by modulating both the cytoskeleton and receptor
activities. The absence of FMRP would lead to misregulated network of connections affecting
both transport, localization, and translation of crucial mRNAs and resulting in abnormal spine
morphologies that are the major “hallmark” in Fragile X patient brains.
Introduction
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Aim of my thesis
Understanding the molecular functions of FMRP, its ability to specifically bind
mRNA targets and regulate their fate is a crucial step to better understand the Fagile X
Syndrome. When I started my work, several groups had proceeded by a large screening
looking for putative FMRP RNA targets. FMRP was shown to bind specifically its own
mRNA via a G-quartet structure thus, the first question that raised :
Is FMRP able to recognize specifically any other mRNA structure ?
If so, what would be the functional significance of this interaction? And what would it
enlighten in the physiopathology?
On another hand, FMRP has two other homologues FX1P and FXR2P with whom it interacts,
since FXR1P and FXR2P were never correlated to any know disease, their molecular function
was always suggested relying on the high homology degree that the three proteins share, and
it is commonly hypothesized that FXR1P and FXR2P may compensate for the absence of
FMRP. Here again, another question was crucial :
Do the three family members exhibit the same function, at least in their RNA binding
properties ?
If a mechanism of compensation occurs, what could be the influence of either FXR1P
or FXR2P on FMRP ?
Results
Results
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Publication 1
Several FMRP mRNA putative targets were described by many groups using a vast
panel of  experimental procedures, however, a specific interaction was shown for very few
targets. As detailed in the introduction, Miyashiro and colleagues had developed a technique
that allowed them to fish for in vivo FMRP targets. Based on their observations, we used
several of their putative mRNA targets and screened them for the presence of a G-quartet
Aim : Among the provided list of putative FMRP mRNA targets, is there any novel
mRNA structure bound specifically by FMRP ?
Procedure  : To analyze the presence of any RNA harbouring a G-quartet structure,
we used the binding assays in presence of potassium or sodium and to confirm the presence or
the absence of a G-quartet we performed a reverse transcription assay in presence of either ion
as described by Schaeffer and colleagues.
Once established, we therefore analyzed the functional significance of this interaction by
determining the distribution of the mRNA on polyribosomes in the absence of FMRP and the
effect that FMRP may exert on the translation of this mRNA.
Results : We were able to demonstrate that FMRP binds specifically to a 64 base
fragment in the Sod1 mRNA that folds in triple stem loops separated by short single strand
region. FMRP/ Sod1 mRNA interaction did not seem to affect the stability of the mRNA but
it may regulate positively its translation.
Conclusion : The take home message from this study was FMRP binds specifically a
novel RNA structure and depending on the structure features, FMRP might act as a negative
or a positive regulator of translation.
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2Abstract
Background:Fragile X syndrome, the most frequent form of inherited mental retardation, is
due to silencing of Fragile X Mental Retardation 1 (FMR1) gene, encoding FMRP (Fragile
X Mental Retardation Protein). FMRP is an RNA-binding protein involved in several steps
of RNA metabolism: nuclear export, trafficking in dendrites and axons, stabilization and
translational control of a subset of mRNAs. Up to date, only two RNA motifs have been
found to mediate FMRP/RNA interaction: the G-quartets and the «kissing complex».
Interaction between FMRP and each of these RNA motifs induces translational repression
via different mechanisms of action: prevention of ribosome scanning and retention of
mRNAs in translationally inactive ribonucleoparticles, respectively. Results:We show here
that Super Oxide Dismutase 1 (Sod1) mRNA is specifically bound with high affinity by
FMRP through a novel RNA motif, SSLIP (Sod1 mRNA Stem Loop Interacting with
FMRP), which is folded as three independent stem-loop structures. SSLIP/FMRP
interaction improves the association of Sod1 mRNA with polyribosomes, resulting in a
decreased expression of Sod1 protein in FMR1 null cells and brain. Conclusion: These data
are pointing out that the RNA motif bound by FMRP determines its mechanism of action
and FMRP can also positively regulates translation. In addition, we propose that the
disregulation of Sod1 expression is at the basis of pathophysiology of the syndrome.
Indeed, an increase of oxidative stress in brain of FMR1 knock-out mice has been recently
described and modifications of oxidative stress have been linked to anxiety, sleep troubles
and autism: all phenotypic characters displayed by Fragile X patients.
3Introduction
Fragile –X Mental Retardation Protein (FMRP) is an RNA binding protein whose absence
causes the Fragile X Mental Retardation syndrome, the most frequent form of inherited
mental retardation. In addition to mental retardation, the phenotype of patients includes
facial dysmorphies, macroorchidism in post-pubertal boys, connective tissue dysplasia,
hyperkinetic behavior, anxiety, sleep disorders, autism and epilepsy (Hagerman and
Hagerman, 2001). FMR1 null mice display enlarged testes, hyperactivity and a mild spatial
learning impairment in the Morris water maze (Bardoni et al., 2006). The pleiotropic effect
of the absence of FMRP suggests that it has a complex function and it reflects its
involvement in the control of hundreds of mRNA targets via its different RNA-binding
domains. Indeed, FMRP contains two KH domains and one RGG box domain, which can
mediate RNA/protein interaction (Khandjian et al., 2005). While a specificity of binding
for KH1 domain was not proved, the KH2 domain was shown to specifically bind a
category of synthetic aptamers (« kissing complex ») a sequence-specific element within a
complex tertiary structure stabilized by Mg++ concentration (Darnell et al., 2005). On the
other hand, the RGG box domain is able to bind with high affinity the RNA G-quartets, a
structure that is present in several FMRP RNA targets, such as FMR1, MAP1B, PP2Ac,
APP ((Schaeffer et al., 2001); (Lu et al., 2004); (Castets et al., 2005); (Westmark and
Malter, 2007)) and is stabilized by K+ ions, whereas smaller size cations (e.g. Na+ or Li+)
cause their destabilization (Schaeffer et al., 2001). The subcellular localization of FMRP is
consistent with that of a protein involved in several steps of metabolism and maturation of
RNA. Indeed, FMRP is able to shuttle between nucleus and cytoplasm. In the cytoplasm, it
is mostly associated to polyribosomes but was also found to colocalize with stress granules
and PBodies (PBs), (Barbee et al., 2006; Bardoni et al., 2006; Khandjian et al., 2005). In
addition, in neurons, FMRP is involved in RNA trafficking along dendrites and axons
4being a component of RNA granules and functioning as a molecular adaptor between these
complexes and the neurospecific KiF3C kinesin (Davidovic et al., 2007). Moreover, after
traveling along neurites, FMRP associates to polyribosomes localized at the synapse to
participate to the translational control of proteins synthesized in this compartment
(Grossman et al., 2006).
Taking into consideration the results obtained from different laboratories, several
mechanisms of action of FMRP have been proposed: i) Polysomal stalling for MAP1B
mRNA expression regulation (Lu et al., 2004); ii) Retention of mRNAs in translationally
inactive mRNPs via a specific RNA structure, as suggested by the effect of the kissing
complex motif and the FMRP presence in these structures (Darnell et al., 2005); iii)
Inhibition of translation preventing ribosome scanning via a G-quartet structure localized
in the 5’UTR of a target mRNA, as for PP2Ac mRNA (Castets et al., 2005). In addition,
iv) the interaction between FMRP and a G-rich sequence in the 3’UTR of Post Synaptic
Density 95 (PSD95) mRNA stabilizes this mRNA in the hippocampus (Zalfa et al., 2007).
Here, we show that the interaction between FMRP with one of its known RNA targets,
Super Oxide Dismutase 1 (Sod1) mRNA, is mediated by a novel structure the Sod1 Stem
Loops Interacting with FMRP (SSLIP). FMRP specifically recognizes and binds this motif
with high specificity and affinity, comparable to the one for G-quartets. The SSLIP/FMRP
interaction improves the association of Sod1 mRNA with polyribosomes, as shown by a
decrease of the expression level of Sod1 protein in FMR1 null cells and brain. The
characterization of this novel interaction of FMRP sheds new light on the ability of FMRP
to be associated with mRNAs and to function as a translational activator. In addition, we
are pointing out the disregulation of Sod1 expression as one of the determinants of the of
physiopathology of Fragile X syndrome.
5Results
FMRP binds Sod1 mRNA with high affinity via its C-terminal domain
The RNA binding specificity of FMRP is not completely understood. Up to date only a
single structure, the G-quartets, was found to mediate the interaction of FMRP with several
of its target mRNAs (Castets et al., 2005; Khandjian et al., 2005; Schaeffer et al., 2001). In
addition a synthetic RNA with a specific structure, called the kissing complex, binds with
high affinity FMRP but up to date is not found harbored by any natural mRNA, yet
(Darnell et al., 2005; Khandjian et al., 2005). Furthermore, the 3’UTR of PSD95 mRNA
has been reported to interact with FMRP via a novel structure that was not precisely
defined (Miyashiro et al., 2003; Zalfa et al., 2007). The specific sequence/region mediating
the interaction of most putative mRNA targets with FMRP is poorly investigated
(Khandjian et al., 2005; Miyashiro et al., 2003). Aiming to find novel mRNA structures
specifically recognized by FMRP, we performed a systematic analysis of already identified
FMRP mRNA targets, in order to exclude the presence of G-quartets and kissing
complexes in these mRNAs. It is important to underline that the detection of G-quartets
structure in FMR1 and PP2Ac mRNAs was only possible in an experimental way and not
by an in silico analysis (Schaeffer et al., 2001). Then, as a first step, we screened several
FMRP RNA targets by their capacity to bind a recombinant FMRP protein by gel-shift
analysis or filtration method in the presence of Na+, K+ or Mg++. Indeed, K+ ions
stabilize the mRNA G-quartets structure leading to a solid interaction with FMRP, while
Mg++ favours the interaction FMRP/Kissing complex (Darnell et al., 2005; Schaeffer et
al., 2001).
Using the APRA (Antibody-Positioned RNA Amplification) technique Sod1 mRNA was
found to be a neuronal target of FMRP (Miyashiro et al., 2003). FMRP/Sod1 interaction
6takes place in the presence of K+ (Fig.1a) and is not affected by the presence of Na+
(Fig.1b), while, as expected, Na+ affects the binding of FMRP to the G-quartets containing
N19 RNA, the portion of FMR1 mRNA harbouring a G-quartets structure as we have
previously characterized (Schaeffer et al., 2001). To definitely exclude the presence of a G-
quartets structure in the Sod1 mRNA, we performed a reverse transcriptase (RT)
elongation reaction, as previously described (Schaeffer et al., 2001). In the presence of K+,
G-quartets structures are very stable, blocking RT progression at its 3’ edge and resulting
in a truncated transcription product. Conversely, in the presence of Na+, G-quartets
structures are destabilized and the RT can proceed to the end of the RNA. The RT
elongation test on Sod1 mRNA did not reveal any K+ dependant stop of the enzyme
(Supplemental Figure), demonstrating that the Sod1 mRNA is not able to form a G-quartets
structure. Moreover, the FMRP/Sod1 interaction was not dependent on the presence of
Mg++, an ion that is necessary to stabilize the “kissing complex” RNA structure (data not
shown). Taken together, these findings suggest that FMRP binds to Sod1 mRNA via a
novel sequence/structure.
In order to define the affinity of FMRP/Sod1 mRNA interaction, we tested the ability of
Sod1 mRNA to compete the binding of FMRP/G-quartets forming RNA structure
(Schaeffer et al., 2001). Indeed, 5 nM of unlabelled Sod1 mRNA competed very efficiently
(65%), with the previously identified FMRP binding site N19 in a gel-shift assay while a
negative control, N8 RNA (corresponding to the mRNA region of FMR1 1-654), was not
able to compete the same interaction (Fig.1c). To precisely define the region of Sod1
mRNA interacting with FMRP, we generated 3 different constructs from Sod1
encompassing its full-length cDNA: its 5’UTR and a portion of its coding region (Sod1-
5’region), a stretch part of the coding region (Sod1-mid region) and, finally, a fragment
overlapping the end of the coding region and the 3’UTR (Sod1-3’ region) (Fig.2a). RNA
7sequences corresponding to each fragment were produced and tested for their ability to
interact with FMRP. Among the different RNAs synthesized, only the Sod1-5’ region
(spanning Sod1 mRNA from –70 to +148) competed with N19 binding to FMRP with the
same affinity as for full-length Sod1 mRNA (3 nM of both cold probes compete 50% of
N19/FMRP binding) (Fig.2b). To identify the sequence of Sod1 mRNA that is recognized
and bound by FMRP, we performed a site boundary determination (Schaeffer et al., 2001).
In this experiment the 3’- or 5’- end labeled Sod1-5’ RNA was treated by mild alkaline
hydrolysis in order to generate a pool of smaller fragments. The RNA fragments retaining
capacity to bind to FMRP were selected on immobilized GST-FMRP, as previously
described (Schaeffer et al., 2001). Bound RNAs were analyzed by electrophoresis on a
denaturing polyacrylamide gel (data available on request). The border positions were at -30
and +34 for 3’- and 5’-end labeled fragments, respectively. This technique allowed us to
define a 64-base region spanning both sides the Sod1 AUG start codon that is protected by
FMRP. We subcloned this sequence and we synthesized its corresponding mRNA,
generating the Sod1-64 RNA. This RNA was bound specifically by FMRP, since it was
able to compete the FMRP/Sod1 full-length mRNA interaction (Fig.2c). Interestingly, this
interaction could be competed at the same extent by the G-quartets-N19-containing RNA
(not shown).
To assess which portion of FMRP was able to interact with the Sod1 mRNA, we produced
protein fragments of the different RNA binding domains of FMRP (e.g. KH1, KH2, KH1/2
and RGG box-containing-C-terminal domains)(Adinolfi et al., 1999) as recombinant
proteins in a bacterial system, and we used them in binding assays with the Sod1-64 RNA.
Interestingly, we observed that only the C-terminal domain has the ability to interact with
Sod1-64 RNA (Fig.2d). Indeed, the Sod1-64 region was not able to interact with any of the
KH domains even at high protein concentration (Fig.2d). Since the C-terminal domain of
8FMRP contains the RGG box that binds to the G-quartets RNA structure (Darnell et al.,
2001), it is possible that this domain binds to different structures. Indeed, the G-quartets
forming structure RNA and Sod1 mRNA compete with each other to interact with it or
alternatively FMRP recognizes similar structural features in both RNAs (e.g. specific
atoms properly spatially oriented and/or in the correct electrostatic environment).
FMRP binding site on Sod1-64 RNA folds in three stem loops
To assess whether the Sod1-64 RNA binds FMRP in the same ions conditions that the full-
length Sod1 mRNA, we performed a binding assay of this RNA to FMRP in the presence
either of K+ or Na+. As shown in Fig.2e, no differences were observed in the RNA/protein
interaction in both conditions. To determine the secondary structure of Sod1-64 RNA, we
performed the probing of the structure of this 64-base region in solution, using a panel of
chemical and enzymatic modifications as described (See Methods) (Brunel and Romby,
2000). This technique is based on the reactivity of RNA molecules towards chemicals or
enzymes that modify or cleave specific atomic positions in RNA respectively. The probing
experiments were performed using unlabeled or radioactively end-labeled in vitro-
transcribed RNAs (Sod1-5’region), which were subjected to statistical digestions with
RNases T1, T2, V1 or chemical modifications with dimethyl sulfate (DMS) and a
carbodiimide derivative (CMCT). RNase T1 cut after G residues present in single-stranded
regions, RNase T2 cleaves after all single-stranded residues, but preferentially after. As,
whereas RNase V1 cuts at doubled-stranded or stacked bases. DMS alkylates N1 position
of As and N3 of Cs while CMCT modifies N1 of Gs and N3 of Us. The sites of cleavage or
modification were then identified by primer extension with reverse transcriptase, using
radiolabeled primer complementary to Sod1-5’region. Analysis of the resulting cDNAs
was performed on sequencing polyacrylamide gels that were run together with the
9corresponding RNA sequencing ladder to allow identification of the modified residues
(Fig.3a). A secondary structural model was further derived by combining experimental
data and free energy data calculated using the mFOLD program
(http://helix.nih.gov/apps/bioinfo/mfold.html). The structure of Sod1-64 RNA appears
as a succession of three independent stem-loop structures that are separated by short single
stranded regions. (Fig.3b). We called this novel target of FMRP SSLIP for Sod1 Stem
Loops Interacting with FMRP.
Sod1 mRNA stability is not affected by the absence of FMRP
Recently, FMRP could stabilize PSD95 mRNA by interacting with a G-rich sequence in its
3’UTR in hippocampal primary neurons (Zalfa et al., 2007). To investigate a putative role
of FMRP to act the same way on the SSLIP structure, we explored Sod1 mRNA decay in
primary cultured hippocampal neurons after blocking transcription by Actinomycin D
treatment. We did not observe any significant alteration in Sod1 mRNA level in the
presence or in the absence of FMRP, even after twelve hours of Actinomycin D treatment
(Fig.4a). The same results were obtained in STEK cells expressing or not a FMR1
transgene (not shown). Our results show that the interaction between FMRP and SSLIP has
no role in regulating stability of Sod1 mRNA.
Association of Sod1 mRNA to polyribosomes is reduced in brain and cells lacking
FMRP
The association of FMRP to polyribosomes has been clearly established (Corbin et al.,
1997; Khandjian et al., 2004), as well as its shuttling between different mRNP complexes
(Barbee et al., 2006; Bardoni et al., 2006; Khandjian et al., 2005) and polyribosomes,
revealing thereby its involvement in translational control. We asked whether the
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SSLIP /FMRP interaction could influence the association of Sod1 mRNA with
polyribosomes. First we analyzed the level of Sod1 expression in cytoplasmic RNA
extracts from STEK cells (Castets et al., 2005), total mouse brain, hippocampus and
cerebellum expressing or not the FMR1 gene. Using quantitative (q) RT-PCR, the amount
of Sod1 mRNA was found to be equivalent in both wild type and Fmr1 knock-out cells and
tissues when compared to the level of Hprt mRNA (Fig.4b). Since no difference has been
observed in Sod-1 mRNA expression level between wild type and FMR1-null mice brains
and in the STEK cells line expressing or not FMRP (Fig.4a), we analyzed cytoplasmic
Sod1 mRNA distribution on 15-45% sucrose gradients prepared with extracts of STEK
cells expressing or not FMR1 transgene and of whole brain of wild type and FMR1 null
mice (Khandjian et al., 2004). In the absence of FMRP, we observed a decreased level of
Sod1 mRNA in polyribosome fractions (light and heavy) obtained from fibroblasts as
quantified by qRT-PCR (and using Hprt mRNA as standard) (Fig.4c) as well as in the
same polyribosome fractions obtained from total brain (Fig.4d). We used the purification
of polyribosomes previously described (Khandjian et al., 2004) since this method is based
on the concentration of polyribosomal franctions, avoiding contamination of mRNP. These
results suggest that the absence of FMRP plays a role in Sod1 mRNA incorporation in the
translating machinery.
Sod1 expression is impaired in FMR1 null mice
To assess whether the reduction of the association of Sod1 mRNA to polyribosomes
impaired the expression of Sod1 protein in the absence of FMRP, we analyzed total protein
extracts obtained from STEK cells expressing or not a FMR1 transgene (Castets et al.,
2005) and we observed that Sod1 protein expression is reduced around 40 % in FMR1 null
cells as compared to cells expressing FMRP (Fig.5a). Similarly, we observed a significant
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decrease of Sod1 level in total protein extracts from total brain (Fig.5b), hippocampus
(Fig.5c) and cerebellum (Fig.5d) of 12 days old from FMR1 knock out mice as compared
to wild type littermates. Sod1 levels were also reduced in FMR1 null mice embryos at
10dpc (Fig.5e). We therefore concluded Sod1 levels are directly correlated to the reduced
localization of its mRNA on active polyribosomes in FMR1 knock out mice. In addition,
our findings confirm a perturbed expression of Sod1 in the absence of FMRP and are not
compatible with the sole proposed role of FMRP as a translational repressor.
12
Discussion
 Primary function of FMRP is its ability to bind a subset of mRNAs. It is inferred that the
functional significance of the FMRP/RNA interaction is the critical step to understand the
molecular bases of Fragile X syndrome. Based on conclusions from several laboratories, it
has been considered that FMRP behaves exclusively as a translational repressor
(Laggerbauer et al., 2001; Schaeffer et al., 2001). However, recent results have pointed out
to a more complex function of FMRP, possibly depending on the specific binding of its
target RNAs or due to conformational changes in its structure or on the influence of
FMRP-interacting proteins (Bardoni et al., 2006; Khandjian et al., 2005; Miyashiro et al., ;
Zalfa et al., 2007). In this study, we dissected the mechanism of binding of FMRP to the
Sod1 mRNA that was identified as a target of FMRP in dendrites of cultured primary
neurons by the APRA technique (Miyashiro et al., 2003). Indeed we show here that FMRP
recognizes the Sod1 mRNA via a novel motif, SSLIP, organized in three stem loops
separated by short sequences. In the absence of FMRP, Sod1 mRNA association to
polyribosomes is reduced and Sod1 protein is less expressed in brain from the FMR1
knock out mice. For the first time, our results clearly exclude the model that FMRP
behaves exclusively as a translational repressor, since in the absence of FMRP the
expression of one of its bound target mRNA, the Sod1, is reduced. Furthermore we suggest
that, even in this novel function, the mechanism of action of FMRP is mostly dependent on
the RNA structure to which it binds. Interestingly, we have precisely defined the secondary
structure of the RNA motif that mediates the FMRP/ Sod1 mRNA interaction. FMRP binds
G-quartets RNA and SSLIP RNA  trough its C-terminal region containing the RGG-box,
even if in different ions concentrations. For this reason, we are tempted to speculate that
the binding may occur in an alternative way depending on the local ion concentration (K+
vs Na+) and this possibility might be particularly intriguing at the synaptic level.
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Interestingly, the FMRP homologue, Fragile X Mental Retardation Related Protein 1
(FXR1P) that by homology has been considered to have the same function that FMRP
(Laggerbauer et al., 2001), was reported to functionas a translation activator when
associated with the TNFα ARE and in response to serum starvation (Vasudevan and Steitz,
2007).
It has been shown that FMRP is associated in the cell to structures with different
translational status. In this scenario FMRP might shuttle not only between nucleus and
cytoplasm, but also between polyribosomes (translationally active) and translationally
inactive structures, such as PBodies, RNA granules or stress granules. Our results help in a
more precise definition of the mechanism of action of FMRP, since it appears that it can
regulate the translatability of an mRNA favouring its association to polyribosomes. It is
possible that the FMRP binding to other sequence determine its association to other
cytoplasmic compartment, as suggested by its interaction with “kissing complex” motif.
Unfortunately, no natural mRNA harbouring a kissing complex have been identified so far
and it is impossible to performe comparatif studies with Sod1 expression level (as mRNA
and protein) in the presence or in the absence of FMRP. In addition Sod1 mRNA is present
in dendrites and in axons meaning that is an axonally synthesized protein essential for axon
development and axonal transport and implicating that FMRP may also regulate its
neurites trafficking and it association to synaptic polyribosomes (Willis et al., 2005). Sod1
has anti-oxidative properties and gene mutations in Sod1 can cause familial amyotrophic
lateral sclerosis (SLA). Several Sod1 mutants found in SLA patients perturb fast axonal
transport (De Vos et al., 2007) and can cause motor axonopathy in zebrafish (Lemmens et
al., 2007). Sod1 is also regulated by cellular stress, suggesting that the axonal localization
of its mRNAs may provide a mechanism to locally respond to axonal injury.. Alterations of
axons development have been described in the Fragile X models in zebrafish and
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drosophila (Morales et al., 2002; Tucker et al., 2006) as well alterations of the white matter
of frontostriatal in Fragile X patients (Barnea-Goraly et al., 2003). Modifications of
oxidative stress have been linked to anxiety (Gingrich, 2005), sleep troubles (Cirelli,
2006), and autism (Ming et al., 2005): all phenotypic characters displayed by Fragile X
patients (Hagerman and Hagerman, 2001). Alterations of oxidative stress have been
proposed to exist in FMR1 null flies since changes in the expression of proteins involved in
redox reactions have been observed (1-cys peroxiredoxin in brain and peroxiredoxin and
thioredoxin peroxidase in testis) (Zhang et al., 2005; Zhang et al., 2004) and a moderate
increase of oxidative stress in brain of FMR1 knock-out mice has been recently described
(El Bekay and al., 2007). These data lead to the suggestion that abnormalities of Sod1
expression may contribute to the physiopathology of the Fragile X syndrome.
The facts that i) hundreds of putative target RNAs of FMRP have been identified, but only
few of them have been validated (Miyashiro et al., 2003); ii) this protein contains several
RNA binding domains that, as in the case of the C-terminal region, may have multiple
(alternative?) capacity of binding (Darnell et al., 2001; Zalfa et al., 2007) and this study;
iii) FMRP-interacting proteins can modify its ability to bind to RNA or compete for the
same binding (Bechara et al., 2007; Davidovic et al., 2006), all suggest that the
comprehension of the mechanism of action of FMRP is just in its infancy. Our study sheds
new light on the physiopathology of the Fragile X syndrome, since that the alteration of
Sod1 expression, we described here, probably generates the modification the cellular
reduction/oxidation observed in Fmr1 KO mice (El Bekay and al., 2007) and may
represent one of the molecular defects resulting in the complex phenotype of Fragile X
patients.
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Materials and methods
Cells culture
Primary cultures of hippocampal neurons were obtained from wild type and FMR1 null
mouse embryos at 18 days of gestation. STEK cells FMR1 null and after reintroduction of
FMR1 cDNA (Rescued) (Castets et al., 2005) and 10 days in vitro cultured neurons were
treated with 5 µM of Actinomycin D (Sigma) for 2, 4, 6 and 12 hours. Total RNAs was
purified from actynomicin-treated cells using the Qiagen RNeasy Mini Kit and the RNA
quality was verified on a 1% agarose gel and by O.D. measurement.
Plasmids constructions
Primer sequences used to amplify Sod1  and FMR1  cDNAs are summarized in
Supplemental Table, in the “Supplemental Data” section.
Sod1 full-length (BC002066), and two of its deletion constructs (mid region and Sod1-64)
were subcloned into the pGEM-T vector (Promega), Sod1 3’UTR construct was subcloned
into the pCR2.1-TOPO (Invitrogen).
Sequences coding for KH1, KH2, KH1/2 and FCT domains were amplified by PCR from
obtained from FMR1 ISO7 cDNA (Adinolfi et al., 1999) using the appropriate primers.
The PCR products were subcloned into the pET 151/DTOPO vector (Invitrogen) and the
constructions verified by sequencing.
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Table I
Immunoblot analysis
Protein extraction and immunoblot were performed as previously described (Castets et al.,
2005). The antibodies used in immunoblot analyses were used at the following
concentrations: anti-FMRP antibody 1C3 1:10000 (Castets et al., 2005), rabbit polyclonal
anti-Sod1 antibody (Sod-100) (Stressgen) 1:5000, monoclonal anti β-Tubulin (E7)
antibody (Iowa Hybridoma Bank) 1:5000 and rabbit polyclonal anti-L7a antibody (a gift
from A. Ziemiecki) 1:40000.
Forward Reverse
Sod1 full-
length
5’CCCACGCGTCCGCTCGTC3’ 5’CTCTTCAGATTACAGTTT3’
Sod1 mid-
region
5’GGGTTCCACGTCCATCAGT3’ 5’GGCCAATGATGGAATGCTC3’
Sod1
3’UTR
5’CCGTACAATGGTGGTCCAT3’ 5’CTCTTCAGATTACAGTTTAAT3’
Sod1-64 5’CGCCGCGCGTCTTCCG3’ 5’GACCGTCGCCCTTCAGC3’
FMRP-
KH1
5’CACCGCTAGTAAGCAGCTG
G3’
5’CTAAAATTCGAGAAAGCTTCTA
G3’
FMRP-
KH2
5’CACCGCTGAAGATGTAATA
CAAGTTC3’
5’CTATAAATAGTTCAGGTGATAA
TCCAA3'
FMRP-
FCT
5’CACCGCTCCAACAGAGGAA
GAGAG3’
5’CTAGGGTACTCCAATCACGAGT
G3’
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RNA binding assay
Protein expression and purification were performed as previously described (Bechara et al.,
2007). All RNAs were produced using the T7 RNA polymerase (Promega) according to
the manufacturer protocol starting from linearized plasmids. The pGEM-T and pTL1
vectors were linearized using PstI, pCR2.1 TOPO with BamH1. Sod1 5’ region was
obtained by digesting pGEM-T Sod1 full-length with BstXI. Restriction enzymes were
purchased at New England Biolabs. RNAs were purified on NucAway spin columns
(Ambion) and their quality was verified on an Acrylamide-Urea gel after staining with the
Stains-All (Sigma). RNA-Protein interactions were analyzed either by Electro Mobility
Shift Assay or by filter binding assay, as previously described (5, 33).
RNA forming structures detection
The presence of a G-quartets structure in the Sod1 mRNA was tested both by binding assay
and by reverse transcription with different primers along the Sod1 mRNA, as previously
described (Schaeffer et al., 2001) in the presence of Na+ or K+ in both experiments. For
the primer extension assays, RT was performed as described (Schaeffer et al., 2001) and
using the following primers γ-32ATP 3’ end labeled.
I 5’CTCTTCAGATTACAGTTT3’; primer II 5’GTACGGCCAATGATGGAATG3’;
p r i m e r  I I I  5 ’ G G A T T A A A A T G A G G T C C T G C 3 ’ ;  p r i m e r  I V
5’CTTCTGCTCGAAGTGGATG3’; primer V 5’CTTCAGCACGCACGC3’.
The Sod1-64 RNA boundaries were determined as previously described (Schaeffer et al.,
2001).
Chemical and enzymatic probing the Sod1-5’UTR region to determine the Sod1-64
structure.
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5’UTR Sod1 RNA (5pmoles) was renatured at 40°C for 15 min in the appropriate native
buffer (50 mM Hepes buffer pH 7.5 for DMS or Borate buffer pH 8 for CMCT, 5 mM Mg
Acetate, 50 mM KOH acetate, 2 mM β-mercaptoethanol). Chemical modifications were
performed in 20 µl final volume using either 1µl of DMS diluted 1/2 (v/v) in ethanol or 60
µg of CMCT (Carbodiimide), at 20°C for 5 and 15 min, respectively and in the presence of
2µg of E. coli total tRNA. Enzymatic modifications were performed with V1 (0,0002U and
0,001U), T1 (0,05U, and 0,1U) and T2 (0,05U and 0,1U) nucleases, followed by a
phenol/chloroform (v/v) extraction. After ethanol precipitation and solubilization in the
appropriate buffer, modified RNAs were reverse transcribed using the labeled primer III,
sequencing reactions and gel analysis were carried out as previously described (Brunel and
Romby, 2000; Schaeffer et al., 2001).
Polyribosomes Purification.
Polyribosomes purification and analysis was performed as previously described
(Khandjian et al., 2004). Fifteen fractions of 800 µl each were collected from sucrose
gradient. 100 µl of each fraction were ethanol-precipitated, resuspended in 50 µl of
Laemmli buffer and analyzed by immunoblot. The other 700 µl of each fraction were
treated with Trizol (Invitrogen) to purify RNA. The quality of RNAs was verified on a 1%
agarose gel and by O.D. measurement.
Quantitative Real time PCR
The reverse transcription reactions were performed with 2µg of RNA using the
ThermoScript RT-PCR system (Invitrogen). The PCR reactions were carried out with the
qPCR core Kit for Syber Green I (Eurogentec), in an ABI PRISM 7000 (Applied
BioSystems). To amplify the Sod1  cDNA the following primers were used: F-
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5’ACCATCCACTTCGAGCAGAA3’; and R-5’AGTCACATTGCCCAGGTCTC3’. The
level of expression of the Sod1 was normalized to the standard housekeeping gene, Hprt,
that was amplified with the F-5’GTAATGATCAGTCAACGGGGGAC3’ and the R-
5’CCAGCAAGCTTGCAACCTTAACCA3’ primers. Relative changes in mRNA amounts
were calculated based on the ΔCT method (Livak and Schmittgen, 2001).
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Figures Legends
Figure 1.
FMRP specifically binds Sod1 mRNA.
FMRP binding to Sod1 mRNA is not dependent on K
+
. Labelled G-quartets RNA (N19) or
Sod1 full length mRNA were incubated with increasing amounts of recombinant His-
FMRP in the presence of K
+
(a) or Na
+
(b). FMRP-Sod1 binding was not affected by ionic
conditions while, as expected, the presence of Na
+
 affected FMRP binding to N19.
(c) Gel-shift experiments were performed using a 32P-labeled N19 probe incubated with
0.1 pmole of recombinant His-tagged FMRP, in the presence of increasing amounts of
unlabelled competitors, ranging from 10-9 to 10-7M [lane 3-5 (N19), lane 6-8 (Sod1), lane
9-11 (N8)].  Lane 1, no protein control, lane 2, no competitor control. Note that both N19
(G-quartets-containing RNA and positive control) and Sod1 compete equally for binding to
FMRP, whereas N8 (negative control) only competes out at high concentration (non-
specific binding).
Figure 2.
FMRP binds a 64 base fragment of Sod1 mRNA via its C terminal region.
a) Schematic representation of Sod1 mRNA and the fragments subcloned from full-length
cDNA and used to map the binding domain of FMRP on Sod1 mRNA.
b) Filter binding assay using FMRP and 32P-labeled N19. The competition was performed
using various regions of unlabeled Sod1 mRNA: Sod1-5’ region, Sod1 mid region, and
Sod1-3’ region. The graph depicts the fraction of bound labelled N19 RNA plotted against
unlabelled competitor RNA concentration.
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c) Binding specificity of FMRP to Sod1-64 fragment. Filter binding assay using FMRP and
32P-labelled Sod1 mRNA. Competition was performed with different unlabelled mRNA
fragments. The Sod1-64 RNA fragment shows a competition profile similar to the one of
Sod1 full-length mRNA.
d) Filter binding assays using various recombinant RNA-binding domains of FMRP: KH1,
KH2 and the C-terminal domain containing the RGG box and 32P-labeled RNAs reveal that
the FMRP C-terminal domain (FCT) displays equal affinity for Sod1 mRNA or G-quartets
containing the N19 fragment, whereas the KH domains are not able to bind Sod1 mRNA.
e) Filter binding assay using increasing amount of recombinant His-FMRP and 32P-labeled
RNA fragments in the presence of K
+
 or Na
+
. FMRP-Sod1-64 RNA binding is not
dependent on ionic conditions, excluding the presence of a G-quartets forming structure
RNA.
Figure 3.
Secondary structure of the Sod1-64 RNA fragment
Enzymatic (a) and chemical (b) probing of in vitro-transcribed Sod1-5’ region. Cleavage
and modification sites were detected by primer extension using the 32P- 5'-end-labelled
primer IV. The resulting cDNA was separated on 8% polyacrylamide/8 M urea sequencing
gel and analyzed by autoradiography. RNA sequencing reactions were run in parallel. The
nature and positions of different loops and stems are indicated at right. Increasing
concentrations of RNase V1 (V1), RNase T1 (T1) (left panel) or chemical agents (DMS,
CMCT) (right panel) were added before the reverse transcription step (-) indicates the
lanes where the untreated RNA was loaded.
c) RNA secondary structure model of the Sod1-64 mRNA fragment showing results from
enzymatic cleavage and chemical modification experiments. White and black arrows
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represent weak, moderate and strong RNase T1 cleavage sites, respectively. White and
black triangles represent weak, moderate and strong RNase V1 cleavage sites, respectively.
Dashed and white circles represent weak, moderate, and strong modifications by DMS,
CMCT, respectively. “x” represents reverse transcriptase pauses.
Figure 4.
FMRP does not affect Sod1 mRNA stability but rather controls its translation status.
a) Primary cultured hippocampal neurons derived from Fmr1 knock-out or wild-type mice
were incubated with 5µM ActinomycinD for 12 hours. Sod1 mRNA levels in cells
expressing or not FMR1 was monitored at various time points after treatment. The ratio of
these levels is shown.
b) Cytoplasmic RNA was extracted from cells and mice tissues expressing or not FMRP.
Sod1 mRNA levels were analysed by qRT-PCR and normalized to Hprt in each sample. As
shown in the diagram, Sod1 mRNA levels were not affected by the absence of FMRP.
c-d). Polyribosome association of Sod1 mRNA in STEK cell lines expressing or not FMR1
and in brain obtained from wild type and FMR1 null mice. RNA purified from fractions
corresponding to monosomes, light polyribosomes and heavy-sedimenting polyribosomes
were pooled and the amount of Sod1 mRNA in each pool was determined by quantitative
RT-PCR, normalized to Hprt in each sample. Sod1 mRNA is less associated to light
polyribosomes in the absence of FMRP.
Figure 5.
Decreased level of Sod1 protein in FMR1 null cells, brain, embryo
a) Western blot analysis of one FMR1+ STEK clone (where FMR1 was reintroduced;
Castets et al., 2005) and one STEK FMR1 null clone. The result shown on the left panel is
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representative of the analyzed clones. (On the right panel) Densitometric analysis showing
a significant decrease of Sod1 expression, comparing five wild-type rescued clones and
five FMR1 knock-out clones. Two independent experiments were quantified. Results are
the average of Sod1 levels normalized for beta-tubulin expression (Student’st-test, P=
0,05). The same analysis described in (a) was repeated for mouse total brain (b), mouse
hippocampus (c), mouse cerebellum (d) and mouse 10dpc embryo extracts (e) obtained
from wild-type and FMR1 null mice.
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Publication 2
FMRP is suggested to be component of granules that are in a state of dynamic flux, in
activity- regulated equilibrium with the surrounding translational control granules. Several of
FMRP interactors were shown to be RNA binding proteins. FXR1P and FXR2P, two
homologues and interactors of FMRP were predicted to have similar functions as those of
FMRP simply by homology comparison. Indeed, the three proteins share high homology
degree in both their sequence and structural domains, but the fact that FXR1P and FXR2P
were never correlated directly to any disease, their molecular functions were poorly
investigated. The role of FXR1P in both muscle development and translation regulation
started to emerge but still needs a profound analysis to be more understood.
Aim : Does FXR1P show any affinity for FMRP targets ? if so, what would be the
influence of FXR1P on the RNA binding properties of FMRP ?
Procedure  : To analyze the RNA binding specificity and affinity, we used RNA
binding assays in presence of the G-quartet as specific competitor. To study the affinity of the
heterodimer FMRP/FXR1P, equal amount of protein was used in the same kind of binding
experiments. We therefore dissected the dynamic of FMRP/FXR1P/G-quartet association and
dissociation by time lapse RNA binding assays.
Results : Only FXR1P Isoe showed an affinity to G-quartets lower than that of FMRP
whereas the two other isoforms FXR1P Isod and Isoa bind unspecifically the G-quartet
structure. FMRP/FXR1P heterodimer has a higher dynamic association and dissociation with
and from RNA than the homodimers.
Conclusion : we tried to analyze the RNA binding affinities of FMRP in presence of
its interactors. We showed that despite the high homology degree between FMRP and
FXR1P, both proteins exhibit different affinity for RNA ( at least for RNAs harbouring a G-
quartet structure) and that FXR1P may have more a “synergic” effect rather than
compensatory for the absence of FMRP.
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ABSTRACT
Fragile X syndrome, the most frequent form of
inherited mental retardation, is due to the absence
of expression of the Fragile X Mental Retardation
Protein (FMRP), an RNA binding protein with high
specificity for G-quartet RNA structure. FMRP is
involved in several steps of mRNA metabolism:
nucleocytoplasmic trafficking, translational control
and transport along dendrites in neurons. Fragile X
Related Protein 1 (FXR1P), a homologue and inter-
actor of FMRP, has been postulated to have a
function similar to FMRP, leading to the hypothesis
that it can compensate for the absence of FMRP in
Fragile X patients. Here we analyze the ability of
three isoforms of FXR1P, expressed in different
tissues, to bind G-quartet RNA structure specific-
ally. Only the longest FXR1P isoform was found
to be able to bind specifically the G-quartet RNA,
albeit with a lower affinity as compared to FMRP,
whereas the other two isoforms negatively regulate
the affinity of FMRP for G-quartet RNA. This result is
important to decipher the molecular basis of fragile
X syndrome, through the understanding of FMRP
action in the context of its multimolecular complex
in different tissues. In addition, we show that the
action of FXR1P is synergistic rather than compen-
satory for FMRP function.
INTRODUCTION
Fragile X related genes are members of a small gene family
whose founding member is the Fragile X Mental Retardation
1 gene (FMR1). Inactivation of FMR1 causes Fragile X syn-
drome, the most common cause of inherited mental retarda-
tion (1,2). The other members of this family, FXR1 and
FXR2, are autosomal and have not been associated so far
with any human disease (2–4). Animal models have been
generated for Fmr1 deficiency, recapitulating the phenotype
of Fragile X syndrome (5,6). Fxr2 null mice are viable and
show some behavioral phenotypes, such as hyperactivity,
similar to those observed in Fmr1 knockout mice (7). Fxr1
null mice die shortly after birth most likely because of
heart and/or respiratory failure due to alterations in muscle
development (8). In Xenopus, complete or partial inactivation
of xFxr1 expression has dramatic muscle-specific effects (9).
In vertebrates, members of the FXR protein family are
structurally very similar and share a high degree of sequence
homology in clustered regions corresponding to functional
domains (2–4). Like FMRP, FXR1P contains several RNA
binding domains: two KH domains and one RGG box. It
also contains a nuclear localization signal (NLS), a nuclear
export signal (NES) and a protein–protein interaction domain
(2,10). They also share the same gene structure, derived from
their common ancestor in Drosophila melanogaster (11).
FXR proteins are able to bind RNA (3,4), but binding speci-
ficity has been studied in detail only for FMRP. Indeed, even
if a few hundreds of different RNAs have been proposed to be
putative targets of FMRP, only two structures are specifically
bound by this protein, the G-quartet and the kissing complex
(12–14) and one sequence, a poly(U) stretch (15). FXR1P has
been reported to bind AU rich element (ARE) and, through
the interaction with this element, to regulate the expression of
the proinflammatory cytokine tumor necrosis factor (TNFa)
in macrophages (16). In the cytoplasm the three FXR proteins
are associated with polyribosomes (17), while they share
only two interacting proteins, CYFIP2 and MSP58, with
FMRP (2,18,19). The FXR1 primary transcript is alternatively
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spliced, with the possibility to generate upto 15 isoforms (20),
see also www.ncbi.nlm.nih.gov/IEB/Research/Acembly/. Of
notice, some of these isoforms are differentially expressed
in various tissues (21). Up to date, the ability of full-length
FXR1P and FXR2P to bind a G-quartet RNA structure in a
specific manner has not been reported. We analyzed here
the RNA binding properties of the three most abundantly
expressed FXR1P isoforms and show that they have different
affinities for the G-quartet RNA structure. Since all protein
members of the FXR family are able to heterodimerize with
FMRP, they are believed to act together (4). In the present
study we determined that, when complexed to FMRP, FXR1P
isoforms can modulate its affinity for G-quartet RNA and also
the dynamics of this complex. Our data demonstrate that
FXR1P has a synergistic molecular function with FMRP
rather than a redundant role.
MATERIALS AND METHODS
Purification of recombinant proteins
Glutathione S-transferase (GST)-FMRP produced in the
baculovirus system was purified as described previously
(22). pET21a/FMRP (ISO1) vector was described previously
(23). To construct pGex-4T-1/FMRP, ISO1 cDNA was
excised from pTL1/FMRP ISO1 and subcloned into the
EcoRI/NotI sites of pGex-4T-1 (Amersham). To construct
pET21a/FXR1P, Isoe, Isod and Isoa isoforms were amplified
by PCR using the primers (Eurogentec): EcoRI forward-50-
GGCGAATTCATGGCGGACGTGACGGTG-30; XhoI reverse-
50-GCCCTCGAGTTATGAAACACCATTCAGGAC -30, the
PCR consisted of 1 cycle at 94C for 4 min, 30 cycles of
three steps each, 94C for 30 s followed by 60C for 30 s
and 68C for 2 min using the Pfx polymerase (Invitrogen).
PCR fragments were purified, digested and cloned into the
EcoRI/XhoI sites of pET21a (Novagen). The sequences of the
cDNAs corresponding to the different FXR1P isoforms were
verified by sequencing. The proteins were produced in bacteria
and purified following the manufacturer’s protocol. GST-
MSP58 was produced and purified as described previously (19).
GST-pull down
GST-pull down assays were performed as described previ-
ously (22). Briefly, an increasing amount of recombinant
His-FXR1P (1, 2 or 4 mM) was mixed with 4 mM of GST-
FMRP. Pull down assays were carried out in the following
buffer: [50 mM Tris–HCl (pH 7.4) at 4C, 1 mM MgCl2,
1 mM EDTA, 150 mM KCl, 1 mM DTT], as described (22).
After washing with the same buffer, the proteins bound to the
beads and their interactors were eluted using 30 mM glu-
tathione and separated by electrophoresis on 8% SDS–
polyacrylamide gels. FMRP was visualized by immunoblot
using the 1C3 monoclonal antibody (24), FXR1P was
revealed by the 3FX monoclonal antibody (21). The proteins
were also visualized on gel by Coomassie staining.
RNA binding assays
The different RNA fragments used in this study, N19
[RNA sequence derived from FMR1 cDNA and containing
a G-quartet forming structure (13)] and N8 [RNA sequence
not containing G-quartet structures and corresponding to the
30-untranslated region (30-UTR) of PP2Ac (25)], were cloned
in pTL1 plasmid. For filter binding assay, pTL1 plasmids
linearized with PstI were in vitro transcripbed with T7
RNA polymerase (Promega) (13). The RNAs were purified
using the NucAway Spin columns (Ambion). RNAs were
then ethanol precipitated and resuspended in a appropriate
buffer. For binding experiments, N19 was labeled co-
transcriptionally by incorporation of [a-32P]ATP. Labeled
RNAs were purified on a 1% low-melting agarose gel
(Ambion). Labeled RNAs (80 000 c.p.m., 5 fmol) were rena-
tured for 10 min at 40C in 4 ml of binding buffer [50 mM
Tris–HCl (pH 7.4) at 4C, 1 mM MgCl2, 1 mM EDTA,
150 mM KCl, 1 mM DTT] in the presence of 8 U RNasin
(Invitrogen), 0, 1 mg of Escherichia coli total tRNA and
0.01% BSA. An increasing amount of protein was then
added to the RNA. RNA–protein complexes were formed
for 10 min on ice. After incubation, binding solutions were
passed through MF-membrane filters (0.45 HA, Millipore)
and washed with 2 ml binding buffer. Filters were air dried
and the amount of radioactivity was measured by Cerenkov
counting. Data were plotted as percentage of total RNA
bound versus the protein concentration. Competition experi-
ments to determine the relative binding strength of the differ-
ent proteins to G-quartet RNA were carried out using labeled
N19 RNA incubated with 1 pmol of protein in the presence of
increasing concentrations of unlabeled competitors. FMRP
was used as an internal positive control. For association
rate determination, 5 fmol of labeled N19 were incubated
with 1 pmol of the appropriate protein in the binding buffer
between 10 and 300 min on ice. For dissociation rate deter-
mination, 5 fmol of labeled N19 were incubated with 1
pmol of the appropriate protein in the binding buffer for 10
min on ice, 106 M of competitor RNA (N19 or N8) were
then added to the mixture and incubated between 10 and
300 min. Each binding curve is the result of at least three
independent experiments performed with three replicates for
each binding point. All data obtained for the different experi-
ments of RNA binding, calculating the standard deviation for
each binding point, are shown in Supplementary Data. All the
values and curves were analyzed using the PRISM Graphpad
version 4 Software.
RESULTS
Our first aim was to assess whether FXR1P is able to bind
G-quartet RNA structure, which is considered to be a frequent
structure recognized by FMRP and present in many of
its mRNA targets (12,13,26). Due to extensive alternative
splicing of FXR1 mRNA, at least seven isoforms of FXR1P
are differentially expressed in various tissues (20). We
decided to study the RNA binding properties of three
FXR1P isoforms: Isod and Isoa (Figure 1), the two isoforms
most highly expressed in brain (3), and Isoe (Figure 1) that is
a FXR1P isoform highly expressed during myogenesis and in
adult cardiac and skeletal muscle (21). The FXR1P-Isod and
Isoa isoforms both lack exon 12 and 15 and only differ in
their C-terminus due to the choice of a different splicing
acceptor site in the mRNA of the FXR1P-Isoa isoform, result-
ing in a frameshift that induces an early stop codon
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(Figure 1A). On the other side, it is interesting to underline
that the only differences between FXR1P-Isod and Isoe iso-
forms are the insertion of 28 amino acid encoded by exon
12 and the presence of 27 amino acid encoded by exon 15
(20,21) (Figure 1A). This 27 amino acid stretch is strongly
recognized as a putative RNA binding motif by two different
predictive programs available online [http://bindr.gdcb.
iastate.edu/RNABindR/main.aspx (27) and http://129.130.
115.77/cgi-bin/bindn.pl (28)], whereas the sequence of exon
12 does not apparently display such properties. The presence
or absence of exon 15 raises then the possibility that the 3 iso-
forms share different RNA binding abilities.
As the tissue distribution of FXR1P isoforms had not been
investigated completely, we performed RT–PCR on various
RNA samples extracted from cell lines and tissues. FXR1P
containing exon 15 RNA was detected at very low level in
brain, and in particular in the cerebellum, cortex and hip-
pocampus, as well as in the neuroblastoma cell line NG108,
together with FXR1P isoforms lacking exon 15 (data not
shown).
To investigate the G-quartet binding properties of the three
FXR1P isoforms, we generated in a bacterial system recom-
binant FXR1P isoforms: Isoe, Isod and Isoa (Figure 1A)
(3,21), FMRP ISO1 (29) and as a control MSP58, a recently
described G-quartet binding protein (19), tagged with His or
GST (Figure 1B).
In a filter binding assay, recombinant FMRP protein pro-
duced in bacteria displays the same affinity for RNA contain-
ing a G-quartet structure as recombinant FMRP produced in
an insect cell system (data not shown), confirming that the
system of production does not change FMRP affinity for
G-quartet RNA, in agreement with studies by Darnell and
colleagues (30). Also it has been shown that FMRP acts as
a nucleic acids chaperone in low-salt binding conditions
(31) and is also able to bind RNA non-specifically, raising
the possibility of introduction of a bias in the assesment of
its binding affinities, as already suggested (13,32). Consider-
ing the high level of homology that exists between the FXR
proteins (4), we reasoned that FXR1P could also display the
same properties of aspecific binding to RNA. As a result, to
assess the RNA binding properties of FXR1P isoforms, we
used the rigorous and sensitive RNA competition assays,
which alleviate the contribution of aspecific binding (13,25).
Using the previously described filter binding assay (30), we
observed that FXR1P-Isod and Isoa isoforms do not bind spe-
cifically G-quartet RNA structure since the amount of bound
G-quartet radiolabeled probe is not competed by either the
unlabeled G-quartet RNA [N19, corresponding to the portion
of the FMR1 transcript containing the G-quartet structure
(13)] or another RNA not containing G-quartet structures
and not binding FMRP [N8, corresponding to the 30-UTR
of the PP2Ac transcript (25)] (Figure 2B). Indeed, at the equi-
librium state, the dissociation constant (Kd) is around 5 mM
for FXR1P-Isod isoform and 0.8 mM for FXR1P-Isoa.
Conversely, FXR1P-Isoe binds G-quartet RNA but with a
lower affinity compared to FMRP or MSP58 (Figure 2A).
As little as 1 nM of competitor RNA is able to displace
50% of FMRP from G-quartet labeled probe, whereas 10
nM are necessary for FXR1P-Isoe (Figure 2A). When we
used as competitor the N8 probe, that does not bind FMRP
(25), no binding was observed for all proteins analyzed
here (Figure 2B). To confirm that FXR1P-Isoe interaction
with G-quartet RNA is specific for the structure, we per-
formed the binding assay either in the presence of K+ or in
the presence of Na+. Indeed, FXR1P-Isoe, like FMRP and
MSP58 (13,19) is unable to bind G-quartet containing
FMR1 RNA in the presence of Na+, a cation destabilizing
the G-quartet structure (Figure 2C). This finding suggests that
the effect observed is not due to the recognition of a specific
RNA sequence, but to the G-quartet structure localized in
Figure 1. The FXR1P isoforms. (A) Schematic representation of the C-terminal region of the three FXR1P isoforms analyzed: Isoe 84 kDa, Isod 78 kDa, Isoa
70 kDa. In the upper part of the figure the alternatively spliced sequences are indicated. A (+) under each amino acid indicates the predicted ability of the
sequence to bind RNA accordingly to the algorithm described by Terribilini and coworkers (28). (B) Production of recombinant proteins. Equal amounts of
Hist-FMRP, His-FXR1P-Isoe, Isod, Isoa and GST-MSP58 were loaded on a 10% SDS–PAGE gel and revealed by Coomassie blue staining.
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the assayed RNAs (13). In addition, we repeated the same
analysis by competing the binding of 32P-labeled N19 probe
with the G-quartet forming RNA structures obtained from
the 50-UTR of PP2Ac (that contains four G-quartet forming
structures) (25) and obtained the same results (data not
shown) that are described in Figure 2A using N19 RNA
competition.
Since FXR1P isoforms display different G-quartet binding
specificity, we asked whether they would affect differently
FMRP binding affinity to G-quartet. First, we verified the
Figure 2. RNA binding properties of FMRP and FXR1P isoforms. (A) Filter binding assay using FMRP, FXR1P-Isoe, Isod, Isoa and MSP58. The RNA probe
used is 32P-labeled N19 RNA, and competition was performed using the same unlabeled RNA. (B) The same experiment was repeated using as competitor the N8
RNA sequence, not containaing any G-quartet forming structure. (C) Filter binding assay was repeated with an increasing amount of FMRP and Isoe in the
presence of Na+ or K+. (D) GST-pull down was performed as described in Materials and Methods. On the right part of (D), proteins used in GST-pull down assay
were revealed by immunoblot. FMRP was detected by monoclonal 1C3 antibody, FXR1P by the monoclonal 3FX antibody. Lane 1: 4 mM GST-FMRP
complexed with 1 mM His-FXR1P, Lane 2: 4 mM GST-FMRP complexed with 2 mM His-FXR1P, Lane 3: 4 mM GST-FMRP complexed with 4 mM His-FXR1P.
On the left part of (D), proteins used in GST-pull down experiment were revealed by Coomassie stained gel. (E) Competition assay to determine the Kd at the
equilibrium state binding FMRP, the heterodimers FMRP/Isoe, FMRP/Isod, FMRP/Isoa and the complex FMRP/MSP58, with the 32P-labeled N19 probe and
competed with unlabeled N19. (F) The same experiment described in (E) was repeated using the N8 RNA as unlabeled competitor.
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amounts of FXR1P and FMRP that integrate the heterodimer
complex. To this purpose, we performed GST-pull down
experiments by mixing 4 mM of GST-FMRP with increasing
amounts (1, 2, 4 mM ) of His-FXR1P-Isoe, Isod or Isoa (In
Figure 2D, the results are shown only for interaction bet-
ween FMRP and FXR1P-Isoe). The beads were then treated
with glutathione and the eluted proteins were revealed by
immunoblot using the two monoclonal antibodies 1C3 (24)
and 3FX (21) recognizing FMRP and FXR1P, respectively.
As shown in Figure 2D, the ratio of released FXR1P and
FMRP is around 1:1 when mixed in stochiometric amounts.
This result shows that when the two proteins are mixed
in vitro their association is dose-dependent and, on the other
side, also shows that our results are not due to an unbalanced
ratio of the two interacting proteins in the FXR heterodimers.
Subsequently, we tested the ability of the FXR1P-Isoe/
FMRP heterodimer to bind G-quartet RNA. Indeed, the
FXR1P-Isoe/FMRP complex binds G-quartet RNA with a
comparable affinity as the FMRP homodimer at different
concentrations of competitor RNA (Figure 2E). Surprisingly,
FXR1P-Isod and Isoa inhibit FMRP binding to G-quartet
RNA when these form a heterodimer with the latter
protein (Figure 2E). As a control, MSP58 protein, that
binds G-quartet RNA in a specific manner (19), was used
(Figure 2E), and its binding to FMRP leads to the same
results as when FMRP is complexed to FXR1P-Isoe. When
we used the N8 probe as a negative control, no displacement
of the equilibrium was observed, as shown in Figure 2F.
In view of these results, we decided to better dissect the
dynamics of FXR1P/G-quartet RNA and FXR1P/FMRP/
G-quartet RNA interactions. We evaluated the velocity of
interaction of the two FXR proteins with G-quartet RNA. For
this purpose 1 pmol of each protein was mixed with 5 fmol of
labeled N19 RNA. At different time points (10, 30, 60, 120,
240 or 300 min), the assay was stopped and the amount of
radioactivity bound by the proteins evaluated by the filter
binding assay. The time necessary for FMRP/FXR1P-Isoe
heterodimer to bind the half amount of total bound RNA
ligand was estimated to be 9.93 min, which is lower
than the time employed by FMRP or FXR1P homodimers
(33.65 and 19.04 min, respectively) to bind the same amount
of RNA probe (Figure 3A and B ). This result indicates that
the Kon for the heterodimer is higher than the Kon for both
homodimers. Conversely, the presence of MSP58 complexed
with FMRP did not influence its binding to G-quartet RNA.
We then investigated the kinetics of FXR1P-Isoe and
FMRP dissociation from the G-quartet RNA structure,
when both bind to it as homodimers or as heterodimers.
FMRP was mixed with 32P-labeled N19 RNA and the com-
plex was allowed to form for 10 min on ice. Then 1 mM of
cold RNA [N19 or N8, as a negative control (25)] was
added, the reaction was stopped after 10, 30, 60, 120, 240
or 300 min and the amounts of retained radioactivity evalu-
ated by filter binding assay. In this experiment, it is interest-
ing to observe (Figure 4A) that the FXR1P-Isoe homodimer
releases 50% of total bound RNA after only 15 min. As
expected from its higher affinity, the FMRP homodimer
releases the same amount of bound RNA after a longer lapse
of time, around 45 min. The negative controls are shown in
Figure 4B. In this case the binding of recombinant proteins
to G-quartet containing RNA was competed using the N8
probe. Indeed, only 20–25% of the binding is competed
after more than 4 h of incubation.
Finally, the heterodimer FXR1P-Isoe/FMRP and the
complex MSP58/FMRP were analyzed. The effect of the
heterodimer was dramatic: 50% of the labeled RNA was
released after 5 min and 65% of labeled RNA was released
after 10 min (Figure 4C), while the interaction with MSP58
does not change significantly the dynamics of the interaction
between the G-quartet RNA and FMRP. In Figure 4D the
negative controls are shown, confirming the specificity of
the action described in Figure 4C. This data shows that
formation of the FXR1P-Isoe/FMRP heterodimer increases
the dynamics of protein–RNA interaction, favoring the
release of bound mRNA.
DISCUSSION
FMRP is a component of multimolecular complexes involved
in different steps of mRNA metabolism (2,12). A growing list
Figure 3. Association rate of FMRP, Isoe and MSP58. (A) Each protein was mixed with 32P-labeled N19 RNA probe for a time lapse of 10, 30, 60, 120, 180, 240
and 300 min and then each reaction was filtered and the amount of retained radioactivity evaluated. (B) The same experiment described in (A) was repeated
with the complex FMRP/MSP58 and FMRP/Isoe as indicated in the figure.
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of proteins interacting with FMRP has been described, most
of them being RNA binding proteins (19,33). In addition,
several hundreds of mRNAs have been described as putative
targets of FMRP (12,26), however the functional significance
of most of the multiple interactions established by FMRP is
still elusive (12,34). A widely accepted hypothesis proposes
that FMRP can transport mRNA in mRNPs shuttling between
structures where RNA translation is repressed and polyribo-
somes (2). In the absence of FMRP, the equilibrium in mRNP
normally containing FMRP is perturbed, resulting in the
deregulation of the expression and localization of a subset
of its target mRNAs (12,26). Based on these considerations,
we reasoned that RNA binding proteins belonging to the
same mRNP complex, FMRP and its interacting proteins
may enter in contact with the same mRNAs and decided to
test the ability of FXR1P to bind the same mRNA targets
and to influence its affinity for them. Up to date, the functions
of FXR1P (or FXR2P) were inferred to be, by homology and
analogy, similar to that of FMRP (1). Here we propose that
it is not the case, at least for FXR1P.
First, we tested FXR1P affinity for G-quartet forming RNA
structures. It is surprising that among the three isoforms
analyzed only one, the Isoe is able to bind a G-quartet
RNA forming structure, present in a large amount of putative
target RNAs of FMRP (26). The three FXR1P isoforms share
the same RGG box domain. However, it has been reported
that, even though a peptide corresponding to the RGG box
of FMRP binds specifically G-quartet forming RNA (30),
the corresponding peptide of the RGG box of FXR1P does
not (35), strongly suggesting that the RGG box of FXR1P
is not sufficient per se to bind the G-quartet structure. The
only difference between the two isoforms Isoe and Isod are
two short sequences of 28 (exon 12) and 27 amino acid
(exon 15) (cf. Figure 1A). Only this latter amino acids stretch
appears to have putative RNA binding properties and is
encountered solely in the Isoe isoform able to bind specific-
ally the G-quartet structure. This 27 amino acid stretch
encoded by FXR1P exon 15 being in close proximity to the
RGG box of FXR1P encoded by sequences of exon 14
(Figure 1A), it may contribute to the binding to G-quartet
mRNA structures together with the RGG box. Alternatively,
the presence of this additional sequence in the FXR1P-Isoe,
as compared to the other shorter isoforms, may alter the struc-
ture of the C-terminal portion of FXR1P, thereby allowing
the binding. In a similar way, a different affinity for RNA
was also shown for different FMRP isoforms. Indeed,
ISO18, a minor isoform of FMRP lacking a small portion
of exon 17 (29), is still able to bind G-quartet RNA (36),
Figure 4. Dissociation rate of FMRP, Isoe, MSP58 and the two complexes FMRP/Isoe and FMRP/MSP58. (A) Each protein was mixed with 32P-labeled N19
RNA probe for 10 min on ice and then an equal amount of unlabeled N19 RNA was added as competitor to each reaction, which was then filtered after a
precise time lapse of 10, 30, 60, 120, 180, 240 and 300 min. The radioactivity retained on the filter was evaluated. (B) The same experiment described in (A)
was repeated using unlabeled N8 RNA as competitor. (C) The same experiment described in (A) was performed using the protein complexes FMRP/Isoe and
FMRP/MSP58. (D) The same experiment described in (C) was performed using the cold N8 RNA as competitor.
304 Nucleic Acids Research, 2007, Vol. 35, No. 1
like ISO1 and ISO7 (13,30). In addition, ISO 18 is able to
bind the 30-UTR of FMR1 mRNA (36), that, conversely, is
not bound by ISO1 and ISO7 (13,30).
In adult muscle, where both FMRP and FXR2P are absent,
the FXR1P isoforms encountered both contain exon 15
sequences and correspond to a doublet of 82 (Isog) and
84 kDa (Isoe) (20,21,37). Their ability to bind G-quartet
RNA structure suggests that, in this tissue, specific RNAs
might be recognized by FXR1P via the interaction with
G-quartet forming structure. Since FXR1P absence has a
strong impact during muscle development (8,9), its RNA
binding capacities are critical per se, independently from
FMRP’s fonction. Indeed, a recent knock-down analysis
for xFxr1 produced a list of putative FXR1P target RNAs.
Interestingly, several of their human homologues harbor a
putative G-quartet structure [(9), and our unpublished data].
In addition, very little is known concerning the precise
function of FXR1P in muscle, and it is possible that muscle-
specific FXR1P interacting proteins might modulate its
affinity for RNA.
Our analysis to dissect the binding capacities to G-quartet
RNA FXR1P and its heterodimer with FMRP yielded
unexpected findings. We observed a dramatic effect of the
FMRP/FXR1P heterodimer on the dynamics of complex
formation with G-quartet RNA. This effect was not observed
when FMRP and its other partner MSP58 were mixed
together, suggesting that MSP58 can probably compete for
the same binding site as FMRP. In addition, the interaction
of FMRP with FXR1P-Isoa or Isod strongly reduced FMRP
specificity for G-quartet RNA. These different behaviors of
the two FMRP-interacting proteins illustrate the complexity
of the functions and interactions that take place in FMRP-
containing mRNPs and in different tissues. FXR1P-Isod and
Isoa are the FXR1P isoforms with the highest expression
in brain, suggesting that in neurons FMRP interacts mostly
with these two isoforms that might regulate negatively its
action. Since in brain and cerebellum FXR1P-Isoe mRNA
is expressed at a low level as revealed by RT–PCR (our
unpublished data), probably only a very small portion of
FMRP may be regulated by FXR1P-Isoe. Conversely,
FMRP and FXR1P-Isoe and Isog isoforms are co-expressed
in myoblasts and in myotubes, suggesting a particular regula-
tion of G-quartet containing target mRNAs during muscle
differentiation but not in adult muscle, where FMRP is not
expressed anymore (21). The present study highlights the
functional differences between FXR1P isoforms and there-
fore emphasizes the importance of the extensive tissue-
specific alternative splicing undergone by FXR1 mRNA. In
view of these results, it is clear that in each mRNP the
ratio between FMRP and FXR1P different isoforms becomes
important to precisely regulate FMRP function. The modula-
tion of the affinity and/or of the dynamics observed for the
FXR1P/FMRP heterodimer may reflect a regulation of the
exchange of mRNAs between mRNPs or trafficking granules
and polyribosomes.
The interaction domain of the two FXR proteins is local-
ized in the N-terminal region of both proteins. This domain
mediates the interaction between FMRP and several other
proteins (FXR2P, CYFIP1, CYFIP2, NUFIP and 82-FIP)
(10,33). On the other hand, despite the high level of homo-
logy, the N-terminal region of FXR1P seems to interact
only with CYFIP2 and FXR2P (18). CYFIP2, together with
CYFIP1, that only interacts with FMRP, belongs to a small
family of proteins linking FMRP to the Rac pathway
(18,33,38). We have previously proposed that the CYFIP pro-
teins might modulate the ability of the FXR family members
to homo and/or heterodimerize (18).
FXR1P and FXR2P are believed to have distincts but
overlapping function in conjunction with FMRP, with the
possibility to partially compensate for its absence. Our results
show here a completely different function for two different
FXR1P isoforms, which modulate the action of FMRP. This
data reveals how a full understanding of FMRP function may
be achieved through the deciphering of the global action of
FMRP-containing mRNP complexes.
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Publication 3
Using a yeast two hybrid system, MSP58 was shown to interact specifically with FMRP. In
the cytoplasm, MSP58 is associated with polyribosomes. MSP58 showedan affinity for RNA
homopolymers. As an interactor of FMRP that shows to some extent the same localization,
my contribution to this study was to analyze the ability of MSP58 to recognize and bind G-
quartets as FMRP.
We demonstrated that MSP58 binds specifically the G-quartets structure with an affinity
similar to that of FMRP.
We further analyzed the dynamics of FMRP/MSP58 G-quartet association and dissociation
and showed that MSP58 acts in a different way than the other interactor, FXR1P (see
publication 2)
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The fragile X syndrome, the leading cause of inherited mental retardation, is due to the inactivation of the
fragile mental retardation 1 gene (FMR1) and the subsequent absence of its gene product FMRP. This
RNA-binding protein is thought to control mRNA translation and its absence in fragile X cells leads to altera-
tion in protein synthesis. In neurons, FMRP is thought to repress specific mRNAs during their transport as
silent ribonucleoparticles (mRNPs) from the cell body to the distant synapses which are the sites of local syn-
thesis of neuro-specific proteins. The mechanism by which FMRP sorts out its different mRNAs targets might
be tuned by the intervention of different proteins. Using a yeast two-hybrid system, we identified
MicroSpherule Protein 58 (MSP58) as a novel FMRP-cellular partner. In cell cultures, we found that MSP58
is predominantly present in the nucleus where it interacts with the nuclear isoform of FMRP. However, in
neurons but not in glial cells, MSP58 is also present in the cytoplasmic compartment, as well as in neurites,
where it co-localizes with FMRP. Biochemical evidence is given that MSP58 is associated with polyribosomal
poly(A)1 mRNPs. We also show that MSP58, similar to FMRP, is present on polyribosomes prepared from
synaptoneurosomes and that it behaves as an RNA-binding protein with a high affinity to the G-quartet struc-
ture. We propose that this novel cellular partner for FMRP escorts FMRP-containing mRNP from the nucleus
and nucleolus to the somato-dendritic compartment where it might participate in neuronal translation
regulation.
INTRODUCTION
The fragile X syndrome (FXS) is the leading cause of
inherited mental retardation, due to the silencing of the
fragile X mental retardation 1 gene (FMR1) and the sub-
sequent absence of FMRP, its gene product. FXS affects
1/4000 males and 1/7000 females worldwide and is characteri-
zed by moderate to severe mental retardation. The phenotype
is complex and is also accompanied by physical abnormalities
such as facial dysmorphism, postpubertal macro-orchidism
in males and mild connective tissue dysplasia (1–4). FMRP
is an RNA-binding protein widely expressed in mammalian
tissues (5) and particularly abundant in neurons (6) and is an
element of messenger ribonucleoprotein (mRNP) complexes
associated with brain polyribosomes (7–9). Its presence
within the translational apparatus suggests that it is involved
in the translational control of certain mRNAs. In addition,
FMRP is present in mRNA cargoes that are transported
along neurites and dendrites (10,11). Its interaction with the
RNA-induced silencing complex in the cytoplasm suggests
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that it can also play a role in the control of the stability of
mRNA and/or it acts as translational inhibitor via the inter-
action with the AGO proteins (12).
Two KH domains and an RGG box modulate the ability of
FMRP to bind RNA. The RGG box has high affinity for the
RNA G-quartet structure (13,14) present in several of
FMRP’s mRNA targets (15), whereas the KH2 domain
seems to recognize synthetic RNAs aptamers presenting a
loop–loop pseudoknot-specific motif or ‘kissing complex’
(16). In Fmr1 null mice, a series of mRNA display change,
both in localization and abundance, pointing out the critical
role that FMRP plays in the targeting of specific mRNAs
(17,18). It is proposed that the absence of FMRP would lead
to alterations in the local synaptic synthesis of proteins that
are essential for synaptic development and maturation. One
of the consequences of the absence of FMRP is the presence
of abnormal looking immature and surnumerary neuronal den-
dritic spines in the brains of fragile X patients (19,20), which
ultimately lead to mental retardation in FXS patients.
FMRP is able to interact directly through its N-terminal
domain with a series of protein partners. Among these,
FXR1P and FXR2P are two closely related paralogues that
show high levels of homology with FMRP (21,22) and can
form heterodimers with FMRP. The FMRP-interacting
protein 82-FIP is an RNA-binding protein that is present in
polyribosomal mRNPs (23), whereas NUFIP1, also an RNA-
binding protein, is a nucleocytoplasmic shuttling protein that
is associated with active synaptoneurosomes (24). Two paralo-
gous proteins, CYFIP1 and CYFIP2, that interact with FMRP
also provide a link to the Rho GTPase pathway that controls
actin cytoskeleton dynamics (25,26). More recently, IMP1, a
zip-code protein involved in mRNA transport, has also been
found to directly interact with FMRP (27). RanBPM, a
protein involved in the microtubule-organizing centre has
been reported to bind to the C-terminus of FMRP (28). In
addition, other RNA-binding proteins such as nucleolin,
YB-1/p50, Pur-a and Staufen have been detected in com-
plexes containing FMRP, but it is not known whether they
interact directly or indirectly with FMRP (29–31). Only a few
non-RNA-binding proteins have been shown to interact with
FMRP, including myosin Va (31) and Lgl in Drosophila (32).
In this study, we describe a novel FMRP-interacting protein
named MicroSpherule Protein 58 (MSP58). We provide evi-
dence that MSP58 associates with polyribosomal poly(Aþ)
mRNP and is also found as a polyribosome component in syn-
aptoneurosomes. Moreover, we show that MSP58 is a novel
nuclear RNA-binding protein able to bind G-quartet RNA.
RESULTS
MSP58 is a novel FMRP-interacting proteins
To identify new FMRP-interacting proteins specific to
neurons, we screened a human fetal brain cDNA library
using a yeast two-hybrid system, with the major FMRP Iso7
form as a bait. From 2.8  106 clones screened, 78 positive
clones displayed adenine and histidine prototrophy as well as
b-galactosidase activity. PCR and restriction analysis of
selected colonies showed that among these, three clones
were redundant and carried a 1.7 kb insert. This insert
corresponded to the full-length cDNA of a human nuclear/
nucleolar protein of 58 kDa called MSP58 (33). The predicted
open-reading frame encodes a protein of 462 residues. The
cDNA obtained from the yeast two-hybrid screening also har-
boured the 50 and 30-untranslated regions which were identical
to the previously established sequence (33).
The specificity of the interaction of MSP58 with FMRP was
confirmed in yeast by co-transforming the AH109 strain with
plasmids encoding MSP58 and FMRP (Table 1). Given the
high degree of similarity between all members of the FXR
family, we also tested the ability of MSP58 to interact with
FXR1P and FXR2P, the two other members of the FXR
family. MSP58 was found to interact with FMRP, FXR1P
and FXR2P (Table 1), whereas no interaction was detected
with control plasmids bearing unrelated proteins cDNA. The
strong interaction between MSP58 and the FXR proteins
induced us to further investigate FMRP/MSP58 interaction.
MSP58 is a highly evolutionarily conserved
nuclear protein
MSP58 was initially shown to interact with the nucleolar
protein p120, and its overexpression led to enlargement of
nucleoli (33). Also, MSP58 was reported to play a role in
modulation of Daxx-dependent transcriptional repression
(34). Recently, a study revealed that MSP58 behaves as an
oncogene and that its transformation activity can be inhibited
by physical interaction with the PTEN tumour suppressor (35).
Moreover, it was reported that MSP58 associates to and stabil-
izes the transcriptional activity of the bHLH trancription factor
STRA13 (36). Finally, MSP58 was shown to interact with
Mi-2b in the nucleolus and to up-regulate ribosomal gene
transcription (37). However, despite of all these data, the
cellular role of MSP58 remains unclear because divergent
properties/functions have been attributed to the protein.
We searched for sequences displaying similarities with
human MSP58 cDNA and found homologues in species as
distant as human (hMSP58, also called MCRS1), mouse
(mMSP58), Xenopus laevis (xMSP58 or xMCRS1), zebrafish
(zMSP58 or zMCRS1), quail (qMSP58 or qTOJ3) and
finally Drosophila melanogaster (dMSP58 or CG1135-PA)
(Fig. 1A). Alignment of all sequences revealed that all homolo-
gues share a high level of similarity. Indeed, human and
mouse MSP58 proteins are 98.7% identical, differing by
only six residues over 462, whereas human shares 81% iden-
tity with its frog counterpart. As the presence of highly
conserved residues stretches should delineate domains
essential for MSP58 function(s), we performed computational
analysis of these sequences. The N-terminal part contains a
highly conserved domain bearing a putative bipartite nuclear-
localization signal (amino acids 32–46), as well as a putative
nucleolar-localization signal (amino acids 44–56). This
stretch of residues 44–56 KRRSSR-IKRKKFDDELVSS is
100% conserved over species, showing slight divergences only
in Drosophila, suggesting functional relevance of this
domain. Further down the sequence, a putative monopartite
nuclear-localization signal (amino acids 113–123) is detected,
whereas a coil–coil domain is predicted at position 301–350.
Despite the high level of conservation of the central part
of MSP58, i.e. amino acids 125–294, no similarity to
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known functional domains were found. The C-terminus of
all MSP58 homologues contains a highly conserved
forkhead-associated (FHA) domain (Fig. 1B). FHA domains
are known to interact with phosphorylated residues and
indeed, MSP58 FHA domain was shown to specifically bind
phosphorylated residues of STRA13 and PTEN (35,36).
MSP58 N-terminal domains interact with the
phosphorylation domain of FMRP
To confirm the results obtained in yeast and to verify whether
the FMRP/MSP58 interaction was direct and specific, we per-
formed a series of pulldown assays using the FMRP full-
length protein, as well as FXR1P (Iso7) and FXR2P. These
proteins were produced and labelled with [35S]methionine by
in vitro transcription–translation using the rabbit reticulocyte
lysate, whereas human MSP58 was produced as a fusion
protein with glutathione S-transferase (GST) in bacteria. The
GST–MSP58 fusion protein immobilized on glutathione–
Sepharose was incubated with either in vitro-translated
FMRP, FXR1P, FXR2P or luciferase as a negative control.
The three members of the FXR family were shown to bind
to the immobilized GST–MSP58, whereas luciferase did not
(Fig. 2A). No binding to GST was observed, confirming the
specificity of the interaction. To verify that the interaction
between FMRP and MSP58 was direct and not RNA-
dependent, GST pulldowns between in vitro-translated
FMRP and GST–MSP58 bound to beads were performed in
the presence of RNase A, RNase T1 and DNase I. This treat-
ment did not alter FMRP binding to MSP58 (data not shown),
indicating that the interaction occurs at the protein–protein
level.
To refine the area of interaction between MSP58 and
FMRP, MSP58 fragments were fused to GST and tested for
their ability to retain 35S-radiolabelled FMRP. As shown in
Figure 2B, MSP58 N-terminus encompassing amino acids
1–124 was sufficient to bind FMRP, and a fortiori the
stretch of amino acids 1–294 as well as the full-length
MSP58, indicating that FMRP-binding domain lies in the
N-terminus. In contrast, to determine the region of FMRP
that binds MSP58, several FMRP variants and deletion con-
structs were tested for their ability to bind GST–MSP58. As
MSP58 has been previously reported to behave as a nuclear
protein, we also tested its ability to bind the nuclear FMRP
isoform (Iso6) lacking exon 14 (amino acids 426–490) that
encompasses the NES. As shown in Figure 2C, FMRP full-
length (Iso7) and Iso6 and all FMRP versions truncated
before (amino acids 1–526) and after the RGG box (1–554)
were able to bind recombinant GST–MSP58. Because
FMRP version truncated at amino acids 426 was not able to
bind MSP58, although FMRP Iso6 lacking amino acids
426–490 still interacts with MSP58, we concluded that the
binding domain to MSP58 lies between amino acids 490 and
526 (Fig. 2E). Interestingly, it encompasses the phosphoryl-
ation domain of FMRP which has been mapped at amino
acids 444–526 (38–40). This domain is also present in
FXR1P and FXR2P and displays a highly conserved block
of residues among the three proteins (Fig. 2D).
We then questioned whether point mutations in the serine
500 residue of FMRP, known to be phosphorylated (38),
would affect its binding to MSP58. Substitution of the S500
by the unphosphorylable residue alanine or by the acidic
residue aspartate, which mimics a charged phosphorylated
serine, did not, at least in vitro, affect the binding of MSP58.
Subcellular localization of MSP58
According to the few reports available in the literature, MSP58
is supposed to be either exclusively nucleolar or nucleolar and
nucleoplasmic (33,34,36,37) or even cytoplasmic (35). It is
worth mentioning that most of these studies utilized cells tran-
siently expressing an HA-tagged MSP58 that was revealed
with anti-HA antibodies, whereas the cellular distribution of
the bona fide endogenous MSP58 has not been fully documen-
ted. We first raised an anti-MSP58 antibody in rabbit against
the central part of human protein (amino acids 125–294).
Table 1. MSP58 interacts with FMRP, FXR1P and FXR2P in yeast
Plasmid 1 Plasmid 2 Growth on
AHLT medium
b-galactosidase
activity
Interaction
Interaction test pGBKT7/FMRP pACT2/MSP58 þþþþ þþþþ þ
pGBKT7/MSP58 pACT2/FMRP þþþþ þþþ þ
pGBKT7/FXR1P pACT2/MSP58 þþþþ þþþ þ
pGBKT7/FXR2P pACT2/MSP58 þþþþ þþþ þ
Positive control pGBKT7/FMRP pACT2/FXR1P þþþþ þþþþ þ
pGBKT7/p53 pACT2/T antigen þþþþ þþþþ þ
Negative control pGBKT7/MSP58 pACT2 2 N/A 2
pGBKT7/MSP58 pACT2/T antigen 2 N/A 2
pGBKT7 pACT2/MSP58 2 N/A 2
pGBKT7/p53 pACT2/MSP58 2 N/A 2
AH109 yeast strain was co-transformed with the indicated plasmids. Test for interaction was performed by plating the transformants on a medium
depleted in adenine and histidine, to check for activation of the reporter genes ADE2 and HIS3. All transformants positive for interaction on
medium depleted in adenine and histidine showed a blue colour in the presence of X-Gal, confirming the Lac Z activation. Interaction could be detected
between FMRP and MSP58, FXR1P and MSP58 as well as FXR2P and MSP58. Growth was comparable to strains transformed with FMRP, FXR1P,
FXR2P as well as with p53 and the T antigen which are known to interact, whereas no growth was observed when MSP58 was transformed together
with the empty pGBKT7 vector or with pGBKT7-p53 which is an unrelated protein.
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One antiserum was obtained, and after immuno-affinity purifi-
cation, its specificity towards MSP58 was determined by both
immunoblot analyses and immunofluorescence staining using
HeLa and Cos-1 cells transfected with an expression vector
for hMSP58. In addition, we observed that different staining
patterns were obtained depending on the procedures used
to fix the cells prior to the immunofluorescence stainings,
and we assumed that the discrepancies observed in its
subcellular localization reported by others were due to the fix-
ation procedures. A classical 10 min 4% PFA fixation fol-
lowed by a 0.5% Triton permeabilization treatment revealed
an exclusively nucleolar staining (Fig. 3A), whereas a
10 min fixation with 4% PFA in the presence of 0.5% Triton
showed both nuclear and nucleolar localization (Fig. 3B). In
contrast, a combined fixation and permeabilization procedure
using formaldehyde in a mixture of acetone and methanol
Figure 1. MSP58 is highly evolutionarily conserved. (A) MSP58 is widely represented among species as divergent as human (h), mouse (m), Xenopus (x),
zebrafish (z), quail (q) and Drosophila (d). The amino acids highlighted in black are conserved among all species; those highlighted in grey are similar.
Note the high level of conservation among the different species, especially in the C-terminal portion of the protein. Clusters of amino acid identity can be
detected all along the sequence, particularly in the predicted functional domains. (B) Analysis of MSP58 sequences among species reveals conserved features.
The N-terminus bears a putative nucleolar-localization signal (NoS) as well as putative monopartite nuclear-localization signal (NLS). In the second half of the
protein lies a predicted coiled-coil domain and finally in the C-terminus a highly conserved FHA domain. (C) Phylogenetic tree of the MSP58 family. Sequences
alignments used to construct the tree were obtained using Clustalx software. The phylogenetic tree was then generated using the program PhyloWIN and the
neighbour-joining algorithm, with 500 bootstrap replicates. Respective lengths of the tree branches are indicated and illustrate the ratio of amino acid differences
between sequence pairs.
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(2/19/19 by vol) allowed to visualize both nucleoplasmic and
nucleolar distribution of MSP58 and also a faint cytoplasmic
staining. In control analyses, no staining was detected when
the antibodies were pre-incubated with recombinant purified
GST–MSP58 amino acids 125–294 that was used for immu-
nization (Fig. 3D). On the basis of these results, we concluded
that MSP58 lies predominantly in the nucleus, whereas a small
fraction is detected in the cytoplasm.
MSP58 recruits FMRP nuclear Iso6 into the nucleolus
To better visualize in vivo the subcellular localization of MSP58,
we fused its cDNA to the red fluorescent protein (RFP)
and transfected Cos-1 cells with this construct. Exogenous
RFP–MSP58 strongly accumulates in the nucleolus but is also
present in the nucleoplasm (Fig. 4A). We also noticed that
upon overexpression of RFP–MSP58 nucleoli became enlarged,
in agreement with Ren et al. (33). This nucleolar accumulation
was also reproducible in HeLa and Fmr12/2 STEK cells
(data not shown). The specificity of the distribution was assessed
by immunostaining of the RFP–MSP58 fusion protein with
anti-MSP58 and indeed a co-labelling of RFP–MSP58 and the
endogenous MSP58 was observed (not shown). In this series
of analyses, we were not able to detect a cytoplasmic staining
due to the relative extremely strong nucleolar accumulation of
exogenous RFP–MSP58. Alternatively, we speculate that high
levels of RFP–MSP58 present in the nucleolus might have
deleterious effects on the metabolism of the cell and prevents
normal nuclear export of the protein.
To study in vivo the interaction between MSP58 and FMRP,
we used in transfection experiments the two constructs encod-
ing, respectively, RFP–MSP58 and the nuclear Iso6 FMRP
fused to GFP. In single transfected Cos-1 cells, GFP–FMRP
Iso6 localizes in the nucleoplasm and is excluded from
Figure 2. In vitro interaction of FMRP with MSP58 in a pulldown assay. (A) Pulldown assay using 1 mg of the fusion protein GST–MSP58 and in vitro-
translated 35S-labelled FMRP, FXR1P and FXR2P. (B) In vitro-translated FMRP binds to GST–MSP58 as well as to its amino acids 1–124 and 1–294 frag-
ments, indicating that MSP58 N-terminal domain is the minimal binding domain for FMRP. (C) In vitro-translated FMRP Iso7 and the nuclear Iso6 form as well
as the N-terminal truncated FMRP fragments were used to map the domain of interaction between FMRP and MSP58. FMRP Iso7 and Iso6 as well as FMRP
versions truncated just before (amino acids 1–526) and after the RGG (amino acids 1–554) were able to bind recombinant GST–MSP58. FMRP fragments
truncated more N-terminally: amino acids 1–207 and 1–426 did not bind to GST–MSP58. (D) The domain encompassing amino acids 490–526 that binds
MSP58 corresponds to the phosphorylation domain of FMRP and is highly conserved in FXR1P and FXR2P. (E) Schematic diagram summarizing the data
presented in (A–C).
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the nucleolus (Fig. 4B). Interestingly, co-expression of RFP–
MSP58 and GFP–FMRP Iso6 drastically altered the nucleo-
plasmic distribution of the latter. Indeed, in co-transfected
cells, GFP–FMRP Iso6 was clearly recruited into the nucleo-
lus (Fig. 4C). To ascertain that this phenomenon was not arte-
factual owing to the presence of the fusion proteins RFP and
GFP, which are known to form homo and heteromultimers
in vivo, we transfected Cos-1 cells with untagged versions of
pTL1-FMRP Iso6 together with pTL1-MSP58 and revealed
both proteins by immunofluorescence staining using
anti-MSP58 antibody and mAb1C3 to FMRP, and the same
phenomenon was observed (data not shown). To assess
whether the ability of MSP58 to attract FMRP Iso6 in the
nucleolus was not cell-type-specific, RFP–MSP58 and
GFP–FMRP Iso6 were also co-expressed in different cell
lines, i.e. HeLa and Fmr12/2 STEK cells, and similar obser-
vations were made suggesting that MSP58 has the ability to
drag and retain FMRP Iso6 in the nucleolus.
In a second set of experiments, we co-transfected RFP–
MSP58 with the cytoplasmic GFP–FMRP Iso7 and observed
that GFP–FMRP Iso7 remained in the cytoplasm, whereas
RFP–MSP58 accumulated in the nucleoplasm and the nucleo-
lus (Fig. 4D). These results strongly suggest that MSP58
recruits the nuclear FMRP Iso6 while leaving the FMRP
full-length in the cytoplasm. Indeed, MSP58 failed also to
translocate the cytoplasmic FXR1P and FXR2P as seen in
transfection assays with expression vectors coding for these
homologues (data not shown).
Expression of MSP58 in rat tissues
Because MSP58 expression was previously studied in murine
tissues by RT–PCR or northern blot analyses (36), we deter-
mined the distribution of the protein by immunoblotting
analyses using our new specific anti-MSP58 antibody. In
agreement with previous studies at the mRNA level, MSP58
is detected in all tissues tested, albeit at different levels
(Fig. 5). The highest levels of MSP58 were detected in
spleen and testis, although strong signals were also present
in brain. In muscular tissues such as cardiac and skeletal
striated muscle, only trace amounts of MSP58 could be
detected.
Figure 3. Apparent cellular distribution of MSP58 is conditioned by the
fixation procedures prior to immuno-labelling with anti MSP58 antibodies.
Cos-1 cells were proceeded for three fixation regimes. (A) A 10 min fixation
with 4% PFA followed by a 30 min permeabilization step with 0.5% Triton
reveals an exclusively nucleolar staining. (B) A 10 min fixation with 4%
PFA in the presence of 0.5% Triton shows a nuclear and nucleolar
localization. (C) In contrast, a one-step fixation/permeabilization with
formaldehyde/methanol/acetone mixture (2/19/19 by vol) not only displays a
nucleoplasmic and nucleolar distribution of MSP58, but allows the detection
of cytoplasmic MSP58. Shown in (D) is a control experiment performed on
cells fixed as described in (C) and incubated with anti-MSP58 antibodies
pre-incubated with recombinant GST–MSP58 amino acids 125–294 protein
fragment used for immunization. Nuclei were stained with DAPI.
Figure 4. MSP58 recruits FMRP Iso6 into the nucleolus. (A) In Cos-1 cells,
the majority of transiently expressed RFP–MSP58 is localized in the nucleo-
lus. (B) Transiently expressed GFP–FMRP Iso6 is exclusively nucleoplasmic.
(C) In cells co-expressing nuclear GFP–FMRP Iso6 and RFP–MSP58, both
proteins co-localize in the nucleolus. (D) In cells double-transfected with cyto-
plasmic GFP–FMRP Iso7 and RFP–MSP58, MSP58 fails to attract FMRP
Iso6 which remains in the cytoplasm.
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MSP58 co-localizes with FMRP in the cytoplasm
of neurons
Because high levels of MSP58 are detected in brain extract,
we determined its distribution in adult rat brain sections by
immunohistochemical approaches using the MSP58 antibody.
We observed strong staining in all nuclei throughout the brain
with a specific nuclear localization in all glial cells (Fig. 6).
Surprisingly, strong MSP58 staining was also detected in all
cortical pyramidal neurons present in the cortex, and in
neurons of the CA3 region of the hippocampus as well as in
Purkinje cells in the cerebellum, where it co-localized with
FMRP. We failed to detect MSP58 in the nucleolus, most
probably due to the difficulties of penetration of the antibody
in a fixed tissue. Essentially, the same distributions of MSP58
and FMRP were seen in paraffin-embedded sections of rat
brain (data not shown). These observations illustrate that
MSP58 is abundant in the cytoplasm of neurons, contrary to
other cells, and co-localizes with FMRP and are in favour of
an interaction between MSP58 and FMRP.
To further document the cytoplasmic localization of MSP58
in neurons, electron microscopy analyses were performed on
immunogold-labelled rat brain sections using the purified
MSP58 antibody. In granular cells of the cerebellum,
MSP58 was restricted to the nuclei, whereas in Purkinje
cells additional cytoplasmic localizations could be observed
(Fig. 7A). At higher magnification, MSP58 could be detected
associated with the ER, both in Purkinje cells (Fig. 7B) and in
CA3 hippocampal neurons (Fig. 7C).
To verify whether MSP58 was also present in neurites, as is
the case for FMRP, we used primary cultures of rat hippocam-
pal neurons and double stained them with anti-MSP58
(revealed in red) and anti-FMRP (in green) and analysed
both distribution by confocal microscopy. In neurons in
primary culture, the majority of MSP58 is detected in the
nucleus and nucleolus whereas FMRP was not. In contrast,
while FMRP was predominantly detected in the cytoplasm, a
substantial amount of MSP58 co-localized with FMRP in the
cytoplasm (Fig. 8A). When a high gain that resulted in the
saturation of the fluorescent signal in the cell body was
used, a granular-like punctuate MSP58 staining was also
clearly observed in the dendritic arborizations. At higher
magnification, co-localization of FMRP and MSP58 was
evident in the majority of granule-like structures in neurites
(Fig. 8B).
MSP58 is present in polyribosomal mRNP complexes
It is well established that FMRP is present in mRNP
complexes associated with heavy sedimenting polyribosomes
prepared from total brain (8,9,41). Because MSP58 is strongly
expressed in brain and is also encountered in the cytoplasm
of neurons close to the ER (Figs 6 and 7), we asked whether
it could be present within the translation machinery.
We prepared brain polyribosomes as previously described
and analysed by velocity sedimentation through sucrose
density gradients (8). In the presence of Mg2þ, MSP58 was
detected in fractions corresponding to heavy sedimenting
polyribosomes and its distribution along the gradient mirrors
that of FMRP (Fig. 9A). In the presence of EDTA that
dissociates ribosomes into their subunits concomitant with
the release of free mRNP complexes, MSP58 and FMRP
were detected sedimenting in the same fractions, suggesting
that MSP58 is present in mRNP complexes that also carry
FMRP (Fig. 9B).
In neurons, polyribosomal aggregates are also present in
dendritic spines and synapses and these structures contain
FMRP (7,42). We therefore asked whether MSP58 would
also escort mRNPs to synaptic polyribosomes. To test this
hypothesis, we prepared a polyribosomal fraction from puri-
fied synaptoneurosomes and analysed this fraction by velocity
sedimentation through sucrose density gradients. Two main
results were obtained: first, FMRP is indeed associated with
synaptosomal polyribosomes, in contradiction with the
results obtained by Zalfa et al. (43), and secondly that
MSP58 also is present in these structures (Fig. 9C). FMRP
as well as MSP58 could be released from synaptosomal poly-
ribosomes after treatment with the chelating EDTA agent
(data not shown).
MSP58 is a novel RNA-binding protein associated with
poly(A1) mRNP
We questioned the ability of MSP58 to be present in poly(A)þ
mRNPs by performing oligo(dT) selection on purified
150–500S rat brain polyribosomes treated with EDTA to dis-
sociate ribosomal subunits and to release their associated
mRNPs. We observed that MSP58 is retained onto the
oligo(dT) column and is eluted together with FMRP at 0.5 M
NaCl. These results suggest that, similar to FMRP, MSP58
is an RNA-binding protein associated with poly(Aþ)
mRNPs pointing out its ability to bind RNA in vivo as well
as with other interacting proteins present in RNP complexes
(Fig. 10A). Because most of the proteins interacting with
FMRP present on polyribosomes are known to be RNA-
binding proteins (8), we searched for the ability of MSP58
to bind RNA and performed RNA-homopolymers binding
assays with purified recombinant GST–MSP58. Indeed,
GST–MSP58 could selectively bind to polyG and polyU,
but not to polyA or polyC (Fig. 10B), a pattern of binding
to RNA homopolymers similar to that observed for FMRP
(44). Interestingly, the binding activity to polyG and polyU
was retained in a truncated version of MSP58, suggesting
that the RNA-binding domain lies within the N-terminal
domain of MSP58 encompassing amino acids 1–124. It
should be noted that this domain appears also to bind FMRP
Figure 5. MSP58 is widely expressed in rat tissues. Distribution of FMRP
in extracts from different tissues and organs from adult rat. Equal amounts
of proteins (60 mg) were subjected to immunoblot analyses using
anti-MSP58 serum.
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(Fig. 2E). Despite our efforts, no consensus RNA-binding
sequence could be detected in this domain, suggesting that it
should contain a yet uncharacterized sequence.
Because RNA homopolymers correspond to synthetic RNA
segments, the affinity of MSP58 to these structures might not
reflect its ability to bind biologically relevant mRNA struc-
tures encountered in vivo. Therefore, we questioned whether
it could have affinity to a well-known mRNA structure
called G-quartet. This structure is a recognition motif that
allows binding with high affinity to FMRP and is present in
several FMRP-mRNA targets, and particularly in the coding
region of FMR1 mRNA (13,14). Electrophoretic mobility
shift assays were performed with recombinant GST–MSP58
in the presence of the N19 fragment corresponding to FMR1
mRNA G-quartet minimal binding site (14). The results
showed that MSP58 was able to bind N19, whereas a fragment
corresponding to amino acids 125–294 was not (Fig. 10C). To
ascertain that MSP58 binding to the G-quartet structure was
not due to a general affinity for RNA, we performed nitro-
cellulose filter-binding assays (13,14) which allowed to
titrate by competition assays the specificity of the binding of
MSP58 to the G-quartet N19 sequence. Indeed, similar to
Figure 7. MSP58 is present in the nucleus and in the cytoplasm of neurons. (A) Electron micrograph of the soma of labelled Purkinje and granular cells. Immu-
nogold particles are present in both nuclei, whereas only the Purkinje cell displays a cytoplasmic MSP58 distribution. (B) Higher magnification of the Purkinje
cell shown in (A). In a CA3 neuron (C), MSP58 is detected in the nucleus as well as in close association with the endoplasmic reticulum (ER). Purk, Purkinje; Gr,
granular; N, nucleus; nu, nucleolus; C, cytoplasm.
Figure 6. MSP58 and FMRP distribution in rat brain. Immunostaining of rat brain sections were carried out using anti-MSP58 polyclonal serum (green) and
anti-FMRP mAb1C3 (red) and couterstained with DAPI. In small glial cells (arrow heads), MSP58 is concentrated in the nucleus, whereas in Purkinje cells
of the cerebellum, and in pyramidal neurons in the cortex and in neurons in the CA3 region of the hippocampus, MSP58 is both nuclear and cytoplasmic
(arrows) and co-localizes with cytoplasmic FMRP.
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FMRP, the binding of MSP58 to the N19 RNA was efficiently
competed by the same sequence, whereas an unrelated
fragment of FMR1 mRNA called N8 was unable to displace
the binding (Fig. 10D). The binding of MSP58 to the N19
sequence was clearly dependent on the presence of the
cation Kþ, known to stabilize the G-quartet structure as pre-
viously demonstrated (13,14), whereas reduced binding was
observed in the presence of Naþ (Fig. 10E). All these results
taken together suggest that MSP58 is a novel RNA-binding
protein with high affinity to a G-quartet motif.
DISCUSSION
In this study, we have identified a novel partner for FMRP.
MSP58 is evolutionarily conserved from fly to man. Its
N-terminal part contains putative nucleolar and nuclear
localization signals which seem to control its targeting to the
nuclear compartment and is necessary to bind FMRP, whereas
Figure 10. MSP58 is a novel RNA-binding protein. (A) MSP58 associates with
poly(A)þ mRNP from brain polyribosomes. MSP58 is retained on oligo(dT)
cellulose matrix loaded with EDTA-dissociated brain polyribosomes. The
column was first washed (W) and then eluted with increasing salt concen-
trations from 0.3 M to 1 M NaCl and the majority of MSP58 was recovered
in the 0.5 M NaCl fraction, together with FMRP, indicating their presence in
poly(A)þ mRNPs. (B) MSP58 binds RNA homopolymers in an in vitro
binding assay. Purified recombinant GST–MSP58 selectively binds to
poly(G) and poly(U), but not to poly(A) or poly(C). This pattern of binding
appears similar to that observed for FMRP. Only MSP58 fragments containing
the N-terminal amino acids 1–124 domain were able to bind poly(G) and
poly(U), suggesting that the RNA-binding domain of MSP58 lies in this
region. No binding on homopolymers was observed for GST alone. (C) Elec-
tromobility shift analyses. Labelled N19 RNA was incubated with increasing
amounts of MSP58 or as controls the MSP58 125–294 fragment. (D) Nitrocel-
lulose filter-binding assay. Competition experiments on nitrocellulose filter-
binding assay to determine the relative affinity of GST–MSP58 for the
N19-G-quartet structure. Fraction of bound N19 (32P-labelled), retained on
either FMRP or GST–MSP58, plotted against competitor (either N19 or N8)
RNA concentration. Each point reflects the results obtained in three indepen-
dent experiments. (E) MSP58/G-quartet interaction occurs in the presence of
the stabilizing cation Kþ and is disrupted in the presence of Naþ.
Figure 8. MSP58 co-localizes with FMRP in the cytoplasm and neurites in
primary cultured hippocampal neurons. Double-labelling of FMRP (green
with antibody 1C3) and MSP58 (red with anti-MSP58) showing
co-localization of MSP58 and FMRP in the cytoplasm (A) as well as in
neurites (B) as dot-like punctuations.
Figure 9. MSP58 co-sediments with FMRP in polyribosomes prepared from
total brain and from synaptoneurosomes. Aliquots (containing 10 OD at
A260 nm) of total rat brain polyribosomal preparations were analysed by sedi-
mentation through sucrose density gradient in the presence of MgCl2 or after
treatment with 25 mM EDTA. Synaptoneurosomal polyribosomes were pre-
pared as described in Materials and Methods and two OD at A260 nm ana-
lysed by sedimentation in a smaller sucrose density gradient. Fractions from
the sucrose gradients were tested for the presence of MSP58, FMRP and
L7A ribosomal protein (L7) using the rabbit anti-MSP58 antibody, mAb1C3
and rabbit anti-L7a serum, respectively. ‘ss’ and ‘ls’ indicate small and
large ribosomal subunits, whereas 80S indicates the position of monosomes.
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FMRP appears to bind MSP58 through its C-terminal domain
(amino acids 444–526) that contains a phosphorylation
domain. Despite the fact that mutations on the putative phos-
phorylated serine 500 did not seem to affect the binding to
MSP58 in vitro, we cannot exclude that in vivo phosphorylation
might modulate the interaction between MSP58 and FMRP.
Additional serines (Ser 494, 497, 504) that are highly evol-
utionary conserved in the phosphorylation domain of the
FXR proteins have not been yet tested for their putative
phosphorylation.
Previous studies have suggested that MSP58’s functions are
related to transcriptional regulation in the nucleus and nucleo-
lus. This assumption is based on the observation that it has
been exclusively detected in the nuclear compartment where
it was reported to interact with transcription factors (34,36)
and to up-regulate ribosomal gene expression (37). Our
study reveals an additional important function of MSP58 as
an RNA-binding protein presumably involved in translation
regulation. We have shown that MSP58 is present in the cyto-
plasm of neurons in association with poly(Aþ) mRNP present
in heavy sedimenting brain polyribosomes. The case of such a
nuclear protein that is also present in association with the
translation machinery is not isolated, because several proteins
that have been characterized initially as nuclear proteins, such
as hnRNP A1, PTB, La, hnRNP, YB-1/p50 and nucleolin,
turned out to be present also in the cytoplasm and even
implicated in translation control [for discussion and cross-
references see (45)]. Of particular interest is YB-1/p50,
which has been originally defined as a transcription factor,
but which is the major protein of cytoplasmic mRNPs (46).
Moreover, several FMRP-interacting proteins such as
FXR1P, FXR2P, 82FIP and NUFIP are also nucleocyto-
plasmic shuttling proteins associated with polyribosomes
(23,24). However, to our knowledge, MSP58 is the only
FMRP partner which is also present in the nucleolus.
In co-transfection experiments, we observed a clear
co-localization between MSP58 and FMRP nuclear Iso6 in
the nucleolus. FMRP Iso6 being normally exclusively nucleo-
plasmic and excluded from the nucleolus (47), we conclude
that overexpression of MSP58 results in the translocation of
FMRP Iso6 into the nucleolar compartment. This suggests
that in overexpression assays a fraction of FMRP can enter
the nucleolus, as previously shown by immunoelectron
microscopy studies performed on Cos-1 cells (48,49). Even
though FMRP lacks the nucleolar targeting sequence present
in FXR1P and FXR2P (50), the exceptional detection of
FMRP in the nucleolus, if relevant, might result from an alter-
nate mechanism, perhaps by interaction with FXR1P or
FXR2P or even with other nuclear proteins. The binding of
MSP58 to FMRP could directly participate in the translocation
of FMRP-containing mRNP in the nucleolus.
Recent data indicate that the initial steps of RNA recog-
nition and the packaging of mRNP complexes by RNA-
binding proteins to be transported in the cytoplasm occur in
the nucleus (51–53). We propose that FMRP binds its target
mRNA in the nucleoplasm to be assembled in an mRNP
with MSP58 and other RNA-binding proteins and RNA. The
binding of MSP58 might change the conformation of FMRP
and therefore affect the binding of its RNA targets on the
RGG box, owing to the close proximity of the phosphorylation
MSP58-binding domain and the RGG box. Moreover, the
ability of MSP58 to bind with high affinity RNA G-quartet
structures suggests that it might, in vivo, compete with
FMRP for the binding of mRNA harbouring this structure.
The protein composition of the FMRP-containing mRNP
complexes might indeed modulate the type of mRNA targeted
to the nascent mRNP. In addition to its central role in ribo-
some biogenesis, the nucleolus has been proposed to be the
site of the assembly of pre-mRNP complexes (54,55). Accord-
ing to this point of view, the nucleolus would function as a
nuclear checkpoint to verify the functional integrity and rele-
vancy of these particles. Following this attractive model, it can
be envisioned that the FMRP-containing mRNPs transit in the
nucleolus where their potential functionality are verified
before they are exported in the cytoplasm. Together with the
other known FMRP-interacting proteins, such as FXR1P,
FXR2P and 82-FIP, the interaction between MSP58 and
FMRP in mRNP at the polyribosomal level might modulate
FMRP function in the control of translation.
In neurons, a population of FMRP/MSP58-containing
mRNP will be sorted from the neuronal cell body at a hypo-
thetic RNP-triage centre (56,57) to be translocated at very
distant locations in the form of mRNP granules. These
mobile structures contain a reservoir of mRNAs that are main-
tained in a repressed state during migration (58) until they
reach the synapse where FMRP is thought to play a key role
in the control of their local translation. The presence of
MSP58 in polyribosomes at the synapse as well as its ability
to bind G-quartet containing mRNA raises the possibility
that it would play a role, in concert with FMRP and/or other
factors, in the control of local de novo protein synthesis, an
essential phenomenon for synaptic development and
maturation.
In summary, we have shown that MSP58 is a nucleocyto-
plasmic shuttling protein able to bind RNA and that it is
associated with the cytoplasmic translation apparatus both in
the cytoplasm and at the synapse. We therefore propose that
in neurons MSP58 may be part of structures that are trans-
ported from the nucleus to translation sites, in a similar way
as FMRP. However, the present study does not allow us to
conclude whether MSP58 is an active essential partner to
translocate mRNPs or whether it is dispensable to the cellular
machinery. Also, it will be necessary to study whether MSP58
neuronal distribution is altered in Fmr1 KO neurons. Through-
out this paper, we have presented FMRP as a central key mole-
cule and hypothesized that its affinity to RNA could in theory
be modulated by protein interactors. An other diametrically
opposite view would be that FMRP modulates the activity
of MSP58. As the world of RNA-binding proteins is expand-
ing, understanding the role of MSP58 and of other RNA-
binding FMRP interactors, will be essential to unravel the
functions altered by the absence of FMR1 expression in
the FXS.
MATERIALS AND METHODS
Yeast two-hybrid screen
Full-length cDNA of human FMRP Iso7 from the pTL1-FMR1
Iso7 was subcloned in-frame with the DNA-binding domain
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of the transcription factor Gal4 (Gal4 DNA-BD) into the
EcoRI/Pst1 sites of the yeast expression vector pGBKT7
(Yeast Two-Hybrid System, Clontech). Human fetal brain
cDNA library screening was performed by mating the
AH109 Mata expressing the bait with the Y187 strain pre-
transformed with the human fetal brain library encoded by
the pACT2 vector (Matchmaker pre-transformed library,
Clontech). Strains resulting from the mating carried the
ADE3, HIS3 and LacZ reporters under the control of Gal4
responsive elements. From 2.8  106 clones screened, 78
positive colonies showed adenine and histidine prototrophy
and b-galactosidase activity. Among these, PCR and restric-
tion analysis showed that three colonies were redundant and
carried a 1.7 kb insert. This insert corresponded to the full-
length cDNA of human MicroSpherule protein of 58 kDa
(MSP58 or MCRS1, GenBank accession no. Q96EZ8).
Purification of recombinant fusion proteins and
production of anti-MSP58 antibodies
For expression of recombinant GST–MSP58, the coding
sequence of MSP58 or the fragments corresponding to
amino acids 1–124, 1–294 and 125–294 were amplified by
PCR using the primers (EcoRI F: 50-CGG GAA TTC GAC
AAA GAT TCT CAG GGG CT-30, XhoI R: 50-GGC GAG
CTC TCA CTG TGG TGT GAT CTT GG-30, 125EcoRI F:
50-GCC GAA TTC CCA CTT CAG GTG ACC AAG G-30,
294Bam R: 50-CGG GGA TCC CTT GAG CTT ACT GTC
ATC AAT C-30 and 124Bam R: 50-CGG GGA TCC CTG
TTT ACT CTT CTT CAC ACG C-30) and subcloned
into the EcoRI/XhoI or EcoRI/BamHI sites of pGex-4T-1
(Amersham). Fusion proteins were expressed in BL21(DE3)
Escherichia coli strain (Stratagene) grown in liquid LB until
OD1 and induced overnight with 1 mM IPTG. Bacteria
were then collected and the expressed fusion proteins purified
in non-denaturing conditions on glutathione–Sepharose beads,
according to manufacturers’s protocole (Amersham Pharmacia
Biotech). Fusion protein was eluted from the beads with
10 mM reduced glutathione in 50 mM Tris–HCl (pH 8.0).
Protein yields were estimated by Coomassie staining using
as standard different concentrations of bovine serum albumin
(BSA) ranging from 0.2 to 1 mg/ml. The GST–MSP58
amino acids 125–294 were used to produce antibodies in
rabbit using standard protocol, and anti-MSP58 IgG were
affinity purified with the same fusion protein used for
immunization.
GST-pulldown assays
FMRP and its truncated variants, FXR1P and FXR2P, were
produced by in vitro transcription–translation in rabbit reticu-
locyte system in the presence of [35S]methionine (Amersham)
according to manufacturer’s instruction (Promega, Madison,
WI, USA). Five microlitres of in vitro-translated proteins
were mixed with 1 mg of GST–MSP58 and its variant recom-
binant proteins bound to beads and incubated 2 h, at room
temperature, under constant rotation in 500 ml of pulldown
buffer (10 mM Tris pH 7.4, 150 mM NaCl, 0.5% NP-40,
Protease Inhibitor Cocktail, Roche). Beads were collected
by spinning (3000 g, at room temperature for 2 min) and
washed four times with the pulldown buffer. Final wash was
removed and beads were resuspended in 50 ml of SDS
sample buffer. One-third of the sample was loaded on a
7.5% SDS–PAGE. Gel was then dried and exposed for
3 days to a Biomax film (Kodak).
RNA studies
Homopolymer binding assays. Binding assays were per-
formed according to established procedures. Briefly, 0.5 mg
of recombinant GST-tagged MSP58 were incubated with
immobilized poly(G), poly(U), poly(A) or poly(C)
polyacrylhydrazido-agarose beads (Sigma) in 0.5 ml of
binding buffer containing 20 mM Tris–HCl pH 7.4, 150 mM
NaCl, 0.5% NP-40 and 2.5 mM MgCl2 supplemented with Pro-
tease Inhibitor Cocktail (Roche) for 1 h at room temperature.
After incubation, the beads were washed four times with
binding buffer and bound proteins eluted by addition of SDS
sample buffer followed by heat denaturation. Proteins were
separated by SDS–PAGE and blotted either with anti-GST
antibody (Amersham) used at 1:25 000 or with anti-MSP58
serum. Control analyses were also performed with 35S-labelled
MSP58 produced in the rabbit reticulocyte lysate system (data
not shown). In vitro-translated proteins were detected after
exposure of the gel to an X-ray film.
RNA-binding assays. The different RNA fragments N19 and
N8 derived from FMR1 RNA were synthesized by in vitro
transcription with T7 RNA polymerase from pTL1 (47)
derivative plasmids linearized with PstI. The RNAs were pur-
ified using the NucAway Spin columns (Ambion). RNAs were
then ethanol precipitated and resuspended in the appropriate
buffer. For binding experiments, N19 was labelled
co-transcriptionally by incorporation of [a-32P]ATP. Labelled
RNAs were purified on a 1% low-melting agarose gel
(Ambion). Labelled RNAs (80 000 c.p.m., 5 fmol) were rena-
tured for 10 min at 408C in 40 ml of binding buffer [50 mM
Tris–HCl pH 7.4 at 48C, 1 mM MgCl2, 1 mM EDTA,
150 mM KCl, 1 mM dithiothreitol (DTT)] with 8 U of
RNasin (Invitrogen), 10 mg of E. coli total tRNA and 0.01%
BSA. The RNA was then added to increasing amount of pro-
teins. RNA–protein complexes were formed for 10 min at
08C. After incubation, binding solutions were passed through
MF-membrane filters (0.45 HA, Millipore) and washed with
2 ml binding buffer. Filters were air-dried and the amount of
radioactivity was measured by Cerenkov counting. Data
were plotted as percentage of total RNA bound versus the
protein concentration. Competition experiments to determine
the relative binding strength of MSP58 to G-quartets were
carried using 32P-labelled N19 RNA incubated with MSP58
(0.1 pmol) in the presence of increasing concentrations of
unlabelled competitors. FMRP was used as an internal positive
control. Binding of FMRP and MSP58 to the G-quartet were
performed in the presence of 150 mM of either Kþ or Naþ.
Cell culture, primary neuron culture and transient
transfection assays
HeLa S3, Cos-1 and STEK Fmr1 KO/TSV40 cells were pro-
pagated and maintained in DMEM supplemented with 10%
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FBS and antibiotics (100 U/ml penicillin, 50 mg/ml strepto-
mycin). Transfection assays with different vectors were
performed in the presence of Effectene according to manufac-
turer’s recommendations (Qiagen). Primary neuron culture
was prepared from rat hippocampi as described (59).
Protein studies
Organs were removed from animals, processed according to
standard protocols and protein extracts prepared for SDS–
PAGE as described (60). Immunoblot analyses were per-
formed using mAb1C3 to FMRP, rabbit polyclonal antisera
directed against MSP58 and anti-L7 ribosomal protein. Detec-
tion of bound antibodies was performed with HRP-coupled
secondary antibodies followed by ECL reaction.
Immunofluorescence studies
Immunocytofluorescence. Cos-1 cells grown on glass cover
slips were washed three times with ice-cold phosphate-
buffered saline (PBS) then fixed with the fixation and
permeabilization protocols described in Results. To detect
endogenous MSP58, the anti-MSP58 was used at 1:200
(overnight at 48C), followed by incubation (90 min at room
temperature) with Alexa fluor 488 goat anti-rabbit IgG
(Molecular Probes). Control experiments were performed in
the presence of antibodies that were pre-incubated with the
recombinant purified GST–MSP58 amino acids 125–294
used for immunization. For direct visualization of MSP58 in
eukaryotic cells, MSP58 was fused to the RFP by subcloning
its cDNA from the pGex-4T-1/MSP58 full-length in the
EcoRI–SalI sites of the polylinker of a modified version of
peRFP graciously provided by Paul De Koninck.
Immunohistofluorescence. Adult rats, deeply anaesthetized
with ketamine xylol (40 mg/kg, i.p.) were transcardially per-
fused with 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4). The brain was removed, transferred to cryoprotective
solution (HistoPrep, Fisher Scientific), frozen and serially cut
into longitudinal sections (5 mm) with a Leica CM1900 cryos-
tate. Sections were treated as described (23) and mounted on
slides and processed for double immunofluorescence using
rabbit anti-MSP58 (at 1:200 dilution) and anti-FMRP
mAb1C3 antibody. Double immunofluorescence staining
were performed by separate and sequential incubations of
each primary antibody diluted in PBS at 48C overnight,
followed by the respective secondary antibody coupled to
Alexa594 or Alexa 488 (Molecular Probes) and incubated at
room temperature for 3 h. Samples were analysed with a
Nikon EclipseE800 microscope equipped with a Hammamatsu
CCD camera. Images were then treated with the Adobe Photo-
Shop software program.
Electron microscopy. Pre-embedding immunogold labelling
was performed as described (61). Briefly, free floating fixed
rat brain sections were blocked for 30 min in 0.8% BSA,
0.1% cold fish skin gelatin (Amersham, Piscataway, NJ,
USA) and 5% normal goat serum in Tris-buffered saline
(TBS), followed by incubation with MSP58 antiserum for
48 h at 48C. Sections were washed and incubated with
0.5 nm gold-conjugated secondary antibody (AuroProbe,
Amersham, 1:80 in TBS) for 12 h at 48C and the gold particles
were enhanced with silver solution (IntenSE, Amersham).
Sections were treated with 1% OsO4, dehydrated in graded
ethanol, then in propylene oxide and embedded in Durcupan
ACM (Fluka). Specimens were sectioned and examined
using a Philips Tecnai 12 electron microscope.
Polyribosome preparation and analysis
Total brain polyribosomes were prepared from young
Sprague-Dawley rats (7 days old) and purified as described
(8). For EDTA–mRNPs studies, the fractions of sucrose
gradients corresponding to 150–500S were pooled, diluted
with 1 volume of buffer (20 mM Tris–HCl, pH 7.4, 100 mM
KCl, 1.25 mM MgCl2) and the particles pelleted by centrifu-
gation in a Sorvall TH-641 rotor for 2 h at 34 000 r.p.m. at
48C. The polyribosomal pellets were resuspended in 20 mM
Tris–HCl, pH 7.4, 100 mM KCl, 1% NP-40 containing
25 mM EDTA and analysed after centrifugation in a linear
5–35% (w/w) sucrose density gradient for 3.5 h at
34 000 r.p.m. at 48C.
For preparation of synaptosomes, 16 cortices from young
animals (7 days old) were homogenized by hand using a
glass homogenizer (30 strokes) in a buffer containing 20 mM
Tris–HCl (pH 7.4), 100 mM NaCl, 1.25 mM MgCl2, 0.32 M
sucrose, 1 mM DTT, 50 mg/ml cycloheximide, 5 U/ml
RNasine (Amersham Pharmacia) and protease inhibitors
(Mini Complete, Roche Biochemicals). Purification of synap-
tosomes followed a two-step procedure. After centrifugation at
640g for 10 min, the supernatant was layered on Percoll gradi-
ent and the synaptosomal fraction obtained as described (62).
The second step of purification was performed by floatation in
an Optiprep gradient (63). The purified synaptosomal fraction
was then resuspended in buffer containing 1% NP-40 and the
released polyribosomes were concentrated after ultracentrifu-
gation through a sucrose pad (45% w/w) in a Sorval TH-641
rotor at 34 000 r.p.m. for 3 h. The polyribosomal pellet was
resuspended in buffer containing 1% NP-40 and analysed by
velocity sedimentation in a 15–45% (w/w) isokinetic
sucrose gradient and centrifuged in a 4 ml tube with a
Sorvall TST 60.4 rotor at 30 000 r.p.m. for 2 h at 48C. All gra-
dients were fractionated by upward displacement using an
ISCO UA-5 flow-through spectrophotometer set at 254 nm
and connected to a gradient collector.
Each collected fraction was precipitated overnight
at 2208C after addition of 2 volumes of ethanol. The preci-
pitated material was collected by centrifugation at
12 000 r.p.m. for 20 min and solubilized in SDS sample
buffer before immunoblot analyses. FMRP was detected
with mAb1C3, MSP58 with its corresponding antiserum and
ribosomal L7 protein with rabbit anti-L7 serum. As synapto-
somes account for a very minor fraction of the brain, we
used a total of 16 cortices per extraction, and performed the
sedimentation analyses in small 4 ml tubes instead of the stan-
dard 11 ml used to analyse total polyribosomes extracted from
three brains. Finally, the sensivity of the UV detector used to
follow the polyribosomal profile was tuned to scale 0.5
(optical density at 254 nm) instead of 2.0 (compare the
profile of total brain versus synaptosomes in Fig. 8).
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A look at the RNA binding properties of the FMRP and its interactors !
Characterization of FMRP/Sod1 mRNA interaction
Does FMRP bind specifically to Sod1 mRNA?
FMRP presents a general affinity for RNAs, but it binds specifically to only a small
subset of RNA sequence/structure (Schaeffer et al. 2001). The huge amount of data provided
about putative FMRP mRNA targets lacks crucial information about the specificity of
FMRP/”target” mRNA interaction. Among the hundreds of putative FMRP targets (Brown et
al. 2001; Miyashiro et al. 2003), specific interaction was assessed in detail for only two
mRNAs, FMR1 (Schaeffer et al. 2001) and PP2A (Castets et al. 2005b) in an appropriate and
reliable experimental procedures using both physiological conditions and Protein/RNA
binding assays in presence of specific and unspecific RNA competitors to eliminate any kind
of bias.
Sod1 mRNA was identified as a FMRP putative target “in vivo” by Miyashiro and
colleagues. Based on their observations (Miyashiro et al. 2003) we have analyzed
FMRP/Sod1 mRNA interaction. Using both the experimental conditions developed by
Schaeffer and colleagues, and the presence of adequate competitors, we have proven that
FMRP binds specifically the Sod1 mRNA with an affinity similar to that observed for the G-
quartet (Schaeffer et al. 2001).
How does the recognition FMRP/Sod1 occur ?
When first FMRP was shown to recognize and bind specifically to the G-quartet
structure, several bioinformatics programs were developed to search for sequences that may
adopt a G-quartet structure. Based on alignment with a “canonical sequence” these programs
had been used by many groups while analyzing FMRP targets as putative G-quartet
containing mRNA. Relying on such procedure might be distrustful simply because
manipulating these programs in an “un-proficient” manner would lead to both false positive
and negatives. In another hand, these programs do not take neither the purine quartets into
account nor the possibility of a distant G-quartet formation. Thus, the presence of G-quartets
needs to be confirmed experimentally. We have combined two assays to search for any G-
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quartet structure in the Sod1 mRNA. First, we performed binding assays in presence of
increasing amount of FMRP in buffers containing either Na+ or K+  which would respectively
destabilize or stabilize a G-quartet structure, altering therefore its binding to FMRP. We
observed that FMRP/Sod1  interaction was not affected in either buffer, leading to a
preliminary conclusion that Sod1 mRNA might not contain a  G-quartet. To definitely exclude
any bias, the Sod1 mRNA was reverse transcribed in presence of either Na+ or K+. For both
reactions, the same pattern of migration was observed on polyacrylamide gel (for
experimental procedure, see results and material and method of publication 2) confirming the
absence of a G-quartet in the Sod1 mRNA and therefore, classifying the Sod1 mRNA as the
second novel in vivo validated FMRP sequence/structure target.
Using site boundary determination as described (Schaeffer et al. 2001), we identified a
64 base fragment of the Sod1 mRNA able to be recognized and bound specifically by FMRP
with the same affinity as that of the full length Sod1 mRNA. The border positions of this
fragment were at -30 and +34 spanning both sides the Sod1 AUG start codon. Existence of
bioinformatics programs allowing to predict a secondary structure of a RNA such as the
“MFOLD” (http://helix.nih.gov/apps/bioinfo/mfold.html) was a first attempt do discover the
putative structure of this fragment.
The secondary structure delivered by MFOLD was a single long stem loop interrupted
by 2 bulges. If any constraints are subjected to the program, it will function by joining both
ends of the fragment and to anneal bases that would pair. This could be a first indication about
the putative secondary structure of an RNA that should be confirmed by experimental
procedures. Aiming to better define the structure adopted by this 64 base fragment in solution,
we used a panel of chemical and enzymatic modifications as described (Brunel and Romby
2000). This technique is based on the reactivity of RNA molecules towards chemicals or
enzymes that modify or cleave specific atomic positions in RNA respectively.  Results
obtained from these experiments were applied to MFOLD program that calculated a best
fitting free energy for the structure that resulted as a succession of three independent stem-
loop structures separated by short single stranded regions. This structure was named SSLIP
(Sod1 Stem Loops Interacting with FMRP). Binding assays in presence of competitors
showed that SSLIP is only bound by the C-terminus region of FMRP. Since the C-terminal
domain of FMRP contains the RGG box that binds to the G-quartets RNA structure (Darnell
et al. 2001), and more recently an G-rich “undefined sequence/structure” present in the
PSD95 mRNA (Zalfa et al. 2007) ( Nevertheless, alignment with the “canonical sequence”
predicted the presence of a G-quartet structure (Todd et al. 2003), that was experimentally
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proven (H. Moine, personal communication)) and in the APP mRNA (Westmark and Malter
2007), we found that SSLIP is able to compete the G-quartets for binding to FMRP C-
terminus region. This observation lead us to hypothesize that FMRP recognizes similar
structural features in both RNAs (e.g. specific atoms properly spatially oriented and/or in the
correct electrostatic environment) that may involve an induced-fit mechanism for the
recognition. As already discussed, the RGG box was shown to be flexible and unstructured
(low complexity sequence composition) and that the interaction between the RGG box
peptide and various G-quartets showed a large heterogeneity in both the conformation of the
RNA targets and their RGG binding mode which could be the basis of recognition specificity
(Ramos et al. 2003).
What is the functional significance of FMRP/Sod1 mRNA interaction?
FMRP was widely considered as a translational inhibitor for so called “in vitro” and
“in vivo” models. Nevertheless, taking in consideration the vast repertoire of cell models, the
overexpression of FMRP and the simplistic way to enhance or repress translation in rabbit
reticulocyte lysate, the results obtained by several groups should be revisited in a more
accurate interpretation. FMRP could shuttle not only between the nucleus and the cytoplasm
but also between several different RNPs involved in both translational activation and
repression suggesting that it might be involved not “exclusively” in the translation inhibition.
Recently Zalfa and colleagues revealed a hidden facet of FMRP acting on the stabilization of
PSD95 mRNA, although the G-rich sequence/structure recognized by the C-terminus region
of FMRP was poorly defined by the authors (Zalfa et al. 2007). Strikingly, another group
showed that FMRP recognizes a G-rich sequence in the APP mRNA, but does not act on the
stability of this mRNA (Westmark and Malter 2007). Considering that FMRP could have
distinct effects on mRNAs, its function would strongly depend on the mRNA
sequence/structure that it binds to.
Aiming to understand the significance of FMRP/SSLIP interaction , we first proceeded
by the analysis of the Sod1 mRNA turnover in presence and absence of FMRP in two
different cell types and observed that FMRP does not affect the stability of SSLIP containing
mRNA. However, when analyzing the distribution of the Sod1 mRNA on mouse brain
polyribosomes, we showed that Sod1 mRNA is less associated to active translating
polyribosomes in the absence of FMRP. This alteration was also observed at the protein level
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where the Sod1 protein expression was decreased in the absence of FMRP. These data lead us
to conclude that FMRP may act as a translation enhancer on SSLIP containing mRNAs.
Two major traits were observed in this study, first the ability of the C-terminus region to bind
specifically to a novel structure most probably by fit mechanism and second the role of FMRP
that it might have on its target mRNAs depend mostly on the structure adopted by the mRNA
and recognized by FMRP.
The presence of the triple stem loops around the AUG start codon may reflect to some extent
the role of these structures profiting from FMRP to drive them to polyribosomes. It will be
very interesting to decipher the mechanism by which FMRP could bind a region of mRNA
spanning its AUG start codon and activate its translation. A recent work by Marzi and
colleagues provided new insights in the regulation of translation initiation by both trapping
ribosomes and displacement mechanism in prokaryotes (Marzi et al. 2007). May this
mechanism be the same in eukaryotes? If so, could FMRP be involved in such regulation?
SOD , oxidative stress, brain and mental retardation, any link ?
Under normal conditions, a dynamic equilibrium exists between the production of
reactive oxygen species (ROS) and the antioxidant capacity of the cell. ROS includes
superoxide, hydroxyl, peroxyl, alkoxy, and nitric oxide (NO) free radicals. Superoxide is the
first reduction product of molecular oxygen, and it is an important source of hydroperoxides
and deleterious free radicals. Hydrogen peroxide (H2O2) reacts with reduced transition metals
such as iron, via the Fenton reaction, to produce the highly reactive hydroxyl radical. Most
toxic effects are due to hydroxyl radical formation, which also initiates lipid peroxidation.
Normally, the ROS within the cells are neutralized by antioxidant defense mechanisms.
Superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) are the primary
enzymes involved in direct elimination of ROS whereas glutathione reductase and glucose-6-
phosphate dehydrogenase are secondary antioxidant enzymes, which help in maintaining a
steady concentration of glutathione and NADPH necessary for optimal functioning of the
primary antioxidant enzymes. Oxidative stress occurs when ROS levels exceed the
antioxidant capacity of a cell. These ROS are highly toxic and react with lipids, proteins and
nucleic acids, and lead to cell death via apoptosis or necrosis.
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Oxidative stress and brain
The brain is highly vulnerable to oxidative stress due to its limited antioxidant
capacity, higher energy requirement, and higher amounts of lipids. The brain makes up about
2% of body mass but consumes 20% of metabolic oxygen. The vast majority of energy is used
by the neurons. Due to the lack of glutathione-producing capacity by neurons, the brain has a
limited capacity to detoxify ROS. Therefore, neurons are the first cells to be affected by the
increase in ROS and shortage of antioxidants and, as a result, are most susceptible to
oxidative stress. Indeed, Sod1 mRNA is present in dendrites and in axons meaning that is an
axonally synthesized protein essential for axon development and axonal transport (Willis et al.
2005). Gene mutations in Sod1 can cause familial amyotrophic lateral sclerosis (SLA).
Several Sod1 mutants found in SLA patients perturb fast axonal transport (De Vos et al. 2007)
and can cause motor axonopathy in zebrafish (Lemmens et al. 2007). Sod1 is also regulated
by cellular stress, suggesting that the axonal localization of its mRNAs may provide a
mechanism to locally respond to axonal injury.
Oxidative stress and mental impairment
Fragile X syndrome
Recently, using drosophila model, Zhang and colleagues analyzed by two dimension
electrophoresis the misregulation of proteins in the absence of FMRP and interstingly they
showed an alteration in the expression of  two enzymes (1-cys peroxiredoxin in brain and
peroxiredoxin and thioredoxin peroxidase in testis) concluding that oxidative stress occurs in
in FMR1 null flies (Zhang et al. 2005).
Another study, using the mouse model, showed that brains from Fmr1-knockout mice,
display higher levels of reactive oxygen species, nicotinamide adenine dinucleotide phosphate
(NADPH)-oxidase activation, lipid peroxidation and protein oxidation than brains from wild-
type mice, indicating the presence of markers of oxidative stress in brains lacking FMRP (El
Bekay et al. 2007).Modifications of oxidative stress have been linked to anxiety, sleep trouble
and autism, all features of FXS patients.
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Autism
The brain is highly vulnerable to oxidative stress, particularly during the early part of
development that may result in neurodevelopmental disorders such as autism. In fact, recent
evidence points towards increased oxidative stress in autism.
Several studies have suggested alterations in the enzymes that play a vital role in the
defense mechanism against damage by ROS in autism. For instance, compared to controls,
patients with autism showed decreased activity of glutathione peroxidase reduced levels of
total glutathione and lower redox ratio of reduced glutathione (GSH) to oxidized glutathione
and decreased catalase and Sod activity (Yorbik et al. 2002; Ming et al. 2005).
since the alteration of Sod1 expression may generate the modification of the cellular
reduction/oxidation, and may represent one of the molecular defects resulting in the complex
phenotype of Fragile X patients, our study sheds new light on the physiopathology of the
Fragile X syndrome.
Another aspect of FMRP analyzed during my thesis was the determination of its
interactors RNA binding properties and the influence that they might exert on FMRP when
present together.
The RNA binding properties of FMRP were mainly assessed regardless its belonging
to a macromolecular complex where the majority of its interactors are also RNA binding
proteins. The high homology degree in both sequence and functional domains that FMRP
shares with its two homologues FXR1P and FXR2P suggests that these proteins may have a
similar or redundant function and that they could to some extent compensate the absence of
FMRP, therefore explaining the heterogeneity of symptoms in FXS patients. Nevertheless,
any experimental indication about their ability to bind mRNA was provided. We have
analyzed the ability of two FMRP partners : FXR1P and MSP58 to bind mRNAs and tried to
mimic the “in vivo” behavior of FMRP in its containing complex, by a “simplistic” in vitro
procedure where FMRP was in presence of either interactor.
Could FXR1P or MSP58 bind specifically the G-quartet structure ?
The FXR1 pre-mRNA is highly subjected to alternative splicing giving rise to several
FXR1P isoforms that are differentially expressed in tissues, during development and also
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during cell differentiation (Khandjian et al. 1998; Dubé et al. 2000). We have chosen to
analyze the RNA binding properties of three FXR1P isoforms , Isoe (muscle specific)
together with Isod and Isoa that are mainly expressed in brain (Bechara et al. 2007). In
parallel we analyzed the MSP58 affinity to mRNAs (Davidovic et al. 2006). MSP58 is a
nucleocytoplasmic shuttling RNA binding protein that it is associated with the cytoplasmic
translation apparatus both in the cytoplasm and at the synapse. In neurons MSP58 may be part
of structures that are transported from the nucleus to translation sites, in a similar way as
FMRP (Davidovic et al. 2006).
Filter binding assays in presence of competitors showed that MSP58 binds specifically
the G-quartets structure with an affinity similar to that of FMRP, whereas among the three
FXR1P isoforms, only Isoe showed a specific binding to G-quartets despite a lower affinity
compared to that of FMRP but neither Isod nor Isoa recognized specifically the G-quartet
structure. This was the first evidence that despite their high homology degree, FXR1P has at
least a different affinity for RNAs than that of FMRP and that it may act differently than
FMRP on its targets. It was shown that a peptide corresponding to the RGG box of FXR1P is
not able per se to recognize the G-quartet structure (Zanotti et al. 2006), which was not the
case for the full length protein (Bechara et al. 2007). Indeed, two major observations emerged
from our  analysis. First, the three FXR1P isoforms do not exhibit the same specificity for G-
quartets structure, which could be explained by the presence of  27 amino acids encoded by
exon 15 present in Isoe. The sequence analysis of these amino acids showed that they reveal
an affinity for RNA; what should remain to be investigated is whether these amino acids
influence the RNA binding affinity of Isoe by their direct interaction with RNA or by
modulating the structure of the C-terminus region of Isoe rendering it more flexible for
specific RNA binding. Second, the fact that the RGG box peptide of FXR1P was not able to
recognize a G-quartet structure (Zanotti et al. 2006) could be due either to its uncorrect
folding or stability in solution as that observed for the FMRP RGG peptide. Another
explanation for its limited ability to interact with RNA in a sequence-specific manner might
be due to its recognition sequence that is too short. The presence in the full length protein of
multiple domains are therefore tethered together to create a much larger binding interface that
specifically recognizes a longer sequence.
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How would FMRP react “vis à vis” of G-quartets in presence of its interactors ?
At the equilibrium stage, the formation of  the heterodimer FMRP/FXR1P Isoe
showed a slight effect on the affinity of FMRP for G-quartets, the same case was observed for
FMRP/MSP58 heterodimer. However, both Isod and Isoa reduced both the affinity and
specificity of FMRP to G-quartets. The heterodimer FMRP/FXR1P Isoe also showed an
increased dynamic in both association and dissociation with G-quartets. This observation
could be explained by the fact that protein-protein interactions play crucial role in the RNA-
binding specificity. It has been shown that RNA binding domains (RBD) from different
proteins can cooperate to recognize RNA through a combination of weak protein–RNA.
Moreover, The formation of heterodimers through interactions between an RBD and another
protein can increase the specificity of the RNA interaction as well. For example, the binding
of the RRM of spliceosomal U2B'' to a stem–loop in U2 small nuclear (sn)RNA requires an
interaction with the U2A' protein (Price et al. 1998). Another example was elucidated with the
recent structures of the archaeal and eukaryotic exosomes have revealed extensive
protein–protein interactions between proteins that contain both KH and S1 domains in the
core of the protein complex (Buttner et al. 2005). These interactions can position the S1
domains of specific exosome subunits to recognize the RNAs that are targeted for
degradation.
These different behaviors of the two FMRP-interacting proteins illustrate the
complexity of the functions and interactions that take place in FMRP-containing mRNPs and
in different tissues. FXR1P-Isod and Isoa are the FXR1P isoforms with the highest expression
in brain, suggesting that in neurons FMRP interacts mostly with these two isoforms that might
regulate negatively its action. Our study highlights the functional differences between FXR1P
isoforms and therefore emphasizes the importance of the extensive tissue-specific alternative
splicing undergone by FXR1 mRNA. In view of these results, it is clear that in each mRNP
the ratio between FMRP and FXR1P different isoforms becomes important to precisely
regulate FMRP function. The modulation of the affinity and/or of the dynamics observed for
the FXR1P/FMRP heterodimer may reflect a regulation of the exchange of mRNAs between
mRNPs or trafficking granules and polyribosomes.
Conclusions &
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FMRP is one of the most analyzed RNA binding proteins involved in a genetic
disorder. Its absence results in a dramatic impairment of synaptic connections and plasticity
leading to mental retardation. Several groups had deployed consequent efforts to understand
the molecular functions of FMRP and to decipher the reigning enigma of how the absence of
a single protein can result in such a disease. The ability of FMRP to bind mRNAs, its
shuttling between the nucleus and the cytoplasm, its belonging to several mRNPs and its
involvement in RNA trafficking and local protein synthesis had mainly participated to place
some parts of the puzzle which is still far from being completely assembled.
I deeply believe that both the identification and characterization of FMRP mRNA
targets, in an appropriate manner, together with the analysis of the functional significance of
FMRP/RNA interaction and the post transcriptional regulation that it exert on its targets, are
critical steps in understanding the molecular basis of the Fragile X syndrome.
During my thesis I have analyzed the FMRP/Sod1 mRNA interaction demonstrating
that FMRP is able to differentially regulate its mRNA targets depending most probably on the
mRNA structure recognized by FMRP. On another hand I have also demonstrated that the
affinity of FMRP for its target mRNAs can be influenced by its interactors and that its
function might be regulated by the latter. Further analysis of the FMRP/RNA complex and
FMRP/Protein complex would help in deciphering the molecular mechanism(s) by which
FMRP act and would enlighten the hidden facet of FMRP.
The diversity and divergence of biological materials and technical procedures used by several
laboratories helped to some extent in revealing some functional aspects of FMRP,
nevertheless it created a wide range of controversy that escorted FMRP since its birth fouling
its reputation and making it poorly understood.
Appendix
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Fragile X syndrome, the most common form of inherited mental retardation, is caused by absence of FMRP,
an RNA-binding protein implicated in regulation of mRNA translation and/or transport. We have previously
shown that dFMR1, the Drosophila ortholog of FMRP, is genetically linked to the dRac1 GTPase, a key
player in actin cytoskeleton remodeling. Here, we demonstrate that FMRP and the Rac1 pathway are con-
nected in a model of murine fibroblasts. We show that Rac1 activation induces relocalization of four FMRP
partners to actin ring areas. Moreover, Rac1-induced actin remodeling is altered in fibroblasts lacking
FMRP or carrying a point-mutation in the KH1 or in the KH2 RNA-binding domain. In absence of wild-type
FMRP, we found that phospho-ADF/Cofilin (P-Cofilin) level, a major mediator of Rac1 signaling, is lowered,
whereas the level of protein phosphatase 2A catalytic subunit (PP2Ac), a P-Cofilin phosphatase, is increased.
We show that FMRP binds with high affinity to the 50-UTR of pp2acb mRNA and is thus a likely negative
regulator of its translation. The molecular mechanism unraveled here points to a role for FMRP in modulation
of actin dynamics, which is a key process in morphogenesis of dendritic spines, synaptic structures abnor-
mally developed in Fragile X syndrome patient’s brain.
INTRODUCTION
Fragile X syndrome, the most common cause of inherited
mental retardation, is due to mutations in the FMR1 gene,
resulting in the absence of functional FMRP (fragile X
mental retardation protein) (1). In almost all cases, mutations
consist in an expansion of CGG trinucleotides repeats. Apart
from mental retardation, several features characterize Fragile
X phenotype including facial dysmorphism, post-pubertal
macro-orchidism and connective tissue dysplasia (2). The
shape and density of dendritic spines, which are actin-rich
synaptic structures, are altered in patients and in FMRP
deficient mice brain. These observations suggest a defect in
maturation and/or function of synapses that is thought to be
at the basis of mental retardation (3,4). FMRP contains at
least three RNA-binding domains, two KH domains and one
RGG box. The latter binds with high affinity to RNA
G-quartet structures formed by intrastrand annealing of four
guanine-rich tracts (5,6). FMRP is associated with polyribo-
somes (7) and is most likely involved in translational control
(8–11), perhaps through interaction with the RNAi machinery
(12,13). A point-mutation (I304N) in the KH2 domain has
been reported in a patient with an unusually severe phenotype
(14) and it has been shown that the KH2-I304N mutant FMRP
fails to associate with elongating polyribosomes (15). Several
approaches have led to the identification of few hundreds of
putative mRNA targets (5,11,16,17), but the specificity of
interaction between FMRPs and most of these mRNAs
remains to be confirmed. Moreover, consequences of FMRP
absence for expression and/or subcellular localization of
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proteins encoded by these mRNAs, as well as correlations
with phenotypic features, have been studied only in a few
cases.
FMRP is part of large mRNP complex (7,11,18). Several
FMRP interacting proteins have been described including
its two close paralogs, FXR1P and FXR2P (Fragile X
Related Protein 1/2) (19), NUFIP1 (Nuclear FMRP Interacting
Protein 1) (20,21), 82-FIP (82 kDa-FMRP Interacting Protein)
(22) and the two closely related proteins CYFIP1 and CYFIP2
(Cytoplasmic FMRP Interacting Protein 1/2) (23). Interest-
ingly, CYFIP proteins interact physically with Rac1 and are
genetically linked with this small Rho GTPase in Drosophila
(24–26). Rac1 plays a key role in actin cytoskeleton remodel-
ing (27,28) and notably controls formation, maturation and
maintenance of dendritic spines (29–31). Moreover, mutations
affecting several components of Rho GTPases pathways have
been identified in mentally retarded patients (32,33) and are
associated with dendritic spine defects in the corresponding
mouse models (34).
In this study, we designed a cellular model consisting of
murine fibroblasts which express either no or mutant FMRP
and compared them to FMRP positive cells. Using this
model, we have identified a novel molecular link between
FMRP and the Rac1 pathway: indeed, Rac1 activation leads
to relocalization of four FMRP main interactors (CYFIP1,
FXR1P, NUFIP and 82-FIP) to actin-containing domains
called actin rings. Reciprocally, Rac1-induced actin reorganiz-
ation is modified in FMRP deficient cells and in cells expres-
sing FMRP mutated in KH1 or in KH2 domain. In these
cells, the level of phospho-ADF/Cofilin (P-Cofilin), a major
mediator of Rac1-dependent actin remodeling, is reduced,
whereas the level of the catalytic subunit of protein phospha-
tase 2A (PP2Ac), which controls P-Cofilin dephosphorylation
(35–37), is increased. We demonstrate that FMRP can bind
the 50-UTR of pp2acb mRNA with high affinity via well-
conserved G-quartet structures, suggesting a direct mechanism
of translational repression. Thus, our findings implicate FMRP
in the control of actin cytoskeleton remodeling through the
modulation of PP2Ac expression.
RESULTS
FMRP interacting proteins relocalize to actin ring areas in
PDGF-stimulated fibroblasts
To characterize the interaction between FMRP and Rac1
pathway, we have used a set of immortalized fibroblast cell
lines derived from a Fmr1 knock-out mouse cell line: these
cells express either wild-type FMR1 (FMR1þ), FMR1
alleles with a point-mutation in the KH1 domain (the analo-
gous I241N mutation to the I304N patient mutation in KH2
domain, FMR1KH1) or in the KH2 domain (I304N,
FMR1KH2) or no FMR1 (FMR12) (Supplementary Material,
Fig. S1). Using immunofluorescence co-staining, we first
analyzed the intracellular distribution of Rac1, FMRP and
four of its interacting proteins relatively to actin staining.
Cells were serum starved and then treated with PDGF for
20 min. PDGF is a growth factor which induces a signaling
cascade leading to Rac1 activation and to transient formation
of specific actin structures, called actin rings (reviewed in 38).
Activated Rac1 was previously reported to relocalize in dorsal
ruffles associated with these actin rings (39). P21-activated
kinase 1 (PAK1), a direct downstream target of Rac1, is also
recruited to these dynamic actin structures after PDGF treat-
ment (40).
We indeed observed that Rac1 moves to actin ring areas
after PDGF treatment (Fig. 1B). In this context, we expected
that CYFIP1 subcellular localization would be of particular
interest, because this protein was shown to interact with acti-
vated Rac1 (24,26). While CYFIP1 was found homogeneously
distributed in cytoplasm of non-induced cells (Fig. 1A), as
previously reported (23), PDGF treatment led to CYFIP1 relo-
calization in actin ring areas (Fig. 1B). We then analyzed
FMRP distribution and observed that it is not detectably modi-
fied after PDGF induction (Fig. 1B). However, not only
FXR1P, but also 82-FIP and NUFIP1 (the latter two proteins
being mostly nuclear in serum-starved cells) did relocalize
to these regions upon PDGF activation (Fig. 1B). We
checked whether FXR1P relocalization also occurs in NIH-
3T3 fibroblasts and indeed, we observed its recruitment
close to actin ring areas (Supplementary Materials, Fig. S2).
These relocalizations occurred in both FMR1þ and FMR12
cells, demonstrating that FMRP is not required for recruitment
of its partners to actin polymerization sites (data not shown).
These observations support the existence of a connection
between Rac1 and FMRP interacting proteins.
PDGF-induced actin cytoskeleton reorganization is
enhanced in FMR1 mutant fibroblasts
Dendritic spine morphology and function, that appear affected
in fragile X syndrome patients brain, depend on a dynamic and
precise organization of the actin cytoskeleton network
controlled by Rho GTPases (41). We thus analyzed Rac1-
induced actin cytoskeleton remodeling in the absence of
FMRP. We compared actin cytoskeleton reorganization in
FMR1þ and FMR12 cells at several time points after
PDGF induction, using phalloidin-FITC staining. Before
stimulation, both FMR1þ and FMR12 cells display stress
fibers (Fig. 2A). As expected, actin rings characteristic of
PDGF stimulation were visible at 10 min after treatment in
both cell types (Fig. 2B). Quantitative analysis of cells with
rings revealed that 14% of FMR1þ fibroblasts displayed this
type of structures at 10 min, whereas this percentage was
much higher in FMR12 cells, reaching 47% (Fig. 2C). Pro-
portion of cells with actin rings remained higher in FMR12
cells than in FMR1þ cells also 30 min after PDGF treatment
(Fig. 2C). Consistently, the percentage of FMR1KH1 and
FMR1KH2 mutant cells exhibiting rings 20 min after PDGF
treatment was 2-fold higher than in FMR1þ cells (Fig. 2D).
Macropinocytosis has previously been reported to occur
under Rac1 activation and has been connected to circular
ruffles (42). We did not observe major changes in this
process in FMR12, FMR1KH1 and FMR1KH2 cells (data not
shown).
Thus, Rac1-induced actin remodeling is enhanced in
FMR12, FMR1KH1 and FMR1KH2 mutant cells, further
emphasizing an involvement of FMRP in Rac1-induced
actin cytoskeleton reorganization events.
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Level of the catalytic subunit of protein phosphatase
2A, a phospho-Cofilin phosphatase, is increased in
FMR1–growing cells
Because FMRP is involved in translational regulation, we set
out to identify proteins that are misexpressed in FMR12 cells
and that could account for the altered PDGF-induced actin
phenotype in FMR12 fibroblasts. For this purpose, we com-
pared the proteomes of FMR1þ and FMR12 cells using
2-D gel electrophoresis. Differentially expressed proteins
were identified by mass spectrometry (our unpublished data).
One of the major proteins found is the beta isoform of the
PP2Ac. This enzyme can dephosphorylate P-Cofilin (35–
37), two small homologous proteins acting at the end of
Rac1 pathway to enhance actin depolymerization (reviewed
in 43,44).
We confirmed this quantitative difference by comparing
PP2Ac expression level in several FMR1þ and FMR12
clones. As Rho GTPases are involved in G1-phase regulation
in fibroblasts (45) and PP2Ac is known to be particularly abun-
dant in this phase (46), we synchronized cells in G1 before
protein extraction. PP2Ac level was indeed significantly
Figure 1. Relocalization of four FMRP partners to actin ring areas. Localization of FMRP and some of its interactors in serum-starved fibroblasts (A) and 20 min
after PDGF induction (B). Rac1, Vimentin, FMRP and its interactors are labeled in red (left column). Actin is labeled in green (phalloidin-FITC, middle column).
Merge (right column) corresponds to superposition of indicated protein and phalloidin-FITC labelings. Arrows in (B) indicate actin ring areas. Similar results
were obtained in control experiments performed without phalloidin-FITC staining. Vimentin is used as a negative control.
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higher (2-fold) in FMR12 cells compared with FMR1þ cells
(Fig. 3A and B). No significant difference was observed at
mRNA level (Fig. 3C), in agreement with previous data demon-
strating that PP2Ac expression is regulated at the post-transcrip-
tional level (46).
Phospho-Cofilin level is reduced in FMR12, FMR1KH1
and FMR1KH2 mutant fibroblasts
Rac1-induced reorganization of actin cytoskeleton is mediated
by a signaling transduction cascade, resulting in the activation
of LIMK1, which phosphorylates, and thus inactivates, Cofilin
(43). As we identified an increased level of P-Cofilin phospha-
tase PP2Ac in FMR12 fibroblasts, we analyzed whether
P-Cofilin amount is changed in FMR12 cells compared
with FMR1þ cells. Indeed, using western blot analysis, we
found that P-Cofilin level was significantly decreased (by
50%) in FMR12 cells (Fig. 4B). Conversely, no quantitative
difference in global amount of Rac1, LIMK1 and total Cofilin
was observed between FMR1þ and FMR12 cells (Fig. 4A).
The decreased P-Cofilin and the increased PP2Ac level
are also observed in cells expressing mutant FMRP, this phe-
notype being especially strong in FMR1KH2 mutant cells
(Fig. 4C).
The reduced level of the inactive form of Cofilin may
account for the FMRP-dependent difference in actin reorgan-
ization that was observed after PDGF treatment.
pp2acß mRNA specifically interacts with FMRP
Several in vitro and in vivo data support the role of FMRP as a
translational repressor (8–10). Therefore, we asked whether
the beta isoform of pp2ac (pp2acß ) mRNA is a direct target
of FMRP. The ability of FMRP to bind to pp2acß mRNA
was tested as previously described: we determined the
FMRP affinity for this mRNA by measuring its ability to
disrupt binding of 32P-labeled N19 RNA by GST–FMRP in
gel shift experiments (6). N19 is a short fragment of FMR1
mRNA (nucleotides 1470–1896) that contains a G-quartet
structure and binds with high affinity to FMRP. Subfragments
of pp2acß mRNA (full length, 50-UTR, 30-UTR) were tested
and we found that its 50-UTR did show an affinity for FMRP
similar to that observed for N19 itself (Fig. 5A and B).
G-quartet forming regions can be detected by comparing
reverse transcriptase elongation on RNA templates in the pre-
sence of either Kþ or Naþ: stabilization of G-quartet structures
by Kþ, but not by Naþ, results in cation-dependent pauses
Figure 3. Increased level of protein phosphatase 2A catalytic subunit (PP2Ac)
in FMR1 null cells (FMR12). (A) Western blot analysis of two FMR1þ (þ/1,
þ/2) and two FMR12 (2/3, 2/4) clones. (B) Densitometer analysis showing
significant increase of PP2Ac amount in FMR12 clones (2/3,2/4) compared
with FMR1þ clones (þ/1, þ/2). Two independent experiments were quanti-
fied. Results are means of PP2Ac amounts normalized to Tubulin (Student’s
t-test, P, 0.05). (C) No significant difference was observed at mRNA
level, as determined by LightCycler real-time PCR.
Figure 2. Enhanced actin remodeling response of FMR1 null (FMR12) and
KH-mutant (FMR1KH1 and FMR1KH2) fibroblasts upon PDGF treatment.
Actin cytoskeleton labeling with phalloidin-FITC (A) in serum-starved cells
and (B) 20 min after PDGF treatment. As expected, PDGF treatment leads
to formation of actin ring structures (arrows in B). (C) Quantification of
cells exhibiting actin rings in two FMR1þ clones and in two FMR12 fibro-
blasts clones, at different time points after PDGF addition. One representative
experiment is shown. Five hundred cells per clone were analyzed. For each
cell type, mean and standard deviation between both clones were calculated.
(D) Quantitative analysis of FMR1-, FMR1KH1, FMR1KH2 and FMR1þ
cells with actin rings 20 min after PDGF treatment.
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visible on a gel (6). This allowed us to identify two strong and
two weak G-quartet pauses in the 50-UTR of pp2acß mRNA
(Fig. 5C). One is localized only 18 nucleotides before the
ATG of the messenger: FMRP binding on this G-quartet is
thus likely to produce translational repression of the mRNA,
as previously shown for the FMR1 G-quartet itself (6). Align-
ment of sequences corresponding to G-rich regions of pp2acß
50-UTR in mammals are shown in Figure 5D. High conserva-
tion of these non-coding sequences argues in favor of their
functional importance. Altogether, these results show that
FMRP is able to bind pp2acß mRNA with high affinity and
specificity, most likely via G-quartet structures.
DISCUSSION
Functional properties of FMRP have been extensively studied,
but its precise mechanism of action and the pathways leading
to mental retardation in its absence are still poorly understood.
The goal of this work is to characterize connection(s) existing
between FMRP and Rac1 pathway, given the importance
of this Rho GTPase in nervous system development and in
control of dendritic spine formation (31,47). The first
indication for existence of such a connection was provided
by demonstrating that the CYFIP1/2 proteins are interactors
of both Rac1 and FMRP and that the three orthologous
genes show genetic interaction in Drosophila (23–26). Fur-
thermore, dRac1 mRNA has been reported to be associated
with dFMR1–mRNP complex (48).
We have studied the effect of FMRP function on Rac1-
induced actin cytoskeleton dynamics in murine fibroblasts.
We compared cells that express wild-type FMRP to cells
lacking FMRP or expressing the well-known KH2 mutant
(I304N) or its equivalent in the KH1 domain (I241N). Fibro-
blasts are commonly used to study actin remodeling mechan-
isms that are also implicated in growth cone extension in
neurons (27,28,49,50), since mechanisms of cytoskeletal
actin reorganization leading to membrane protrusions are
believed to be similar in all cells (44,50). Moreover, neurons
are not the only cells affected in fragile X syndrome, because
clinical features also include facial dysmorphism and joints
hyperextensivity (2). Finally, this model allows us to study
the effect of KH1 or KH2 point-mutation, the latter identified
in a severely affected patient. Both mutant proteins are associ-
ated with mRNP particles but not with actively translating
polyribosomes (15) (data not shown for the KH1 mutant).
Figure 4. Decreased level of phospho-Cofilin (P-Cofilin) in FMR1 null (FMR1-) and KH-mutant (FMR1KH1 and FMR1KH2) fibroblasts. (A) Western blot using
anti-Rac1, anti-LIMK1 and anti-Cofilin antibodies on total protein extracts of two FMR1þ clones (þ/1, þ/2) and two FMR1- clones (-/3, -/4) reveal no sig-
nificant difference in total amount of these proteins. (B) Amount of P-Cofilin was determined in same conditions using a specific antibody. Densitometer analysis
indicates a 2-fold reduction of P-Cofilin amount in FMR12 clones (2/3,2/4) compared with FMR1þ clones (þ/1, þ/2) (normalization to Tubulin). Means and
standard deviations were calculated from two independent experiments (Student’s t-test, P, 0.002). (C) Western blot analysis and its quantification reveal both
a decreased P-Cofilin and an increased PP2Ac level in FMR1KH1 (KH1) and in FMR1KH2 (KH2) cells compared with FMR1þ cells.
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We show in this study that Rac1 activation leads to relocali-
zation of four FMRP-interacting proteins (CYFIP1, FXR1P,
NUFIP and 82-FIP) to actin-containing domains involved in
processes protrusions. Relocalization of these proteins is not
FMRP-dependent, as lack of FMRP does not abolish their
recruitment. However, this finding suggests that the assembly
and composition of some FMRP-containing complex are modu-
lated by Rac1. We also observed an enhanced Rac1-induced
actin remodeling in FMR1–, FMR1KH1 and FMR1KH2 mutant
cells. This correlates with a decreased P-Cofilin level and an
increased PP2Ac level in these cells. We, furthermore, showed
that pp2acb mRNA is bound by FMRP with high affinity and
contains in its 50-UTR domains able to form G-quartet structures.
PP2A is a phospho-serine/threonine phosphatase ubiqui-
tously expressed in eukaryotic cells. The core enzyme consists
of one of two closely related isoforms (a and b) of the cataly-
tic subunit, associated with one of the two isoforms of the
structural subunit PR65/A. PP2A is involved in many pro-
cesses such as regulation the of cell cycle events, translational
control and cytoskeleton reorganization (51). Moreover, PP2A
was shown to interact physically with Cofilin and to dephos-
phorylate it (35–37). Cofilin, a downstream component of
Rac1 cascade, is a small actin-binding protein, which plays
a key role in actin cytoskeleton dynamics, enhancing actin
depolymerization and causing actin filaments branching and
severing (44,47). Thus, the difference in Rac1-induced actin
Figure 5. FMRP binding on pp2Acß mRNA via G-quartets. (A and B) Determination of the binding strength of various subfragments of pp2Acß mRNA, using
gel retardation experiments. 32P-labeled N19 subfragment of FMR1 containing G-quartet was incubated with 0.1 pM GST–FMRP, in the presence of increasing
amount of unlabelled competitors. Lane C: control without protein; Lane 0: control without competitor; numbers are logs of competitors concentrations
(N19-FMR1, complete pp2Acß mRNA (total), 50-UTR of pp2Acß mRNA and 30-UTR of pp2Acß mRNA). The graph depicts the fraction of 32P-N19 bound
RNA, plotted against competitors RNA concentrations determined by densitometer analysis. (C) Cation-dependent termination of reverse transcription in the
50-UTR of pp2Acß mRNA. Strong and weak pauses of reverse transcriptase are, respectively, indicated by large and thin arrows. Numbers correspond to
positions of strong pauses, þ1 being A of the ATG codon. (D) Localization and conservation of the two stable G-quartet structures among mammals.
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remodeling that we observed in FMR1–, FMR1KH1 and
FMR1KH2 mutant fibroblasts may be accounted for by
decreased phosphorylation of Cofilin via increased PP2Ac.
The pool of active Cofilin is likely to be higher in FMR1–,
FMR1KH1 and FMR1KH2 cells compared with FMR1þ cells.
Indeed, we found a decrease in P-Cofilin level without
change in global amount of the protein. This may, at a first
glance, appear contradictory with the observation of an
enhanced response to Rac1 signaling in the absence of func-
tional FMRP, because Rac1 is known to act through the inhi-
bition of Cofilin. It has, however, been shown that both a
decrease in P-Cofilin level and Cofilin over-expression
induce the same changes as observed after expression of con-
stitutively active Rac1 (36,47). Indeed, a global and/or local
increase of the ratio of Cofilin to P-Cofilin leads to an increase
in actin turnover. This creates free barbed ends and maintains
a pool of actin monomers, thereby increasing the rate of actin
polymerization. On the other hand, the inactivation of Cofilin
through Rac1 signaling pathway allows local actin polymeriz-
ation, which is also required for the extension of their pro-
cesses (44). Thus, a global and/or local balance between
kinase(s) and phosphatases activities is crucial to precisely
control the cycling of phosphate on Cofilin. As Cofilin
action on spine actin dynamics is implicated in the regulation
of synaptic plasticity (52), an alteration of Cofilin phosphory-
lation may play a role in the alteration of dendritic
spines observed in fragile X patients and in Fmr1 null mice
brain.
We propose that the effect of FMRP on Rac1 signaling
depends at least in part on translational repression of pp2acb
mRNA. We found that FMR1KH1 and FMR1KH2 mutant cells
display the same phenotype than those which lack FMRP.
Thus, the association of FMRP with polyribosomes is required
for its interference with Rac1 signaling. Moreover, pp2acb
mRNA is a likely target of FMRP, because we showed that
FMRP binds specifically and with high affinity to its 50-UTR.
This fits with previous observation that PP2Ac expression is
regulated at the translational level (46).
We identified four G-quartet structures in pp2acb 50-UTR.
Similar repetitions of RNA motifs have previously been
described for iron response elements (53), differentiation
control elements (DICE) (54) and for the UCAU sequence
bound by Nova1, a protein containing three KH domains
(55). Relations between the number of RNA motifs and the
functional significance of RNA–protein interaction have
been established in some cases. For example, translational
inhibition by hnRNP E1 is only observed when at least two
DICE elements are repeated in a reporter mRNA (54). Thus,
FMRP binding on multiple G-quartet sites could cause transla-
tional repression by a similar mechanism. Alpha and beta
isoforms of PP2Ac are very homologous, and alpha isoform
may also be a target of FMRP, as we have noticed the pre-
sence of potential G-quartet forming sequences in its 50-UTR.
Electrophysiological analysis in hippocampal slices of
Fmr1 knock-out mice has revealed an alteration of synaptic
plasticity, manifested by enhanced metabotropic glutamate
receptors-dependent long term depression (LTD) (56). It is
worth to note that PP2A has also been implicated in the modu-
lation of LTD (57), in metabotropic glutamate receptors sig-
naling transduction (58,59) and in other alterations of
synaptic plasticity (such as depotentiation induced by high
theta-burst stimulation) (60).
In conclusion, we have shown that FMRP alters Rac1
signaling in mammalian fibroblasts and modulates P-Cofilin
and PP2Ac levels. Further investigations are now required to
determine whether these alterations also take place in
neurons and whether they could participate in the synaptic
structure and plasticity defects that are considered to be at
the basis of the mental impairment in fragile X syndrome.
MATERIALS AND METHODS
Establishment of stably transfected murine
fibroblasts lines
The fibroblastic 3T-6A STEK cell line, which shares the same
origin but does not correspond to the one previously described
by Mazroui et al. (10), was established from mouse Fmr1 null
C57Bl/6J embryos (mouse strain gR2700 available from The
Jackson Laboratory), according to the procedure of Todaro
and Green (61). Subcultures were propagated as uncloned
mass cultures for a period of 6 months before being consi-
dered as stable. Cell lines were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal calf serum (FCS) and antibiotics (100 units/ml penicillin,
50 mg/ml streptomycin). These cells were transfected using
EffecteneTM (Qiagen), either with pTL10 vector containing
FMR1 isoform 1 fused to FLAG epitope (62,63), by the
same vector containing FMR1 isoform 1 with a point-mutation
in KH1 or in KH2 domain or with an empty pTL10 vector.
The pIREShyg3 plasmid (Clontech-BD Biosciences) was
co-transfected with pTL10 vectors. Hygromycin (150 mg/ml)
was added 48 h after transfection and resistant clones were
isolated and amplified. Expression of FMRP was
controlled in each clone by immunoblot with 1C3 antibody
(Supplementary Material, Fig. S1). Thirteen hygromycin resist-
ant clones (five in which FMR1 is expressed, one in which
FMR1 mutated in KH1 domain is expressed, two in which
FMR1 mutated in KH2 domain is expressed and five FMR1
null, referred to, respectively, as FMR1þ, FMR1KH1,
FMR1KH2 and FMR1–) were selected. All experiments were
performed on several randomly chosen clones: data are presented
for some but results were always consistent for the others.
Morphology of FMR1þ and FMR1– cells are similar in
normal growth conditions (Supplementary Material, Fig. S1).
Site directed mutagenesis of FMRP KH1 or KH2 domain
We performed site directed mutagenesis to introduce the
I304N point-mutation in KH2 domain or an equivalent
one (I241N) in KH1 domain using the ‘QuickChange
Site-Directed Mutagenesis Kit’ (Stratagene) according to
manufacturer instructions and using the following oligo-
nucleotides for KH2 and KH1 corresponding sequences, res-
pectively:
. GTACTCATGGTGCTAATAATCAGCAAGCTA
GAAAAGTACCTG/CAGGTACTTTTCTAGCTTGCT
GATTA TTAGCACCATGAGTAGTAC
. GAAAGCTGAATCAGGAGATTGTGGACAAGTCAG/
CTGACTTGTCCACAATCTCCTGATTCAGCTTTCC.
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Cell culture
Stably transfected cell lines were cultured in DMEM sup-
plemented with 10% FCS and hygromycin (150 mg/ml) until
they reach 80% confluence. NIH-3T3 fibroblasts were cultured
in DMEM supplemented with 10% newborn calf serum.
To induce Rac1 activation, PDGF (platelet-derived growth
factor BB, R&D Systems) was added to a final concentration
of 5 or 10 ng/ml to serum-starved cells (16 h in DMEMþ
0.1% serum). For synchronization in G1-phase, cells were
serum-starved (20 h in DMEMþ 0.1% serum) and then
cultured 6 h in DMEMþ 10% FCS.
Immunofluorescence, immunoblot and antibodies
Cells were fixed for immunofluorescence experiments as pre-
viously described (63). Fixed cells were rinsed with PBS and
incubated with specific antibodies for Rac1 (1/500, Upstate
Biotechnology), CYFIP1 (1/500), FMRP (1C3, 1/1000) (64),
FXR1P (830, 1/500) (65), NUFIP1 (1541, 1/250) (21),
82-FIP (1666, 1/250) (22) or in PBS. After PBS rinses, goat
anti-mouse/rabbit-Alexa594 and/or AlexaFluorTM488 Phalloi-
din (Molecular Probes) were then added. Cells were then rinsed
and mounted in Kaiser’s glycerol gelatin (Merck). Immuno-
fluorescence was analyzed using a Leica DB microscope.
Immunoblot analysis was performed as previously
described (63). Membranes were probed overnight at 48C
with 1C3 antibody (1/2000), anti-P-Cofilin (1/1000), anti-
Cofilin (1/500, Ozyme), anti-LIMK1 (1/500, Santa Cruz
Biotechnology), anti-Rac1 (1/500, Upstate Biotechnology)
or anti-PP2Ac (1/500, Upstate Cell Signaling) and with
anti-Tubulin (1/5000) (Chemicon), and then incubated with
peroxidase-conjugated goat anti-rabbit or goat anti-mouse
antibodies (1/5000). Immunoreactive bands were visualized
with the Supersignal West Pico Chemiluminescent Substrate
(Pierce).
CYFIP1 mouse monoclonal antibody was raised and affinity
purified against the synthetic peptide DEIITILDKYLKSGD-
GEGTPC (CYFIP1 amino acids 1217–1236). Western blot
and immunofluorescence analyses on CYFIP1 transfected
and mock transfected COS cells as well as on fibroblasts
have shown that it specifically recognizes a 140 kDa band cor-
responding to CYFIP1 (data available on request). Macropino-
cytosis was assessed by measuring uptake of 10 kDa dextran
as previously described (66).
Two-dimensional electrophoresis
Cells were harvested by centrifugation and resuspended in
10 mM Tris, 1 mM EDTA, and 250 mM sucrose. Lysis
was performed in four volumes of 2.5 M thiourea, 8.75 M
urea, 5% CHAPS, 50 mM DTT and 25 mM spermine.
DNA was eliminated by 30 min ultracentrifugation at
90 000 rpm. A total of 150 mg of proteins were diluted in
400 ml of rehydratation buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 0.4% ampholytes, 20 mM DTT), which were used
to rehydrate home-made pH4–8 immobilized pH grad-
ient strips. Isoelectric focusing was conducted for 60 000 V/h
at a maximum of 3000 V using the MultiphorII
system (Amersham-Pharmacia, Sweden). Strips were then
equilibrated for 20 min by rocking first in a solution of
0.15 M bisTris/0.1 M HCl, 6 M urea, 2.5% SDS, 30% glycerol,
0.5 M DTT and then in 0.15 M bisTris/0.1 M HCl, 6 M urea,
2.5% SDS, 30% glycerol, 0.3 M iodoacetamide. They were
then embedded onto a 12% SDS/PAGE gel in 800 ml of 1%
agarose. The gels buffer consisted of 0.18 M Tris/0.1 M HCl,
the cathode buffer contained 0.2 M taurine/25 mM Tris, 0.1%
SDS and the anode buffer was 0.384 M glycine/50 mM Tris,
0.1% SDS. Gels were run 25 V for one hour then 400 V/500
mA/12.5 W/gel for 5 h. Fixation was performed 1 h in 30%
ethanol, 10% acetic acid and overnight in 30% ethanol, 0.5 M
potassium acetate and 1 mM potassium tetrathionate. Staining
of gels was done 20 min in 0.2 M potassium carbonate, 0.01%
formaldehyde, and 1.25  1023% sodium thiosulfate and
blocked in 0.3 M Tris, acetic acid 2%. Gels were scanned and
protein differences between FMR1þ and FMR12 fibroblasts
were analyzed. Corresponding spots of interest were excised
from the gel and analyzed by Maldi-TOF as previously
described (67).
LightCycler real-time PCR
RNA extraction from FMR1þ and FMR12 fibroblasts synchro-
nized in G1-phase was performed using RNASolvRReagent
(Omega Bio-Tek) and 1 mg of RNA was retro-transcribed
using AMV Reverse transcriptase (Roche), according to manu-
facturer instructions. pp2acß and hprt cDNA, used as a control,
were amplified by real-time PCR, as previously described
(6), using, respectively, the following oligonucleotides:
. GCCATGGACGACAAGGCG/TTTACAGGAAG
TAGTCTGGGG
. AGAGGTCCTTTTCACCAGCAAG/ATTATGGACAG
GACTGAAAGAC.
Gel shift and identification of mRNA G-quartet structures
GST–FMRP protein production and purification, gel shift
assay as well as identification and characterization of mRNA
G-quartets were performed as previously described (6). We
used pp2acb cDNA clone from rat (NM_017040) (68). Sub-
cloning of 30-UTR was performed by PCR, using following
oligonucleotides: CCTATAAATTCCTCCCCAG and
CTCTCTAAATTGGG AAGTTT. The 50-UTR was obtained
by digesting the full-length cDNA by Nco I at the ATG
position.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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Le syndrome de l’X fragile est la cause la plus fréquente de retard mental héréditaire. Ce
syndrome est du à l’absence de la protéine FMRP (Fragile X Mental Retardation Protein).
FMRPest exprimée dans de nombreux tissus, et surtout dans les neurones et dans les
spermatogonies. Elle possède un signal de localisation nucléaire (NLS), et un signal d'export
nucléaire (NES), des motifs de liaison à l'ARN (deux domaines KH et une boîte RGG). Bien
que la sublocalisation et le rôle de FMRP dans le noyau ne soient pas encore connus, dans le
cytoplasme FMRP est associée aux polyribosomes faisant partie d’un complexe
ribonucléoprotéique où elle interagit avec ses deux homologues FXR1P et FXR2P. Deux
structures de liaison pour FMRP ont été identifiées et caractérisées: le "purine-quartet" (cette
structure est aussi présente dans l’ARNm de FMR1) et le « kissing complex». L'ARNm de
FMR1 est associé aux complexes polyribosomiques synaptiques ainsi que sa traduction sont
modulées par l'activité synaptique. Donc, la présence d'un NLS et d'un NES suggère que
FMRP fasse la navette entre le noyau et le cytoplasme pour le transport de l’ARNm. Plusieurs
ARN ont été identifiés comme cibles potentielles de FMRP. Ces ARN sont derégulés chez les
souris Fmr1 nulles, mais la signification fonctionnelle de l’interaction FMRP/ARN reste
toujours partiellement connue.
L’objectif principal de ma thèse étant la compréhension du mécanisme d’action de FMRP, ce
projet a été abordé en deux points principaux :
-Recherche de l’influence des protéines qui interagissent avec FMRP sur sa capacité (affinité)
à se lier à l’ARN
-Recherche de nouvelles séquences/structures cibles de FMRP et analyse du rôle de
l'interaction FMRP/ARN.
Nous avons pu montrer une interaction spécifique uniquement entre l’isoforme musculaire de
FXR1P avec la structure de G-quartet. Cela nous a permis d’établir un rôle synergique et non
compensatoire de FXR1P sur FMRP.
D’un autre côté, nous avons démontré l’interaction spécifique de FMRP avec une nouvelle
structure présente dans l’ARNm de la Sod1 que nous avons appelé SSLIP (Sod1 Stem Loops
Interacting with FMRP). La distribution de SSLIP sur les polyribosomes est altérée en
absence de FMRP ce qui conduit à une faible expression de la protéine Sod1. En utilisant un
système de gène rapporteur, nous avons montré que l’interaction FMRP/SSLIP favorise la
traduction de la Sod1 ce qui nous a permis d’établir un nouveau mécanisme d’action de la
protéine FMRP sur ces cibles ARN.
